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SUMMARY
Transgenic mice have previously been used as an effective in vivo model to examine the 
role o f genetic lesions in tumourigenesis. The work presented in this thesis describes a 
transgenic approach designed to investigate the consequences of deregulated c-myc and 
loss of the p53 tumour suppressor gene in the pathogenesis of T-cell lymphoma.
Transgenic mice positive for both a CY)2-myc transgene and homozygous p53 null 
mutation were generated by crossing these parental strains together. The p53‘/7CD2- 
myc transgenic mice developed highly malignant, clonal T-cell lymphomas with 
increased frequency and reduced latency compared to either genotype alone. Tumours 
were detected in young p53'/'/CD2-/;7yc+ mice as early as 27 days o f age with clinical 
manifestation of disease occurring at between 50 and 86 days of age. These studies 
revealed the potent synergy between deregulated c-myc and p53 loss in T-cell 
lymphomagenesis. The latency and clonality of p53*/7CD2-/wyc+ tumours however, 
suggested that CD2-myc and p53_/‘ lesions alone were insufficient for the induction of a 
malignant phenotype. This interpretation was confirmed by infection of p53'/7CD2-myc 
neonatal mice with Moloney murine leukaemia virus (MoMuLV) which resulted in a 
further acceleration of tumour onset. The mechanism of synergy between CD2-myc and 
p53v' is unclear but gross examination of malignant tumours demonstrated that the levels 
o f apoptosis in p53'/7CD2-/77yc+ lymphomas were not significantly different to parental 
groups. This suggests that p53-dependent, c-myc mediated apoptosis does not appear to 
play a major role at this stage of tumour development.
Tumourigenesis was not accelerated in animals heterozygous for the p53 null mutation 
suggesting that loss of both wild type p53 alleles was required for efficient synergy with 
the CD2-myc transgene. However studies on p53+/7CD2-wyc+ mice implied that loss of 
the remaining allele could confer a selective advantage on c-myc expressing tumour cells.
Loss of the p53 tumour suppressor gene also collaborated with MoMuLV infection in 
the development of murine T-cell tumours. However the relatively weak synergy 
between these lesions compared to that observed with p53 loss and deregulated c-myc 
may be suggestive of a functional overlap between MoMuLV and p53 loss.
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CHAPTER 1. 
GENERAL INTRODUCTION.
1.1 C a n c e r  a n d  G e n e t ic s .
The general acceptance that cancer is a disease of malfunctioning genes has followed 
many years of intensive research into the underlying causes o f tumour development. 
Neoplastic cancer cells are derived from cells which have escaped the normal 
homeostatic mechanisms of physiological growth. Unrestrained growth o f cancer cells is 
a consequence of alterations in the expression or biochemical function of genes, caused 
by genetic damage. The discovery that a large number o f genes which are mutated in 
cancer are involved in cellular growth has led to a greater understanding of the 
mechanisms governing normal growth as well as neoplastic processes. Early evidence 
for the existence of cancer-causing genes came from studies o f RNA tumour viruses and 
the finding that sequences o f the viral genome were responsible for the induction of 
tumours. The identification of DNA anomalies and isolation of cellular genes associated 
with spontaneous tumour development further emphasized that genetic damage was 
intrinsic to the pathogenesis of tumours. DNA alterations found in spontaneous tumours 
include point mutations, deletions, chromosomal rearrangements and gene amplification 
(Bishop, 1991). Many causative agents o f cancer have now been identified, for example 
radiation, tobacco and certain chronic infections (reviewed by Ames et al., 1995). At 
least some of these agents are known to act directly as DNA mutagens.
Genetic mutations can result in the activation/mutation o f dominant oncogenes, or the 
inactivation of tumour suppressor genes. Dominant oncogenes are derived from cellular 
genes, collectively known as proto-oncogenes, which are involved in normal cell growth 
and differentiation. Inappropriate expression of these genes or their gene products leads 
to a gain of function with increased biological activity. In contrast, tumour associated 
damage to tumour suppressor genes results in loss o f normal function. The gene 
products o f this class o f genes generally restrict cell growth and therefore it is the 
absence o f these gene products which contribute to neoplasia. Tumour suppressor gene
l
mutations are generally regarded as being recessive as both copies of the gene must be 
inactivated for functional loss of the gene product (Knudson, 1985).
Most malignancies occur as a result o f both dominant and recessive lesions. Indeed 
neoplastic transformation is a multistep program which requires numerous changes in the 
biochemical function of ceils (Klein and Klein, 1985). Consequently, damage to multiple 
genes must occur for the initiation and progression of a single tumour (Weinberg, 1989; 
Hunter, 1991). One of the best characterised models of multistep tumourigenesis is 
colorectal cancer. Changes in at least four or five defined genes are required for the 
development o f a malignant colorectal tumour including both mutational activation of 
oncogenes and mutational inactivation of tumour suppressor genes (Fearon and 
Vogelstein, 1990). It has been suggested that it is the accumulation o f genetic changes 
rather than the order in which they take place which is important for the development of 
a malignant tumour (Fearon and Vogelstein, 1990). The accretion o f multiple genetic 
lesions has also been observed in various other tumour types (Bishop, 1991). Evidence 
for the multi step nature o f carcinogenesis has additionally been provided from studies of 
transgenic mice which require more than one genetic abnormality for the development of 
tumours (see section 1.7; Hanahan, 1988). Although co-operation between a number of 
genetic lesions has been recognised, the mechanism of how these events combine to 
achieve the malignant phenotype is still largely unclear (Hunter, 1991).
1.2 A p o p t o s is .
Normal cell homeostasis is a balance between cell proliferation and cell death. Neoplasia 
results from a disruption to this equilibrium, when the rate o f cellular proliferation 
exceeds that of cell death. While deregulation o f cellular proliferation has long been 
associated with tumour development, only in recent years has the importance o f cell 
death in tumourigenesis been widely acknowledged (Marx, 1993). It has been shown 
that the function of certain oncogenes and tumour suppressor genes is to regulate the cell 
death process (reviewed by Williams and Smith, 1993; Hoffman and Liebermann, 1994). 
Inhibition of cell death through the deregulation of these genes can result in aberrant cell
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survival and contribute to tumourigenesis. Furthermore, genetic co-operation between 
lesions which result in enhanced proliferation and increased cell survival appear to be a 
potent combination for tumourigenesis (McDonnell, 1993a).
Apoptosis is an innate mode o f cell death which is an essential part o f many cellular 
processes, including embryonic development, tissue homeostasis and immune regulation 
(Arends and Wyllie, 1991). An active form of death, apoptosis is characterised by 
several morphological and biochemical features including nuclear condensation, 
increased cell density, degradation o f DNA, cell surface blebbing and cell fragmentation 
(Arends et a l, 1990; Arends and Wyllie, 1991; Cohen, 1993; Wyllie, 1993). The 
apoptotic cell splits into membrane-bound fragments of various sizes called apoptotic 
bodies. Apoptotic cells are phagocytosed by neighbouring cells or macrophages and 
therefore do not induce an inflammatory reaction (Savill et al., 1990; Savill et at., 1993).
The process of apoptosis appears to be a complex mechanism which involves several 
different signals, pathways and effectors. Considerable progress has been made in 
defining the pathways which lead to the execution o f cell death (reviewed by Oltvai and 
Korsmeyer, 1994; Green and Martin, 1995). Induction of apoptosis can arise from 
physical insults in the form of genetic damage (e.g. by ionizing radiation), ligation of Fas 
and tumour necrosis factor (TNF) cell surface receptors, glucocorticoid hormones, 
cytokine deprivation and various other environmental stimuli (Zheng et a l , 1995; Nagata 
and Golstein, 1995; Compton and Cidlowski, 1992; Thompson, 1995). Some inducers 
of apoptosis have been found to activate signal transduction pathways like that o f the 
sphingomyelin pathway resulting in increased ceramide accumulation (Jarvis et a l , 
1994). Following induction, apoptosis is regulated by mediator genes, several o f which 
have been identified (Williams and Smith, 1993; Hoffman and Liebermann, 1994). These 
genes are often found to be altered and deregulated in tumourigenesis resulting in 
apoptotic inhibition and inappropriate cell survival. It is the regulatory genes which are 
presumed to influence the final execution pathways that activate the cellular changes 
characteristic of apoptotic cell death. The execution o f the final stages in the apoptotic 
pathway probably occurs through members of the interleukin-lp converting enzyme
3
(ICE) family of cysteine proteases (Whyte and Evan, 1995; Nicholson et a l , 1995; 
Martin and Green, 1995).
1.3 O n c o g e n e s .
Proto-oncogenes are cellular genes which are important for cellular proliferation. 
Oncogenes are the mutant alleles of proto-oncogenes, many o f which promote 
deregulated proliferation in neoplastic cells. The identification o f oncogenes has come 
from several lines o f investigation (reviewed by Varmus, 1984; Bishop, 1987; Spandidos 
and Anderson, 1989) with approximately one hundred oncogenes having been described 
by 1994 (Hesketh, 1994a).
1.3.1 The Identification of Oncogenes.
The first oncogenes to be identified were found within the genomes o f acute 
transforming retroviruses (reviewed by Varmus, 1984), the Rous sarcoma virus (RSV) 
being the classical example. First observed by Rous in 1911 to induce avian sarcomas, 
RSVs transforming abilities were found to be dependent on the presence o f a single gene 
src (Bishop, 1985). Further investigation of RSV and other acutely transforming 
retroviruses revealed that each of the viral oncogenes had a cellular homologue (Varmus,
1984). Retroviral oncogenes arise by transduction o f cellular genes to the viral genome 
during the replicative life cycle of the virus when viral and host genomes recombine. 
Transduction of cellular genes places them under the regulation of viral promoters 
leading to deregulated expression. Viral oncogenes differ from their cellular homologues 
as they do not contain introns and are often altered (Onions, 1991). Oncogenes 
identified as transduced genes in acute transforming retroviruses include c-myc, c-myb, 
c-Ha-ras, c-Ki-ras, c-erbB, c-mos, c-abl, c-raf, c-fos and c-sis (Varmus, 1984; Onions 
and Jarrett, 1987).
Integration of retroviruses into cellular DNA can itself be a mutagenic event. Slow 
transforming retroviruses, which do not express viral oncogenes, activate cellular genes
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by insertional mutagenesis (Kung et a l , 1991). In this process, the retrovirus damages 
the cellular gene directly or places the gene under viral regulatory controls (Kung et al., 
1991; Tsichlis and Lazo, 1991). Viral insertion takes place randomly throughout the 
host DNA. However cells with insertions near to, or at particular proto-oncogenes 
acquire a selective growth advantage (Kung et a l  1991). Many oncogenes have been 
detected at common viral integration sites including c-myc, c-myb and c-erbB (Tsichlis 
and Lazo, 1991; van Lohuizen and Berns, 1990). Targets o f insertional mutagenesis 
have also led to the identification of several novel oncogenes. The pim -1 gene for 
example was discovered in mouse T-cell lymphomas induced by the murine leukaemia 
virus MoMuLV (Cuypers et a l, 1984). The int-\, int-2, ahi-\, evi-1, evi-2, mlvi-l, 
mlvi-2, and mlvi-3 genes have similarly been identified as proviral target genes (Onions 
and Jarrett, 1987; Tsichlis and Lazo, 1991; Hesketh, 1994a).
DNA tumour viruses also have oncogenic potential but unlike RNA tumour viruses do 
not contain transduced cellular genes, nor activate host oncogenes upon viral infection. 
DNA tumour viruses express viral genes which generally do not have cellular 
homologues but are capable of transformation (Bishop, 1985). The transforming 
properties of several of these genes including simian virus 40 (SV40) large T antigen, 
adenovirus E l A and E1B and papilloma virus E6 and E7 genes are related to their ability 
to complex with cellular proteins as will be discussed in later sections.
Cellular oncogenes have been detected in spontaneous tumours at chromosomal 
translocations (Varmus, 1984; Haluska et a l, 1987). Chromosomal translocations result 
in portions o f two chromosomes becoming joined together. Proto-oncogenes situated at 
the breakpoint region between these chromosomes can be activated as a consequence of 
the translocation (Haluska et a l,  1987). The c-myc and c-abl oncogenes are two genes 
which have been identified at chromosomal translocations (Spandidos and Anderson,
1989). The bcl-2 gene was identified as a new oncogene from its location at a 
chromosomal translocation breakpoint which placed it under the regulation o f the 
immunoglobulin heavy-chain locus (Bakhshi et a l, 1985).
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DNA amplification in a number o f tumour types has also led to the identification o f 
cellular oncogenes. Amplification of proto-oncogenes results in high levels o f the 
protein product. The c-myc, c-erbB, c-abl, c-myb and c-Ki-ras oncogenes have been 
detected in amplified DNA (Varmus, 1984). Novel genes identified from amplified DNA 
include the N-myc and L-myc oncogenes (Schwab et al., 1983; Nau et al., 1985).
1.3.2 The Functions of Proto-oncogenes and Oncogenes.
The subcellular location and properties o f numerous proto-oncogenes have been 
determined (reviewed by Varmus and Bishop, 1986; Spandidos and Anderson, 1989; 
Hunter, 1991; Hesketh, 1994a). Proto-oncogenes are located at the plasma membrane, 
in the cytoplasm and in the nucleus. These genes appear to have diverse functions at all 
levels o f the cell signalling pathway from secreted growth factors and membrane 
receptors to protein kinases and transcription factors (Jones and Kane, 1996).
Some proto-oncogenes are related to growth factors, the sis oncogene for example 
encodes a homologue of the platelet-derived growth factor, PDGF (Waterfield et al.,
1983). Constitutive expression of growth factors will provide sustained activation o f cell 
proliferation. This same effect could be achieved by deregulating cell surface growth 
factor receptors. Indeed, a variety of oncogenes encode cell surface growth factor 
receptors such as the truncated epidermal growth factor (EGF) receptor and the colony 
stimulating factor 1 (CSF-1) receptor encoded by the c-erbB and c-ftns oncogenes 
respectively. Oncogenes which encode cell surface growth factor receptors belong to 
the tyrosine kinase and serpentine receptor families (Hunter, 1991). Several proto­
oncogenes, located at the membrane and in the cytoplasm, are involved in mediating 
receptor signalling. Proteins encoded by these genes are protein-tyrosine kinases (for 
example encoded by c-5rc), protein-serine/threonine kinases (for example encoded by c- 
raj) and the membrane-associated G proteins (encoded by the ras family o f oncogenes). 
Proteins encoded by the oncogenes c-fos, c-jun, c-myc and others belong to a class of 
nuclear transcription factors (Eisenman, 1989). These oncoproteins are effectors o f the 
signalling pathways and control the transcription of genes involved in the induction o f
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cell cycle progression. Point mutations or deletions o f these oncogenes can result in 
their constitutive expression leading to continuous cell cycling and uncontrolled growth.
Co-operation between oncogenes occurs between those genes which control different 
signalling pathways (Hunter, 1991). It is possible however that combinations o f certain 
oncogenes controlling the same pathway would be activated to strengthen a particular 
pathway. Synergy often occurs between cytoplasmic and nuclear oncogenes as
exemplified by the co-operation between the ras and myc oncogenes (Land et al., 1983). 
Deregulation of a cytoplasmic oncogene may induce a pathway leading to activation o f a 
second nuclear oncogene i.e. c-fos, which acts on a different set o f target genes (Hunter, 
1991).
Oncogenic co-operation can exist between two nuclear transcription factors. This is 
observed with the c-fos and Q-jun oncogenes (Gillespie, 1991). These genes are 
constitutively activated by gene deletions which result in loss o f normal regulatory 
elements (Hesketh, 1994a). The gene products o f c-jun and c-fos form stable 
heterodimers which enhance the DNA binding affinity o f the c-jun protein to the 
transcription factor AP-1 in order to induce gene transcription (Eisenman, 1989; 
Gillespie, 1991). Constitutive activation of both of these genes may result in 
inappropriate gene expression and uncontrolled proliferation.
The ras family of oncogenes are implicated in a large number of cancers including 
carcinomas, sarcomas and leukaemias indicating that mutation o f ras is a potent 
tumourigenic event. The highly conserved ras family includes the H-ras, K-ras and N- 
ras genes, isolated from Harvey murine sarcoma virus, Kirsten murine sarcoma virus and 
spontaneous tumours respectively (Hesketh, 1994b). These genes encode membrane 
bound G proteins which bind guanine nucleotides and have GTPase activity. The ras 
gene products are signal transducers for cell surface growth factor receptors becoming 
active during growth factor stimulation (Hunter, 1991). Single amino acid substitutions 
constitutively activate the ras gene (Varmus, 1984). Activated ras is thought to co­
operate with tyrosine kinases to cause transformation. It is possible that frequent 
mutation o f the ras oncogene in tumours arises because of the involvement of the gene in
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a large number of signalling pathways. Therefore activation o f the ras oncogene would 
be the equivalent o f two or three oncogenes acting as growth factors or growth factor 
receptors.
1.3.3 The bcl-2 Oncogene.
The bcl-2 oncogene, identified at the t(14;18) translocation breakpoint in follicular 
lymphoma (Bakhshi et a l,  1985), differs from other dominant oncogenes as it does not 
regulate cellular proliferation but rather regulates cell survival through the repression of 
apoptotic cell death (Vaux et al., 1988; Hockenbery et al., 1990). The bcl-2 gene 
inhibits apoptosis in response to a number o f different stimuli (Sentman et al., 1991) 
however it is still not clear how this effect is carried out. A family of Bcl-2-like proteins 
have now been identified including three viral genes (Hacker and Vaux, 1995). Like Bcl- 
2, some of the Bcl-2 family proteins inhibit apoptosis but others, for example the Bax 
protein, have been found to induce cell death (Vaux, 1993; Hacker and Vaux, 1995). It 
is probable that the Bcl-2 family proteins act as a network to regulate apoptosis. Indeed 
it is thought that Bcl-2 must heterodimerise with Bax to suppress cell death. Bax 
homodimers induce cell death, therefore Bcl-2 may protect cells from dying by binding to 
Bax (Oltvai and Korsmeyer, 1994; Hacker and Vaux, 1995). However as other proteins 
have been found to bind both Bcl-2 and Bax, it is likely that regulation o f apoptosis by 
the bcl-2 family is a complex process.
The bcl-2 gene product is a 25 kilodalton integral mitochondrial membrane protein 
(Hockenbery et al., 1990). Consistent with the role o f bcl-2 in repressing cell death, the 
protein has been found to be restricted to long-lived cell types (Hockenbery et a l,  1991; 
Cory, 1995). The bcl-2 gene is found to be expressed in a number o f tissue types 
(Hockenbery et al., 1991) and while expression is not essential for embryonic 
development, it is required to maintain normal homeostasis in adult tissues (Veis et al., 
1993). Deregulation of the bcl-2 gene leads to reduced apoptosis and the accumulation 
o f non-dividing cells (Vaux et al., 1988; McDonnell et a l,  1989; McDonnell et a l,
1990). Overexpression of bcl-2 alone is not a potent oncogenic signal, however it can 
effectively synergise with other oncogenic lesions, particularly overexpression o f the c-
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myc oncogene (Vaux et a l , 1988; Strasser et a l , 1990; McDonnell and Korsmeyer,
1991). It is possible that by prolonging cell survival, bcl-2 contributes to tumourigenesis 
by increasing the cell pool vulnerable to further oncogenic changes.
1.4 T h e  c -m y c  O n c o g e n e .
1.4.1 The myc Oncogene Family.
The w-myc oncogene was first discovered as the transforming sequence in avian 
myelocytoma virus MC29 (Duesberg et a l,  1977). The c-myc gene was subsequently 
isolated and shown to be the cellular homologue of the viral w-myc gene (Vennstrom et 
a l,  1982). Deregulation o f the c-myc proto-oncogene has been frequently associated 
with a large number of diverse neoplasms and has been implicated as having an important 
role in normal cellular growth control (reviewed by Cole, 1986; Marcu et a l,  1992). 
The highly conserved c-myc gene belongs to a family o f /wyc-related genes o f which the 
best characterised are N-myc and L-myc. The N- and L-myc genes, which share limited 
regions o f homology with c-myc, were identified by their overexpression in 
neuroblastoma and small cell lung cancer respectively (Schwab et a l,  1983; Nau et a l,
1985).
1.4.2 The c-myc Gene.
The c-myc gene, like N- and L-myc, has a three exon structure. The first exon has been 
shown to be a long non-coding sequence with important regulatory roles (Spencer and 
Groudine, 1991). Exons 2 and 3 contain the major coding regions. A high degree of 
amino acid homology exists between species especially in the coding regions where, for 
example, the mouse and human genes share over 90% identity (Bernard et a l, 1983). 
Transcriptional initiation occurs at two major promoter sites, PI and P2, and gives rise 
to c-myc mRNA species of approximately 2.4 kb and 2.2 kb respectively (Battey et a l, 
1983; Bernard et a l, 1983). P2 is generally found to be the predominant promoter site 
generating 75-90% of c-myc mRNAs (Stewart et a l,  1984b; Spencer et a l,  1990).
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Expression o f the c-myc gene occurs in normal growing cells, with 10- to 40-fold higher 
mRNA levels in proliferating cells than in quiescent cells (Kelly et a l , 1983; Keath et al.,
1984). Following mitogenic stimulation, c-myc RNA is rapidly induced in the G1 phase 
o f the cell cycle suggesting involvement o f c-myc in the transition from quiescence to 
proliferation (Kelly et al., 1983). Following the initial transient induction, constant levels 
o f c-myc RNA are continuously expressed during proliferation in a cell cycle independent 
manner (Thompson et a l , 1985; Hann et al., 1985). Further evidence that c-myc 
expression was required for cellular growth was provided when transfection o f anti-c- 
myc antibodies in HL60 cells resulted in specific growth inhibition (Iguchi-Ariga et a l,
1987). Moreover, high levels o f c-myc expression correlated with rapidly proliferating 
cells in the late stages of embryonic development (Schmid et al., 1989). The requirement 
for c-myc expression during embryonic development has since been demonstrated by the 
embryonic lethality which occurs in mice homozygous for a c-myc null mutation (Davis 
et a l , 1993).
It has been observed that levels of c-myc expression decrease during cellular 
differentiation in mouse erythroleukaemia cells (Lachman and Skoultchi, 1984). Similar 
observations have been recorded in a number of cell types suggesting that down- 
regulation o f c-myc may be necessary for some cell types to exit cell cycle and undergo 
terminal differentiation (reviewed by Spencer and Groudine, 1991; Marcu et al., 1992). 
Further support for the hypothesis that high levels of c-myc expression maintain cells in 
an undifferentiated form has been provided by transgenic studies. In animals 
overexpressing a c-myc transgene large populations of proliferating cells accumulated 
which did not proceed through the expected differentiation pathway (Langdon et al.,
1986).
It would appear that c-myc expression is controlled by a complex set o f regulatory 
mechanisms operating at various transcriptional and post-transcriptional levels (Spencer 
and Groudine, 1991; Marcu et a l, 1992). Post-transcriptional regulation o f c-myc 
mRNA was found to be important for the transition from growth arrest to proliferation in 
a study by Blanchard et a l (1985). A role for exon 1 in regulating the stability o f mRNA
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has been proposed (Rabbitts et a l,  1985). Another model, not mutually exclusive, is that 
c-myc autosuppression may play a role in the control of c-myc expression at the level o f 
transcriptional initiation (Penn et a l, 1990a). In Burkitt’s lymphoma cells only the 
translocated allele was expressed with no detectable expression o f the normal allele 
(Bernard et a l,  1983). It has been postulated that deregulated expression o f the 
translocated allele shuts down transcription o f the normal allele (Leder et a l,  1983). 
Evidence that the domains required for autosuppression are identical to those required 
for transformation supports this theory (Penn et a l, 1990b).
1.4.3 The c-Myc Protein.
The c-myc gene encodes two major protein products of 439 and 453 amino acids, with 
molecular weights of 64 and 67 kilodaltons (Hann and Eisenman, 1984). The two 
protein products are derived from independent translational initiation sites in the same 
reading frame, the p64 protein initiated at the first AUG in exon 2 and p67 initiated at 
the 3’ end of exon 1 (Hann et a l,  1988). The p64 polypeptide is the major translation 
product found in normal cells (Hann and Eisenman, 1984). Rearrangements in exon 1, 
which occur in many tumour types, result in the loss o f the p67 initiation site and can 
alter the ratio of p64 and p67 proteins in these tumour cells (Hann et a l,  1988).
The c-Myc polypeptides are nuclear phosphoproteins with short half-lives of 20-30 
minutes which localise to the nucleus and can bind to sequence specific DNA (Hann and 
Eisenman, 1984; Stone et a l, 1987; Dang and Lee, 1988; Watt et a l, 1985; Blackwell et 
a l, 1990). A number o f evolutionary conserved regions are important for the function 
o f the c-Myc protein (Stone et a l, 1987; Penn et a l, 1990b; Kato and Dang, 1992). The 
carboxy-terminus which is the most highly conserved domain (Stone et a l,  1987), has 
been shown to contain nuclear localisation signals (Dang and Lee, 1988), a basic region 
important for sequence specific DNA binding, and a helix-loop-helix leucine zipper motif 
(bHLH-LZ) essential for protein dimerisation (Landschulz et a l,  1988; Murre et a l,
1989). The c-Myc protein also contains a functional transactivation domain (Lech et a l, 
1988) which has three independent activation regions and has been mapped to the amino- 
terminus (Kato et a l,  1990). These regions, required for the biological activity of c-Myc
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(Stone et a l , 1987), are characteristic of transcription factors which led to the 
suggestion that c-Myc was involved in transcriptional regulation (Collum and Alt, 1990; 
Luscher and Eisenman, 1990). Sequence specific transactivation by c-Myc has been 
demonstrated confirming the role of c-Myc as a transcription factor (Amin et al., 1993; 
Kretzner et al., 1992; Gu et al., 1993). A role for c-Myc in promoting DNA replication 
has also been suggested in which c-Myc binds to the initiation site o f replication (Iguchi- 
A rigae/a/., 1987).
1.4.4 Max and the Mad Family Proteins.
The c-Myc proteins (as well as N-Myc and L-Myc) form stable heterodimers with Max, 
another bHLH-LZ protein which shares homology to c-Myc (Blackwood and Eisenman, 
1991; Prendergast et a l , 1991). Max is a highly conserved stable nuclear protein which 
is constitutively expressed throughout the cell cycle (Wagner et a l,  1992). Myc and 
Max dimerise through the bHLH-LZ domains and bind to the DNA sequence CACGTG 
through the bHLH-LZ domain of c-Myc (Blackwell et al., 1990; Blackwood and 
Eisenman, 1991; Prendergast et a l, 1991). Dimerisation o f c-Myc to Max is essential 
for all known c-Myc functions including c-Myc transcriptional activation, c-Myc induced 
transformation and c-Myc mediated apoptosis (Amati et al., 1992; Prendergast et al., 
1991; Amati et a l, 1993). Overexpression o f Max can suppress c-Myc/Max 
transactivation (Amati et a l, 1992) as Max, which lacks a transactivation domain, can 
form homodimers which compete with c-Myc/Max dimers to form DNA binding 
complexes (Gu et a l, 1993; Amin et a l, 1993).
A number o f other Myc-like proteins have recently been identified which also form 
dimers with Max (reviewed by Amati and Land, 1994; Henriksson and Luscher, 1996). 
The best characterised of the Mad family proteins are the Mad-1 and Mxi-1 proteins. 
Mad-1 and Mxi-1 are bHLH-LZ proteins which bind the same DNA consensus sequence 
when bound to Max as c-Myc/Max dimers (Ayer et a l, 1993; Zervos et a l, 1993). Mad 
family proteins, which are expressed at low levels in proliferating cells and high levels 
during differentiation (Larsson et a l, 1994; Chin et al., 1995), may antagonize c-Myc 
function by competing with c-Myc for the interaction o f Max during inhibition of growth
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and induction o f differentiation (Ayer et a l , 1993; Zervos et a l , 1993; Henriksson and 
Luscher, 1996). Evidence suggests that Mad-1 and Mxi-1 may mediate antagonist 
activities in part through a putative transcriptional repressor (reviewed by Henriksson 
and Luscher, 1996). Expression of Mad has been found to repress the activity o f c-Myc 
and can suppress oncogenic transformation (Ayer et al., 1993; Chin et al., 1995; Chen et 
al., 1995).
1.4.5 c-Myc, Transcriptional Regulation and Cell Cycle Control.
Expression of the c-myc oncogene is invariably associated with cellular proliferation and 
is downregulated during growth arrest and differentiation (as discussed above and 
reviewed by Marcu et al., 1992; Henriksson and Luscher, 1996). An immediate early 
response gene, c-myc is essential for progression through the G1 phase o f the cell cycle. 
Induced expression of c-myc can also override G1 growth arrest mediated by the RB  and 
p53 tumour suppressor genes (Goodrich and Lee, 1992; Hermeking et a l,  1995). It has 
been proposed that the action of c-Myc on the cell cycle is through the transcriptional 
regulation of genes involved in cellular proliferation (Collum and Alt, 1990; Luscher and 
Eisenman, 1990). It is unclear how c-Myc interacts with the basal transcriptional 
machinery, however the recent demonstration that c-Myc binds to the TATA-binding 
protein (TBP) o f the TFIID transcription initiation complex may provide one possible 
mechanism (Maheswaran et a l, 1994). The transcriptional activation of c-Myc may be 
regulated, at least in part, by the pRb-related p i07 protein which can bind to and 
suppress the transcriptional activation domain of the c-Myc protein (Gu et a l,  1994).
Expression of c-Myc has been correlated with the induction and repression of a number 
genes including the modulation of its own gene expression (Penn et a l,  1990a). Target 
genes which are responsive to c-Myc include the a-prothymosin gene, the ornithine 
decarboxylase (ODC) gene, the p53 tumour suppressor gene, the ECA39 gene and the 
cad gene (reviewed by Henriksson and Luscher, 1996). These genes all possess c- 
Myc/Max response elements. It is anticipated that the number o f genes which are 
regulated by c-Myc may be very large. Recent reports have indicated that c-myc may 
mediate its action on the cell cycle by affecting the expression of G1-phase cyclins, cyclin
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dependent kinases and the cell cycle phosphatase cdc25, therefore allowing progression 
through the restriction point o f the cell cycle (Daksis et a l,  1994; Hanson et a l, 1994; 
Steiner et al., 1995; Galaktionov et a l,  1996). Activation of cyclin D l-cdk4 and cyclin 
E-cdk2 complexes by c-Myc result in the phosphorylation o f the pRb protein and cell 
cycle progression (Hanson et a l,  1994; Steiner et a l , 1995).
1.4.6 c-Myc and Apoptosis.
In addition to its role in mediating cellular proliferation, the c-Myc protein induces 
apoptosis in a number of cell types under conditions of restrained cell growth (Askew et 
a l,  1991; Evan et al., 1992) and is required for T-cell receptor stimulated apoptosis in 
T-cell hybridomas (Shi et al., 1992). Apoptosis is a physiological function o f c-Myc 
which occurs at various points in the cell cycle (Evan et al., 1992) and can be inhibited 
by specific cytokines (Harrington et a l,  1994). Apoptosis induced by c-Myc is also 
abrogated by expression of the bcl-2 survival gene (Fanidi et al., 1992; Bissonnette et 
a l,  1992). The domains of the c-Myc protein required for the execution c>f the apoptotic 
pathway are identical to those domains necessary for transformation, tramsactivation and 
DNA binding, specifically the bHLH-LZ and transactivation domains (Ev&n et al., 1992; 
Stone et a l, 1987). Dimerisation with Max is also essential for c-Myc indluced apoptosis 
(Amati et a l,  1993; Bissonnette et al., 1994). The ODC gene which is a direct target o f 
c-Myc transactivation has been shown to be a mediator of c-Myc-indiuced apoptosis 
(Packham and Cleveland, 1994). Several reports have also demonstratejd that the p53 
tumour suppressor gene may be required for c-Myc induced apoptosis, at least in certain 
cell types (Hermeking and Eick, 1994; Wagner et al., 1994; Saito and (Ogawa, 1995). 
The apoptotic function of the c-Myc protein cannot be separated from its role in cellular 
proliferation. It has been suggested that the outcome o f these conflicting signals in the 
cell context is modulated by other cellular events (Evan and Littlewood, 1993). Proteins 
which inhibit apoptosis therefore would be expected to be potent myc collaborators in 
tumourigenesis, as has been found with the bcl-2 oncogene (Fanidi et al., 1992; 
Bissonnette et a l, 1992).
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1.4.7 c-myc and Tumourigenesis.
Deregulated expression of the c-myc oncogene, which occurs by a variety o f mechanisms 
(reviewed by Cole, 1986; Eisenman, 1989), results in the promotion o f unrestrained 
growth. The domains required for the transforming properties o f the c-myc oncogene 
are the same as those important for the functional activity o f c-myc (Stone et al., 1987). 
Abnormal c-myc expression can result from chromosomal translocations, gene 
amplification and proviral insertions in a variety of tumour types. Amplification of the c- 
myc gene has been observed in a number o f human tumours and is particularly associated 
with advanced stages of malignancy (Little et a l, 1983; Yokota et a l, 1986). 
Amplification of the N-wyc oncogene has similarly been associated with aggressive 
neuroblastomas (Brodeur et a l, 1984). In Burkitt’s lymphoma and mouse 
plasmacytomas, specific chromosomal translocations link the c-myc gene to the 
regulatory elements of immunoglobulin genes (Taub et a l,  1982; Leder et a l, 1983). 
Exon 1 is often deleted or mutated during these translocations giving rise to deregulated 
c-myc transcriptional regulation and elevated expression (Spencer and Groudine, 1991). 
The loss of exon 1 may effect the stability o f c-myc mRNA which could account for the 
increased levels of c-myc in Burkitt’s lymphoma (Rabbitts et a l, 1985). Expression 
levels in the transformed cells were found to be as high, but not necessarily higher than 
the levels of mRNA in normal proliferating cells (Keath et a l,  1984). Therefore, 
deregulation of the c-myc gene in these tumours resulted in constitutive expression rather 
than overexpression.
Proviral insertion by slow transforming retroviruses in murine and feline T-cell 
lymphomas and in avian B-cell lymphomas frequently results in deregulated c-myc 
expression (Selten et a l, 1984; Neil et a l, 1984; van Lohuizen and Berns, 1990). 
Insertion of retroviral sequences near to, or within the c-myc locus leads to disruption of 
exon 1 and the normal transcriptional regulation o f c-myc. This was first observed in 
avian leukosis virus (ALV)-induced lymphomas when the ALV provirus inserted its 
promoter sequences adjacent to the endogenous c-myc gene, placing the cellular gene 
under the control of the viral promoter and augmenting c-myc expression (Hayward et 
a l,  1981).
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The transforming ability o f c-myc has been confirmed using cell culture studies and 
transgenic animals. Transfection o f v-myc and rearranged c-myc genes can immortalise 
rat embryo fibroblast cells (Mougneau et a l, 1984). In addition the c-myc gene has been 
shown to cooperate with an activated ras oncogene to transform primary cells (Land et 
al., 1983). Constitutive expression o f c-myc in transgenic mice has provided direct 
evidence that this proto-oncogene can contribute to tumourigenesis in a number o f cell 
types (Adams etal., 1985; Stewart etal., 1984a; Adams and Cory, 1991a; Morgenbesser 
and DePinho, 1994). These transgenic models will be discussed in section 1.7.
1.5 T u m o u r  S u p p r e s s o r  G e n e s .
Tumour suppressor genes, also referred to as anti-oncogenes and recessive oncogenes, 
are involved in the negative regulation of cell growth. The normal function o f these 
genes can be thought of as the antithesis to the role o f oncogenes which act to positively 
regulate cellular proliferation. Loss of wild type function o f these genes provides a 
distinct growth advantage during cellular transformation. Tumour suppressor genes 
have been found to be functionally inactivated in a variety o f human tumours. Mutations 
at tumour suppressor loci are however generally recessive to the normal allele and 
require functional loss of both copies of the gene in order to promote tumourigenesis. 
Indeed it has been the characteristic loss of heterozygosity at tumour suppressor loci, 
involving deletion of one allele and mutation of the remaining allele, that has become the 
classical way of identifying these genes in human cancers (Ponder, 1988). A number of 
tumour suppressor genes have now been identified and characterised. The products of 
these genes function in a variety o f different ways from transcriptional activation to cell 
adhesion in order to control normal cell growth (Skuse and Ludlow, 1995).
The concept of tumour suppressor genes originated from studies by Knudson on the 
statistical analysis of the childhood cancer retinoblastoma. Knudson proposed that the 
development of both hereditary and sporadic forms o f retinoblastoma required two 
mutational events (Knudson, 1971), and that the same genetic mutations were required
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for both forms (Knudson, 1985). It was suggested that the early onset of bilateral, 
multifocal tumours characteristic of hereditary retinoblastoma was the result o f an 
inherited germline mutation and second mutation occurring in a limited number o f 
somatic cells. In non-hereditary retinoblastoma, two somatic mutations would have to 
occur in a single cell consistent with the later onset of unilateral sporadic tumours. 
Comings extended Knudson’s hypothesis by suggesting that the two mutations should 
occur in both alleles of the same regulatory gene, with the first mutation recessive to the 
normal allele (Comings, 1973). Historically, two lines of investigation have led to the 
identification of tumour suppressor genes, somatic cell hybridisation studies and genetic 
analysis of familial and sporadic human cancers.
1.5.1 Cell Hybrids.
A key observation made from experiments on somatic cell hybridisation was that fusion 
of a malignant cell with a normal cell often produced a hybrid in which the malignant 
phenotype was suppressed (Harris, 1988; Stanbridge and Cavenee, 1989). It was 
deduced that repression of the tumourigenic state was due to genetic information 
inherent to the normal cells. Reversion to the tumourigenic state could be induced by 
subsequent chromosomal loss from the hybrid cell, indicative of suppressor activity at the 
lost site (Harris, 1988). Microcell fusion experiments involving the transfer of single 
chromosomes from normal cells to cancer cells have provided a direct test to assess the 
suppressive nature o f specific chromosomes. Introduction of human chromosome 11 for 
example, can suppress the tumourigenic phenotype of a tumour cell line (Weissman et 
al., 1987).
1.5.2 Tum our Suppressor Genes and Hum an Cancers.
Cytogenetic and DNA polymorphic analyses o f familial cancers have provided much of 
the evidence to support the existence of tumour suppresssor genes. Germline loss of 
genetic material at specific chromosomal loci has been demonstrated for various 
hereditary cancers including retinoblastoma, Wilms’ tumour, neurofibromatosis and 
colorectal carcinoma (reviewed by Stanbridge and Cavenee, 1989; Marshall, 1991; Skuse
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and Ludlow, 1995). Furthermore, loss of heterozygosity involving somatic mutation or 
deletion o f the normal allele often occurs at these loci in the tumours o f affected 
individuals (Ponder, 1988). It is the absence of functional genes identified at these 
tumour suppressor loci which contributes to the tumourigenic phenotype o f familial 
cancers. A variety of non-familial malignancies have also demonstrated homologous 
allelic inactivation at specific chromosomal sites (Ponder, 1988). In tumours where both 
hereditary and sporadic forms exist it is generally the same chromosomal locus which is 
inactivated, although in sporadic cancer both alleles are inactivated somatically. The first 
tumour suppressor gene to be identified was the retinoblastoma susceptibility gene (RB). 
Consistent with Knudson’s hypothesis, familial retinoblastoma had a germline mutation 
which predisposed to neoplasia, with homologous loss of alleles at this locus in 
retinoblastoma tumours (Cavenee et a l,  1983). A functional gene was mapped to this 
locus which was inactivated in the tumours, but not normal tissues, o f affected 
individuals (Friend et al., 1986; Lee et al., 1987a).
Similar to retinoblastoma, homologous loss of alleles was demonstrated in patients with 
sporadic and familial Wilms’ tumour, an embryonal malignancy o f the kidney (Koufos et 
al., 1984; Fearon et al. , 1984). However more than one tumour suppressor locus may 
be involved in Wilms’ tumour making it more complex than retinoblastoma. Two loci on 
chromosome 11, 11 p i3 and 11 p i5, and a site on chromosome 16 have been implicated 
in Wilms’ tumourigenesis (Henry et al., 1989; Maheswaran and Haber, 1995). Although 
multiple genetic loci have been associated with Wilms’ tumour, only one tumour 
suppressor gene has been extensively characterised. The Wilms’ tumour gene (WT1), 
localised to chromosome 11 p 13, is found to be deleted in Wilms’ tumours (Rose et al., 
1990; Gessler et al., 1990; Call et al., 1990) and when re-introduced into a Wilms’ 
tumour cell line can suppress the tumourigenic phenotype (Weissman et al., 1987). The 
WT1 gene encodes a zinc-finger protein (Call et al., 1990; Gessler et al., 1990) which 
functions as a repressor of gene transcription, a property which is lost in tumour cells 
(Madden et al., 1991; Drummond et al., 1992).
Allelic deletions at chromosome 17 led to the hypothesis that a tumour suppressor gene 
was involved in the development of neurofibromatosis type 1 (NF1), the most common
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hereditary condition predisposing to neoplasia (Skuse et al., 1989). The NF1 gene, 
localised to chromosome 17pl 1 (Barker et al., 1987; Fountain et al., 1989; O’Connell et 
al. , 1989), was found to encode a GTPase-activating protein, neurofibromin, which 
interacted with the ras gene product (Xu et al., 1990). Neurofibromin acts by 
converting the active form of RAS to the inactive form, consequently inhibiting RAS 
stimulation o f cell proliferation (Xu et al., 1990). More than fifty germline NFJ 
mutations have been described which are presumed to disrupt or inactivate 
neurofibromin (Colman and Wallace, 1995). Specific loss o f alleles from chromosome 
22 (Seizinger et al., 1987) suggested that inactivation o f a tumour suppressor gene was 
also involved in neurofibromatosis type 2 (NF2), a distinct autosomal disorder from NF1 
(Colman and Wallace, 1995). The NF2 tumour suppressor gene located at chromosome 
band 22q 11 (Seizinger et al., 1987; Trofatter et al., 1993), encodes a protein, merlin, 
which shares homology with a family of proteins proposed to link cytoskeletal 
components with proteins in the cell membrane (Trofatter et al., 1993). Merlin is 
expressed widely in normal cells and deleted in NF2 tumours.
Several tumour suppressor loci have been identified in hereditary and sporadic colorectal 
carcinoma. Loss o f a region of chromosome 5q in colorectal tumours o f patients with 
familial adenomatous polyposis (FAP), an inherited disorder characterised by the 
presence o f multiple colonic polyps, suggested involvement o f a putative tumour 
suppressor gene at this locus (Leppert et al., 1987; Bodmer et al., 1987). The FAP 
gene, APC (adenomatous polyposis coli) was cloned and shown to be inactivated in the 
early stages o f both FAP and sporadic colorectal cancer (Nishisho et al., 1991; Kinzler et 
al., 1991). The APC gene product associates with p-catenin and may facilitate the 
interaction between catenins and cadherin, a cell surface protein important for cellular 
adhesion (Su et al., 1993). Enhanced intercellular adhesion may prevent independent 
growth o f epithelial cells. It has been proposed that APC may play a role in intercellular 
communication via enhanced cellular adhesion and also in intracellular communication 
from the cell surface to the site o f microtubule formation (Dunlop, 1995). Recognition 
o f homologous allelic loss at two other chromosomes, 17 and 18, suggested that more 
than one tumour suppressor gene was involved in FAP (Law et al., 1988; Fearon and 
Vogelstein, 1990). Allelic deletions o f these loci were found to be a frequent event in
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colorectal carcinoma and occurred at a late stage in the progression of tumourigenesis 
(Fearon and Vogelstein, 1990; Fearon et a l, 1990). The p53 tumour suppressor gene 
was identified as the gene at position 17p (Baker et a l, 1989), and DCC (deleted in 
colorectal cancer) as the gene at chromosome 18q (Fearon et a l,  1990). Indicative o f a 
tumour suppressor gene, DCC was expressed in most normal tissues including colonic 
mucosa, but was greatly reduced or absent in most colorectal carcinomas. The DCC 
gene product is found to be a cell surface protein and has been implicated in the 
promotion and maintenance of normal cellular differentiation (Hedrick et a l,  1994). 
Loss o f alleles at chromosomes 5, 17 and 18 have been described for sporadic colorectal 
carcinoma as well as for FAP (Solomon et a l, 1987; Vogelstein et a l,  1989; Fearon and 
Vogelstein, 1990).
A second, more common, form of familial colorectal carcinoma is hereditary 
nonpolyposis colorectal cancer (HNPCC). Two tumour suppressor loci have been 
identified for HNPCC, MSH2 at chromosome 2 (Peltomaki et a l,  1993; Fishel et a l, 
1993) and MLH1 at chromosome 3p (Papadopoulos et a l, 1994). Both o f these genes 
have been implicated in DNA repair mechanisms suggesting that mutations in these genes 
may lead to an increased accumulation rate of spontaneous mutations (Dunlop, 1995).
Genetic linkage studies have led to the identification o f two breast cancer genes which 
confer susceptibility to hereditary breast cancer, BRCA1 on chromosome 17q (Miki et 
a l,  1994) and BRCA2 on chromosome 13q (Wooster et a l, 1994). Mutation o f the 
BRC.Al tumour suppressor gene is thought to affect half o f those families with an 
inherited breast cancer syndrome and most families with early-onset breast and ovarian 
cancer syndrome (Miki et a l, 1994). BRCA2 has been associated with early-onset 
hereditary breast cancer and male breast cancer but has a lower ovarian cancer risk than 
BRCA1 (Wooster et a l,  1994). Loss of heterozygosity at the BRCA1 and BRCA2 loci 
have been described for both familial and sporadic breast cancers (Bishop, 1995; Cleton- 
Jansen et a l, 1995; Collins et a l, 1995).
Some tumour suppressor loci have been associated with more than one form of cancer. 
Allelic deletions of chromosome 3 for example, were reported in renal cell carcinoma
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(Zbar et al., 1987; Kovacs et al., 1988) and small cell lung cancer (Naylor et a l, 1987). 
The p53 tumour suppressor gene has also been associated with an extensive number o f 
sporadic and hereditary cancers (Nigro et a l,  1989; Hollstein et a l,  1991; Greenblatt et 
a l,  1994). Loss of p53 has been implicated in the familial Li-Fraumeni syndrome 
(Malkin et a l,  1990; Srivastava et a l, 1990) and may be important for the development 
o f malignant, but not benign, hereditary NF1 tumours (Menon et a l,  1990) and for the 
progression of familial colorectal carcinoma (Fearon and Vogelstein, 1990). The role of 
p53 in Li-Fraumeni syndrome and sporadic tumours is discussed in section 1.6.2.
More recent has been the identification o f the MTS1 (multiple tumour suppressor 1) 
gene, localised to chromosome 9p21. MTS1 was found to be inactivated in a variety o f 
tumour cell lines by homozygous deletion or mutation (Kamb et a l,  1994) or by DNA 
methylation (Merlo et a l, 1995). The MTS1 gene encodes a cell cycle protein, p i6, 
which has been shown to negatively regulate cell cycle progression by binding to and 
inhibiting cyclin-dependent kinase 4 (cdk4) activity (Serrano et a l,  1993).
1.5.3 The Retinoblastoma Tum our Suppressor Gene.
The retinoblastoma susceptibility gene (RB) is probably the best characterised of all the 
tumour suppressor genes. The RB gene has been found to be functionally inactivated in 
both hereditary and sporadic forms of retinoblastoma (reviewed by Gallie et a l,  1995; 
Goodrich and Lee, 1990), and in a limited number o f sporadic tumour types including 
breast cancer, small cell lung cancer, osteosarcomas and soft tissue sarcomas (Lee et a l, 
1988; Harbour et a l,  1988; Horowitz et a l, 1990; Weichselbaum et a l,  1988). 
Consistent with loss of heterozygosity at chromosomal position 13ql4 in retinoblastomas 
(Cavenee et a l, 1983), the RB gene was mapped to this locus (Friend et a l,  1986; Lee et 
a l, 1987a). RB was found to be expressed in a variety o f tissues, including normal 
retina, but was absent in retinoblastoma tumours and cell lines (Friend et a l,  1986; Lee 
et a l, 1987a; Horowitz et a l, 1990). These studies suggested that inactivation o f RB 
was important for deregulated cell growth and tumourigenesis. This was confirmed by 
Huang et a l,  (1988) who demonstrated that replacement of wild type RB into a 
retinoblastoma cell line lacking functional RB, resulted in growth suppression and a
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reduction in tumourigenicity. Furthermore, the transforming abilities o f several DNA 
tumour viruses were found to be dependent on the inactivation o f RB through the 
binding of viral oncogenes to the RB gene product (Whyte et al., 1988; DeCaprio et al., 
1988; Dyson et al., 1989). These studies suggested that oncogenic viruses may cause 
cancers by sequestering the products o f tumour suppressor genes.
The RB gene product (pRb), a nuclear phosphoprotein with DNA binding affinity (Lee et 
a l, 1987b), negatively regulates cell proliferation by inhibiting cell cycle progression 
(Goodrich et al., 1991). The pRb protein exists in multiple phosphorylation states; 
underphosphorylated in the G0/G1 phase of the cell cycle and hyperphosphorylated in S, 
G2 and M phases (DeCaprio et al., 1989; Mihara et al., 1989; Ludlow et al., 1990). The 
function of pRb is regulated by cell cycle-dependent phosphorylation with protein 
phosphorylation coincident with the onset of DNA replication (DeCaprio et al., 1989; 
Mihara et a l, 1989; Ludlow et a l, 1990). Modulation of pRb phosphorylation occurs 
via cyclin-dependent kinases, cdks (Hinds et a l,  1992; Akiyama et a l,  1992; Gallie et 
a l,  1995). Significantly, the p 16 tumour suppressor protein was found to inhibit pRb 
phosphorylation by blocking cdk4 activity (Serrano et al., 1993), suggesting that p l6  and 
pRb may act on the same tumour suppressor pathway. This hypothesis would explain 
why inactivation of both p i 6 and pRb proteins do not tend to occur in the same tumour 
cells but rather exhibit an inverse relationship (Whitaker et a l, 1995; Kaye et al., 1995).
It has been proposed that pRb functions to control gene transcription in association with 
the cellular E2F transcription factor (Chellappan et a l, 1991; Weintraub et a l,  1992; 
Nevins, 1992). Unphosphorylated pRb, when bound to E2F in G l, interferes with the 
transcriptional activation capacity o f E2F, preventing transcription o f genes that are 
required for cell proliferation. The pRb protein has been shown to have a role in the 
transcriptional regulation of certain cellular growth control genes including c-fos, 
interleukin 6, cyclin D1 and c-myc (Robbins et a l, 1990; Santhanam et al., 1991; Muller 
et al., 1994; Adnane and Robbins, 1995). Physical interaction o f viral oncoproteins with 
pRb (Whyte et a l, 1988; DeCaprio et a l, 1988; Dyson et al., 1989) functionally 
inactivates pRb by blocking association o f pRb with E2F thereby promoting 
transcriptional activation o f genes important for cell cycle progression (Nevins, 1992).
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Binding of the cellular oncoprotein MDM2 to the pRb protein can also perturb the 
growth regulatory function of pRb and relieve suppression o f E2F transcriptional activity 
(Xiao et a l , 1995). The transcriptional regulation o f gene expression by pRb in G1 o f 
the cell cycle is an important aspect of pRb tumour suppression. Recent investigations 
however have indicated that the pRb protein may also play a role in suppressing 
apoptosis (Haas-Krogan et a l , 1995; Haupt et a l,  1995). Consistent with these 
observations, extensive apoptosis was reported to occur in mice which lacked a 
functional RB gene (Clarke et al., 1992). The pRb protein can therefore function to 
inhibit proliferation, tumourigenesis and apoptosis.
1.6 T h e  p 53 T u m o u r  Su p p r e s s o r  G e n e .
1.6.1 Background.
The p53 phosphoprotein, initially classified as a tumour specific antigen, was first 
identified as a cellular protein which was bound by SV40 large T antigen in virally 
transformed murine cells (Lane and Crawford, 1979; Linzer and Levine, 1979) and was 
present in chemically induced sarcomas and spontaneously transformed fibroblasts 
(DeLeo et a l,  1979). An accumulation of the p53 protein was subsequently described in 
a range of spontaneous, chemically and virally induced murine and human tumours, and 
transformed cell lines (Crawford et a l, 1981; Rotter, 1983; Crawford, 1983). Although 
early reports had been unable to detect p53 in normal tissues, it was found to be present 
albeit at much lower levels than in transformed cells (Dippold et a l, 1981; Benchimol et 
a l, 1982; Crawford, 1983). This is due to a very short half life of the protein in normal 
cells and post-translational stabilisation in transformed cells (Oren et a l,  1981; 
Crawford, 1983; Rogel et a l, 1985). The p53 protein was thought to be a dominant 
oncogene with reports that genomic and cDNA clones o f p53 could immortalise cells of 
finite lifespan (Jenkins et a l, 1984; Rovinski and Benchimol, 1988) and cause 
immortalised cells to become tumourigenic (Eliyahu et a l, 1985). Furthermore, these 
p53 clones were shown to co-operate with the ras oncogene in the transformation of 
primary rat fibroblasts (Jenkins et a l, 1984; Parada et a l,  1984). However, it transpired
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that the p53 clones which co-operated with ras to transform cells were mutant forms o f 
the wild type protein and that wild type p53 did not have a transforming role in co­
operation with ras (Finlay et a l, 1988; Hinds et a l, 1989). Indeed wild type p53 was 
found to inhibit oncogene-mediated cellular transformation (Eliyahu et a l,  1989; Finlay 
e ta l ,  1989).
Reports that the p53 protein could suppress transformation and that point mutations in 
the gene abrogated this activity, led to the suggestion that the wild type p53 gene may 
function as a recessive oncogene or tumour suppressor gene (Finlay et a l,  1989; Eliyahu 
et a l,  1989; Lane and Benchimol, 1990). Several lines o f investigation were consistent 
with this hypothesis. It had been observed that the p53 gene was frequently mutated and 
inactivated in Friend virus-induced murine erythroleukaemia cell lines suggesting that 
loss o f p53 activity, rather than gain o f activity, was important for the malignant 
transformation of these cells (Mowat et a l, 1985; Chow et a l, 1987; Ben-David et a l,
1988). The p53 gene was similarly inactivated in cell lines transformed by Abelson 
murine leukaemia virus (Wolf and Rotter, 1984). Moreover, Vogelstein and colleagues 
reported that both alleles o f the p53 gene were inactivated in colorectal cancer, a 
trademark of tumour suppressor genes (Baker et a l, 1989). This group further 
determined that the p53 gene was frequently deleted and mutated in a range o f diverse 
tumour types (Nigro et a l, 1989). Transfection of wild type protein into a variety o f cell 
types inhibited cellular proliferation confirming that p53 could act to suppress cell 
growth (Baker et a l, 1990b; Chen et a l, 1990; Diller et a l,  1990; Mercer et a l, 1990). 
Definitive proof of tumour suppressor activity was later provided by Donehower and 
colleagues with the generation of mice deficient for endogenous p53 function 
(Donehower et a l, 1992). These animals developed normally suggesting that the p53 
gene was not essential for development but were highly susceptible to spontaneous 
tumour development in a range o f different tissues.
1.6.2 p53 and Human Cancer.
Alterations at the p53 tumour suppressor gene have been described for an extensive 
number o f tumour types (Nigro et a l, 1989; Bartek et a l,  1991; Hollstein et a l, 1991;
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Jego et al., 1993; Greenblatt et a l , 1994). The number of reports detailing mutations of 
p53 in human tumours has been overwhelming and has earned p53 the reputation as the 
most commonly altered genetic lesion in human cancer. By contrast, most other tumour 
suppressor genes are inactivated in only one or a few tumour types. This suggests that 
p53 plays a critical role in controlling oncogenesis in numerous tissues. Point mutations, 
deletions and aberrant expression of the p53 gene have been described for colorectal 
carcinoma, breast carcinoma, lung cancer, head and neck tumours, leukaemia and others 
(Baker et al., 1989; Bartek et a l, 1990; Cheng and Haas, 1990; Iggo et a l , 1990; 
Ahomadegbe et a l , 1995). Inactivation of p53 has also been linked to the hereditary Li- 
Fraumeni syndrome (LFS), a familial condition which predisposes kindred at an early age 
to a range of tumour types including breast cancer, sarcomas, brain tumours and 
leukaemia. Kindred often develop two or more of these tumour types. Two groups o f 
workers independently reported that LFS was associated with an inherited mutation in 
the p53 tumour suppressor gene (Malkin et a l , 1990; Srivastava et a l , 1990). 
Furthermore, tumours o f affected individuals had lost the remaining wild type p53 allele. 
The spectrum of tumours in LFS is consistent with the spectrum of sporadic tumours 
associated with loss of p53 function (Malkin e ta l , 1990; Srivastava et a l , 1990).
As is characteristic of tumour suppressor genes, loss o f p53 function is often associated 
with inactivation of both alleles. This has been reported for several tumour types where 
loss o f one p53 allele is accompanied by mutation or deletion at the second allele (Nigro 
et a l , 1989; Baker et a l , 1989; Sakashita et a l , 1992). Loss o f heterozygosity at the 
p53 locus has been found to be important for neoplastic progression, often occurring as a 
late event in tumourigenesis and correlated with poor clinical prognosis (Baker et a l , 
1990a; Malkin et a l , 1990; Ichikawa et a l , 1992; Dohner et a l , 1995). Alterations at 
the p53 gene can also occur as an early event, as has been described for small cell lung 
cancers and head and neck tumours (Kaye et a l, 1995; Ahomadegbe e ta l , 1995).
1.6 .3  Interaction of p53 with Viral and Cellular Proteins.
The p53 gene, like the RB gene, was found to be inactivated in virally transformed cells. 
SV40 large T antigen, adenovirus E1B 55kDa protein and human papillomavirus (HPV)
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types 16 and 18 E6 proteins all complex with the p53 protein (Lane and Crawford, 1979; 
Linzer and Levine, 1979; Sarnow et a l , 1982; Werness et a l , 1990). SV40 large T 
antigen and E1B 55kDa protein stabilise the p53 protein and sequester its tumour 
suppressor activity (Lane and Crawford, 1979; Levine, 1990; Yew and Berk, 1992) 
while the HPV E6 protein promotes p53 protein degradation (Scheffner et a l , 1990). 
There is no selection for p53 gene mutations in virally transformed cells as the viral 
proteins neutralize the tumour suppressor activity o f wild type p53. This is seen with 
cervical carcinoma cell lines where the presence of mutant p53 proteins is detected in 
HPV negative lines but not in HPV positive cell lines (Scheffner e ta l , 1991).
Similar to the action of viral oncoproteins, a cellular protein has been identified which 
complexes with wild type p53 and inactivates its tumour suppressor function (Barak and 
Oren, 1992; Oliner et a l , 1992; Momand et a l , 1992). The murine double minute 2 
(MDM2) oncogene has been found to be amplified in several human sarcomas (Oliner et 
a l , 1992). It was reported that overexpression of MDM2 protein exists only in cells 
with wild type p53 and does not co-exist in cells with mutant p53 (Oliner et a l , 1992; 
Zhou et a l , 1995). MDM2 may provide an alternative method o f inactivating the p53 
tumour suppressor gene in spontaneously occurring tumours.
1.6.4 p53 Gene Structure and Protein Properties.
The highly conserved p53 gene is comprised of 11 exons, the first o f which is non­
coding, and has been localised to human chromosome 17pl3 (Lamb and Crawford, 
1986; Isobe et a l , 1986; Miller et a l , 1986). There are two p53 genes in the mouse 
genome, a functional gene on chromosome 11 and an inactive tpseudogene on 
chromosome 14 (Czosnek et a l , 1984; Rotter et a l , 1984). The human p53 gene spans 
20kbp and encodes a protein o f 393 amino acids with molecular weight 53 kDa as 
determined by SDS-polyacrylamide gel electrophoresis (Harlow et a l , 1985; Lamb and 
Crawford, 1986). The functional murine gene has 11 exons and encodes a protein of 
390 amino acids which, like the human protein, is rich in proline residues (Bienz et a l , 
1984; Pennica et a l, 1984).
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The proteins encoded by the mouse, human, Xenopus laevis and several other species 
share a high degree o f amino acid sequence homology (Pennica et a l , 1984; Harlow et 
al., 1985; Soussi et a l , 1987; Soussi, 1995). The p53 protein consists o f a highly 
charged acidic amino terminus, a hydrophobic proline rich central region and a highly 
charged basic carboxy-terminus. A cluster of three nuclear localisation domains 
(Shaulsky et a l , 1990b; Shaulsky et a l, 1991b) and an oligomerisation domain (Milner 
et a l,  1991; Shaulian et a l,  1992) have been located at the carboxy-terminus o f the 
protein which also exhibits DNA binding activity (Steinmeyer and Deppert, 1988; Kern 
et a l, 1991; Shohat Foord et a l, 1991; Foord et a l, 1993). A transactivation domain 
has been mapped to the p53 amino terminus (O’Rourke et a l,  1990; Fields and Jang, 
1990; Raycroft et a l,  1990). Five regions of the p53 protein have been highly conserved 
throughout evolution (Soussi, 1995). These regions, referred to as domains I, II, III, IV 
and V, are frequent targets for ‘hot spot’ mutations in human malignancies (Nigro et a l, 
1989; Hollstein et a l,  1991). Indeed, 95% o f mutations recorded in human tumours are 
located in the central region of the protein which contains four o f the five highly 
conserved domains (Soussi, 1995). A sequence specific DNA binding domain has been 
mapped to the highly conserved central core o f p53 (Pavletich et a l,  1993; Bargonetti et 
a l, 1993; Wang et a l,  1993c). The DNA binding function o f p53 is necessary for 
tumour suppressor activity and can be activated by phosphorylation, carboxy-terminus 
truncation and small peptides (Hupp e ta l,  1992; 1995).
Although the subcellular location of p53 varies throughout the cell cycle (Shaulsky et a l, 
1990a), the tumour suppressor activity of p53 requires nuclear localisation (Shaulsky et 
a l, 1991b). Wild type p53, but not mutant p53, functions as a transcription factor 
activating gene expression when bound to a p53 specific DNA sequence (Kern et a l, 
1991; Farmer et a l,  1992; Kern et a l, 1992). Mutant p53 proteins, SV40 large T 
antigen, adenovirus E1B 55Kb and MDM2 can inhibit p53-mediated transcriptional 
activation either by blocking DNA binding or by concealing the activation domain 
(Shaulian et al, 1992; Farmer et a l, 1992; Yew and Berk, 1992; Oliner et a l,  1993). 
Genes which do not contain a p53 specific DNA consensus sequence can be 
transcriptionally repressed by wild type p53 (Ginsberg et a l, 1991; Seto et a l,  1992). 
The p53 protein does not directly bind to gene promoters during transcriptional
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repression but binds to the TATA binding protein which interferes with the formation o f 
the transcription preinitiation complex (Seto et a l, 1992; Ragimov et al., 1993). It has 
been suggested that the carboxy-terminus o f the p53 protein is necessary for 
transcriptional repression whereas the amino-terminus is important for transcriptional 
activation (Sang e ta l,  1994; Shaulian e ta l,  1995).
Alteration o f p53 by mutation generally results in loss of wild type protein function (Lane 
and Benchimol, 1990; Levine et a l,  1991). Several differences between the wild type 
and mutant proteins exist (Zambetti and Levine, 1993). Wild type p53 functions as a 
growth suppressor whereas mutant proteins fail to inhibit growth (Hinds et a l,  1989; 
Zambetti and Levine, 1993). Mutant proteins are unable to function as transcriptional 
activators or transcriptional repressors (Raycroft et a l, 1990; Kern et a l, 1992; Seto et 
a l, 1992; Deb et a l, 1992). In general, wild type p53 has a much shorter half life than 
the mutant proteins of transformed cells (Crawford, 1983) although the half life o f wild 
type p53 can be prolonged when complexed to viral proteins (Levine, 1990). Mutant 
p53 proteins have an altered conformational state compared to wild type p53 which can 
be assessed using monoclonal antibodies (Gannon et a l, 1990; Milner and Watson, 
1990). Mutant proteins, unlike wild type p53, fail to bind to viral proteins (Levine,
1990) but have been found to form complexes with heat shock proteins (Pinhasi-Kimhi 
et a l, 1986; Sturzbecher et a l, 1988). Wild type p53, in contrast does not associate 
with heat shock proteins (Pinhasi-Kimhi et a l, 1986; Sturzbecher et a l, 1988). Mutant 
p53 proteins have been shown to form oligomers with the wild type p53 protein and can 
sequester its growth suppressing activity in a dominant negative fashion (Gannon et a l, 
1990; Milner et a l, 1991; Shaulian et a l, 1992). In this way only one allele would need 
to be mutated for loss or reduction of suppressor function in human tumours. In 
addition to loss of function, some p53 mutants have demonstrated a gain of function and 
can directly promote cellular growth in a dominant oncogenic manner. This was 
observed when mutant p53 was introduced into cells which lacked endogenous wild type 
p53 protein resulting in enhanced tumourigenic potential o f the cells (Dittmer et a l,
1993).
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1.6.5 p53, DNA Damage and Cell Cycle Growth Arrest.
Although early studies had suggested a role for p53 in positively modulating growth and 
cell cycle progression (Milner and Milner, 1981; Mercer et al., 1982; Reich and Levine, 
1984; Shohat et a l, 1987) it was soon recognised that overexpression of wild type p53 
in a variety of cell types inhibited cellular proliferation and abrogated cell cycle 
progression by inducing a G1 growth arrest (Baker et al., 1990b; Chen et al., 1990; 
Diller et a l,  1990; Mercer et a l,  1990; Michalovitz et a l, 1990). It has been proposed 
that the activity o f p53 as a promoter and suppressor o f growth is regulated by 
conformational alterations, possibly mediated by phosphorylation (Bischoff et al., 1990; 
Sturzbecher et a l, 1990; Hupp et a l, 1992; Picksley et a l, 1992; Ullrich et al., 1992). 
Consistent with its role in suppressing cellular proliferation, p53 has also been found to 
induce maturation (Kastan et a l, 1991b), differentiation (Shaulsky et al., 1991a) and 
apoptosis (Yonish-Rouach et a l, 1991; Shaw et a l, 1992).
Over the last few years the role of p53 in the response to DNA damage has been 
intensively studied. Levels o f wild type p53 increase following treatment with UV 
radiation and other DNA damaging agents (Maltzman and Czyzyk, 1984; Kastan et al., 
1991a; Fritsche et a l, 1993; Lu and Lane, 1993). It has been proposed that the C- 
terminus of p53 binds to the damaged DNA which stabilizes the protein accounting for 
the accumulation of p53 protein levels in damaged cells (Lee et a l,  1995). Observations 
that enhanced levels o f p53 were coincident with a reversible G1 growth arrest suggested 
that p53 functioned as a G1 cell cycle checkpoint following DNA damage (Kastan et al., 
1991a; Kuerbitz et a l, 1992; Kastan et al., 1992). These studies led Lane (1992) to 
postulate that p53 acted as a guardian o f the genome maintaining DNA integrity in 
response to genetic insult. By mediating a cell cycle arrest, p53 provided time for DNA 
to repair prior to cell division. Lane further suggested that cells with inactivated p53 
would be unable to elicit the DNA damage response pathway which would result in an 
accumulation of genetically unstable cells. This hypothesis was supported by studies 
showing a correlation between loss of p53 cell cycle control and genetic instability (Yin 
et a l, 1992; Livingstone et a l,  1992). Re-introduction o f wild type p53 into these cells 
restored cell cycle control and reduced the frequency of gene amplification (Yin et al.,
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1992). It is probable that p53 operates at more than one point in the cell cycle as recent 
reports have shown that p53 can induce a G2/M cell cycle block as well as a G1 cell 
cycle block (Stewart e ta l , 1995; Aloni-Grinstein e ta l ,  1995; Agarwal et a l,  1995).
The p53 response to DNA damage is elicited through the transcription o f genes which 
contain p53-binding sites in their promoters (Lu and Lane, 1993). Several effector genes 
induced by p53 have been identified. It was demonstrated by Kastan et a l  (1992) that 
the human growth arrest and DNA damage-inducible gene, GADD45, was induced by 
p53. GADD45, which suppresses cellular growth in vitro (Zhan et a l,  1994), was found 
to bind to the proliferating cell nuclear antigen (PCNA) and inhibited entry o f cells into S 
phase (Smith et a l, 1994). GADD45 also stimulated DNA excision repair suggesting a 
link between p53 and DNA repair (Smith et a l, 1994; Smith et a l,  1995). Expression of 
the highly conserved WAF1 (wild type p53-activated fragment 1) gene was also induced 
by sequence specific transactivation by p53 (El-Deiry et a l, 1993). El-Deiry et a l 
demonstrated that overexpression of the WAF1 gene could reproduce the growth 
inhibitory activity of p53. The WAF1 gene, also referred to as CIP1, for cdk-interacting 
protein, was found to encode a protein, p21, which was a potent inhibitor o f G1 cdks 
(Harper et a l, 1993; Xiong et a l, 1993). The binding of p21 to cdks prevented 
phosphorylation of cdk substrates like RB and blocked cell cycle progression (Harper et 
a l, 1993; Xiong et a l, 1993). Direct evidence that p21 was involved in the p53- 
mediated DNA damage response was presented in two papers by Dulic et a l (1994) and 
El-Deiry et a l (1994). These authors showed a p53 dependent accumulation o f p21 
which correlated with inhibition of cdk2 kinase activity during radiation-induced G1 
growth arrest. Studies using p21 deficient cells corroborated these results by 
demonstrating that p21 was an essential component o f the DNA damage induced p53 G1 
growth arrest pathway (Deng et a l, 1995; Brugarolas et a l, 1995). In addition to its 
role in cell cycle arrest, p21 has also been shown to inhibit DNA replication through an 
interaction with the essential DNA replication factor PCNA (Waga et a l, 1994; Chen et 
a l, 1995b). The p53 transactivation of p21 and GADD45 may therefore serve two 
purposes, the first to initiate cell cycle arrest and the other to block replicative DNA 
synthesis.
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Transcriptional activation of other p53 responsive genes may be involved in p53- 
mediated growth arrest. The MDM2, angiogenesis inhibitor thrombospondin-1 and 
transforming growth factor a  genes have been found to be induced by p53 (Wu et a l , 
1993; Dameron et al., 1994; Shin et al., 1995). Several growth promoting genes have 
been found to be transcriptionally downregulated by p53 which may also contribute to 
the cell cycle arrest mediated by p53 in response to DNA damage. Evidence for the 
downregulation o f interleukin-6, c-fos and c-myc has been described (Santhanam et al., 
1991; Ginsberg et al., 1991; Deb et al., 1992; Moberg et al., 1992).
1.6.6 p53 and Apoptosis.
Overexpression o f wild type p53 in some tumour cell lines was shown to induce 
apoptosis (Yonish-Rouach et al., 1991; Shaw et a l, 1992; Wang et al., 1993a). 
Furthermore, p53 was found to be required for DNA damage induced apoptosis. 
Thymocytes deficient in p53 failed to mediate an apoptotic response induced by radiation 
and chemotherapeutic DNA-damaging drugs, but were proficient in other forms of 
apoptosis (Clarke et a l, 1993; Lowe et a l, 1993a). As in thymocytes, myeloid 
progenitor cells and intestinal epithelial cells required wild type p53 to elicit an 
appropriate radiation-induced apoptotic response (Lotem and Sachs, 1993a; Clarke et 
a l, 1994; Merritt et a l, 1994). Whole body irradiation of normal animals showed that 
increased levels of p53 spatially and temporally correlated with apoptosis (Merritt et a l,
1994) but that in p53-deficient animals, intestinal cells were completely resistant to 
radiation with levels of apoptosis not exceeding that o f normal background (Clarke et 
a l,  1994; Merritt et a l,  1994). The requirement for p53 to execute an efficient 
apoptosis pathway in response to radiation and anticancer drugs has important 
implications for cancer therapy as loss of p53 can lead to resistant tumours (Lowe et a l,  
1993b; 1994b).
The involvement o f p53 in apoptotic mechanisms is not restricted to those cells which 
have undergone genetic damage as reports have documented a role for p53 in the 
apoptotic response to withdrawal of survival factors (Lotem and Sachs, 1993 a) and in 
oncogene-mediated apoptosis (Debbas and White, 1993; Lowe et a l, 1994a; Hermeking
31
and Eick, 1994; Wagner et a l, 1994). The viral oncogene E l A was found to induce 
apoptosis in a manner dependent on p53 (Debbas and White, 1993; Lowe et a l, 1994a). 
Inactivation of p53 by mutation or binding to E1B was therefore required for efficient 
viral transformation. The c-myc oncogene similarly required wild type p53 to execute its 
apoptotic pathway in fibroblast cells (Wagner et a l,  1994; Hermeking and Eick, 1994). 
Loss o f p53-dependent apoptosis in response to oncogenic events has been shown to be 
an important determinant of tumour development and tumour progression (Symonds et 
a l, 1994). Symonds and colleagues used a transgenic mouse model to demonstrate that 
wild type p53 directly suppressed tumour growth by promoting apoptosis o f abnormally 
proliferating cells. Inactivation of p53 in this model resulted in the rapid development of 
aggressive tumours (Symonds et a l, 1994).
The evidence put forward therefore suggests that DNA damage elicits both p53-induced 
growth arrest and p53-mediated apoptosis. The data available suggests that these are 
separable functions of p53. Firstly, p53-mediated apoptosis was not dependent on the 
induction of a growth arrest, although cells in G1 were preferentially susceptible to 
apoptosis (Yonish-Rouach et a l, 1993). Secondly, the p21 protein, an essential 
component of the p53-induced growth arrest pathway, was not required for p53-induced 
apoptosis mechanisms (Wagner et a l, 1994; Deng et a l, 1995; Brugarolas et a l, 1995). 
Indeed, p53-mediated apoptosis has been shown to occur in the absence o f p53 activated 
gene expression (Caelles et a l,  1994). However recent investigations indicate that p53 
does induce at least some apoptotic pathways through transcriptional activation (Yonish- 
Rouach et a l,  1996). A strong candidate gene for mediating p53-induced apoptosis is 
the box gene as the direct transactivation of box by p53 has been shown to induce 
apoptosis in a number of cell types (Miyashita and Reed, 1995). Overexpression o f the 
bcl-2 oncogene inhibits p53-mediated apoptosis but not p53-induced growth arrest again 
suggesting that these are distinct properties of the p53 gene which may be regulated by 
cellular factors (Chiou et a l, 1994). Conversely, overexpression o f the c-myc oncogene 
suppressed p53-induced growth arrest but not p53-mediated apoptosis (Saito and 
Ogawa, 1995; Hermeking et a l, 1995). Recent papers have indicated that the fate of 
p53 may be regulated in part by the RB tumour suppressor gene (White, 1994). RB has 
been shown to suppress p53-mediated apoptosis (Haupt et a l,  1995) and to direct the
32
p53-mediated growth arrest response (Slebos et a l, 1994). Therefore in the presence of 
functional RB, p53 would promote a G1 growth arrest programme whereas in cells 
which lacked RB, p53 would initiate an apoptotic pathway. These results may explain 
why certain viruses inactivate both the RB and p53 tumour suppressor genes.
1.7 T h e  U s e  o f  T r a n s g e n ic  M ic e  in  O n c o l o g y  S t u d ie s .
Since its first application over twelve years ago, transgenic technology has provided 
some exciting advances in molecular oncology research. Transgenic animals have 
become very important in directly assessing the role of genes, particularly potential 
oncogenes, in normal development and tumourigenesis in vivo. Cumulative studies have 
established an unequivocal link between more than thirty genes and neoplastic 
transformation (Adams and Cory, 1991a; Adams and Cory, 1991b). Transgenic animals 
further provide a system to test successive events in the progression of disease and to 
investigate potential therapies. The use of genetically altered animals in modelling 
human disease is ever increasing and although oncology has been prominent in these 
studies, it should be noted that good animal models exist for a number o f conditions. 
These include artherosclerosis, diabetes (reviewed in Kappel et a l, 1994), pulmonary, 
immunological and neuropsychiatric disorders (reviewed in Lathe and Mullins, 1993).
1.7.1 Transgenic Technology.
A transgenic animal contains foreign DNA sequences, usually placed there under 
experimental conditions. Current transgenic technology has progressed to a stage where 
it is now routinely possible to not only insert exogenous genes, but to interrupt and 
functionally delete endogenous genes. Furthermore, by directing the transgene 
sequences to target cells, the effects caused by the introduced genetic alteration can be 
made tissue or lineage specific. Introduction of foreign gene sequences into mice was 
first reported by Jaenisch and Mintz (1974) when they microinjected SV40 DNA into the 
blastocyst cavity of the mouse embryo, albeit without integration into the host DNA. 
The first experimental germline integration of foreign sequences and subsequent
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transmission to progeny was achieved by infecting preimplantation embryos with 
Moloney murine leukaemia retrovirus (Jaenisch, 1976).
The introduction of exogenous gene sequences into the mouse genome has been 
achieved by a number of alternative techniques, namely retroviral vectors, pronuclear 
microinjection and embryonic stem cells. The ability of retroviruses to stably insert their 
viral genes into the mouse germline, as demonstrated by Jaenisch (1976), provided the 
basis for the first o f these methods. Retroviruses can be used as vectors to insert viral or 
non-viral genes o f interest into the mouse genome. This is achieved by packaging gene 
sequences into retroviral particles and infecting preimplantation embryos with the 
recombinant retroviral vector, first demonstrated by van der Putten et al. in 1985. 
Retroviral infection allows the efficient transfer of a single copy o f the gene at a single 
chromosomal site (reviewed in Cameron et a l,  1994; Jaenisch, 1988). As infection is 
usually carried out at a late stage in embryonic development (2 cell to morulae stages), 
transgenic animals derived using this method are generally mosaic (Jaenisch, 1976; van 
der Putten et a l, 1985). One disadvantage of this method is that there is a limitation to 
the size of recombinant DNA sequence that can be packaged into the viral vector.
Pronuclear microinjection is the preferred and probably most successful method of 
generating transgenic animals and involves the direct microinjection o f gene sequences 
into the pronucleus of fertilized mouse embryos (Brinster et a l,  1985; Hogan et a l,
1986). As pronuclear microinjection is carried out with embryos at a one-cell stage, the 
inserted gene normally integrates very early during development. As a result, the 
majority of transgenic animals are not mosaic and are capable o f germline transmission. 
DNA microinjected into either of the two pronuclei is usually found to integrate at a 
single, presumably random, site. Unlike retroviral vectors, more than one copy o f the 
gene frequently integrates into the host genome. Multiple copies o f the DNA molecule, 
arranged in a tandem head-to-tail array, are generally found at a single chromosomal site 
(Brinster et a l,  1981; Brinster et a l, 1985). It has been suggested that recombination of 
the coinjected DNA molecules occurs before integration (Brinster et a l, 1985). Gordon 
et a l (1980) were the first to describe the production o f transgenic animals using 
pronuclear microinjection with the insertion of recombinant DNA sequences of herpes
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simplex virus (HS V) and S V40 viral DNA. It was recognized by these authors, and soon 
after confirmed by others, that DNA introduced by this method was integrated into the 
mouse germline and passed to progeny in a Mendelian fashion, giving rise to transgenic 
offspring with the same DNA integration as the parent (Gordon and Ruddle, 1981; 
Brinster et a l,  1981).
Embryonic stem (ES) cells offer a third option for delivering genes into the mouse 
germline. ES cells are derived from blastocysts and have pluripotent potential (Capecchi,
1989). They divide and grow in an undifferentiated state in culture but when they are re­
introduced into blastocysts they are able to colonize the early embryo and can contribute 
to somatic tissues and germ cells, resulting in chimaeric mice (Bradley et a l , 1984). 
DNA can be introduced into ES cells either by microinjection or by electroporation 
(Capecchi, 1989). Manipulated ES cells provide a vehicle in which genetic modifications 
can be introduced from tissue culture to the mouse germline. In addition to the 
introduction of exogenous genes, recent advances using homologous recombination and 
gene targeting strategies have allowed the deletion or alteration o f endogenous genes in 
ES cells (Capecchi, 1989; Thomas, 1994). Gene targeting by homologous 
recombination involves the replacement o f normal genes with transgenes coding for 
mutant or null alleles. The vectors carrying the desired mutation have gene sequences 
homologous to the endogenous sequences with which they can recombine. Vectors 
which have successfully integrated at homologous sites, as opposed to at random sites, 
can then be selected and enriched for (Capecchi, 1989; Hasty and Bradley, 1995). The 
targeted ES cells are introduced into the mouse blastocyst. Transgenic knockout mice, 
also referred to as nulls, are generated by cross-breeding to produce animals 
homozygous for the deleted or disrupted gene.
1.7.2 Targeting and Expression of Transgenic Sequences.
Expression of a transgene can be directed to a range of different tissues or cell types by 
fusing the gene sequence of interest with particular promoters and enhancers (Palmiter 
and Brinster, 1985; Jaenisch, 1988). Depending on the nature o f the regulatory
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elements, it is possible to achieve broad spectrum or tissue restricted expression. 
Brinster et a l (1981) were the first to confirm transgene expression in mice 
microinjected with a fusion plasmid of herpes thymidine kinase linked to the regulatory 
region of the mouse metallothionein-1 gene. These investigators found high levels of 
thymidine kinase activity in the liver and kidney of the transgenic mice. However, it was 
noted that transgene expression was unpredictable, and that even although the transgene 
had integrated into the mouse DNA, this did not always result in gene expression in 
somatic tissues (Brinster et a l , 1981).
The level of transgene expression is generally unpredictable and is usually independent of 
transgene copy number. It has also been shown that expression o f a transgene need not 
be restricted to the targeted tissue. This was observed for example with v-Ha-ras under 
the control of the MMTV long terminal repeat where expression o f the transgene 
occurred in numerous tissues (Tremblay et a l , 1989). A number o f factors, in addition 
to the promoter and enhancer sequences, can influence transgene expression (Jaenisch,
1988). It seems that the site of chromosomal integration is o f particular importance (Al- 
Shawi et a l , 1990). Locus control regions in the transgenic construct can override the 
dependence on the integration site (Grosveld et al., 1987). This was observed with a 
human CD2 transgene (Lang et a l , 1988). Expression o f this transgene was restricted to 
thymocytes, T cells and megakaryocytes. The expression o f the CD2 transgene was 
dependent on the copy number o f genes which had integrated into the genome and 
apparently independent on the site of integration. The presence o f locus control regions 
associated with the CD2 gene accounted for the copy-dependent, position-independent 
expression pattern of this transgene (Greaves et al., 1989).
1.7.3 Transgenic Oncogene Mice.
The inaugural transgenic cancer model was described by Brinster and co-workers (1984) 
who demonstrated that transgenic mice expressing SV40 T-antigen genes developed 
tumours within the choroid plexus. Shortly thereafter, Stewart et a l  (1984a) showed 
that the c-myc oncogene targeted to mammary gland tissue elicited mammary 
adenocarcinomas. There now exist transgenic models for many classes o f oncogene,
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including transcription factors, cell survival genes, growth factors, growth factor 
receptors and viral genes (Adams and Cory, 1991b; Hanahan, 1988; Pattengale, et al.,
1989).
These transgenic models have led to a greater understanding of the mechanisms by which 
oncogenes transform cells. The effect o f an oncogene on a particular tissue can be 
ascertained by targeting expression of the transgene to a restricted cell lineage. For 
example, the c-neu oncogene linked to the MMTV promoter can induce mammary 
adenocarcinomas (Muller et al., 1988). Likewise, mammary carcinomas are induced by 
MMTV-ras' and MMTV-wyc (Stewart et a l, 1984a; Sinn et a l, 1987). The spectrum of 
tissues that are susceptible to a particular transforming gene can also be delineated. The 
SV40 T antigen, ras oncogene and myc oncogene can induce tumours in a number of 
different cell types (Hanahan, 1988; Adams and Cory, 1991b). In contrast, widely 
expressed fo s  and jim  transgenes appeared to induce cell-type specific tumours (Ruther 
et a l,  1987; Schuh, et al., 1990). Therefore, the transforming capabilities o f oncogenes 
can be wide ranging or cell type specific. Although the myc oncogene can transform 
many tissue types, it does not transform all cell types. This was demonstrated in one line 
o f MMTV-wyc mice where, although aberrant expression o f c-myc was recorded in a 
range of tissues including the pancreas, lung and salivary gland, these tissue types did not 
appear to be as susceptible to transformation (Leder et a l,  1986).
1.7.4 Transgenic Models In Lymphomagenesis.
1.7.4.1 The myc oncogenes.
To model the chromosomal rearrangement which occurs in Burkitt’s lymphoma, the 
immunoglobulin heavy chain enhancer (Ep) was fused to the c-myc oncogene (Adams et 
a l, 1985). A high proportion of E \x-myc mice were found to develop clonal tumours of 
pre-B or B cell origin similar to those observed in the human malignancy. By 4 months 
o f age, 94% of YL\\-myc mice, from several independent lines, died o f an aggressive 
lymphoma. The clonality and spontaneous nature o f these tumours suggested that 
secondary events were required for full tumourigenesis. Deregulated myc expression
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induced a pre-lymphomatous hyperplasia in the Tl\x-myc mice (Langdon et a l,  1986) 
which presented as an expanded population of non-malignant, proliferating pre-B cells in 
the spleen and bone marrow (Alexander et al., 1987). The myc expressing cells were 
found to be in cycle (Langdon et a l, 1986), promoting cell division over differentiation. 
It has been suggested that the transgene serves to predispose the tissue to further 
changes by creating a large population o f cells which are then susceptible to secondary 
mutations (Adams and Cory, 1992).
Expression o f the c-myc oncogene has also been targeted to the T-cell lineage 
(Spanopoulou et a l,  1989; Stewart et a l, 1993). The murine c-myc gene was inserted 
into the mouse Thy-1 transcriptional unit to direct expression of the gene to the thymus 
(Spanopoulou et a l,  1989). Thymic tumours arose in the Thy-myc mice between 9 and 
14 weeks of age. The thymomas consisted of proliferating thymocytes and 
unexpectedly, expanded populations of epithelial cells. Histological diagnosis confirmed 
that lymphoid and stromal cell populations had expanded. Both cell types were found to 
establish in long term culture suggesting that they were indeed transformed. Large blast 
cells with the potential to metastasize had populated the thymus in these mice. The 
clonal tumours were mostly Thy-1+, CD4+CD8+ with rearranged T cell receptor (TcR) 
(3-chain, suggesting that transformation had occurred in immature thymocytes. 
Transgenic mice carrying the human c-myc gene under the regulation of the CD2 locus 
control region were also predisposed to thymic lymphoma development (Stewart et a l,
1993). These mice developed clonal CD3+, CD4+/-, CD8+ T-cell tumours. Lymphoid 
tumours also developed in an MMTV-wyc transgenic line which had widespread c-myc 
expression (Leder et a l, 1986). This observation confirms the potency of the c-myc 
oncogene in transforming lymphoid cells, especially as tumours did not arise in all 
transgene expressing tissues of the MMTV-wyc line.
Transgenic mice with expression of the N-wyc gene directed to the lymphoid 
compartment with the Ep. enhancer developed pre-B and B cell lymphomas with a 
preneoplastic stage similar to that observed with E^wwyc mice (reviewed by 
Morgenbesser and DePinho, 1994). Ep-L-w^c mice demonstrated pre-tumourous 
disturbances in the thymus and spleen with a predisposition to developing T-lymphoid
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tumours (Moroy et al., 1990). The preferential expression of E\i-L-myc in T cells was 
surprising considering the usual targeting of myc genes with the Ep. enhancer to the B- 
cell compartment and may be due to elements within the L-myc gene (Moroy et al.,
1990).
1.7.4.2 The bcl-2 oncogene.
The chromosomal translocation associated with human follicular lymphoma was 
recreated in the bcl-2-Ig transgenic mouse (McDonnell, 1993b). This transgene was 
derived from the fusion of the bcl-2 gene with the immunoglobulin (Ig) heavy chain 
locus, leading to deregulated expression of the bcl-2 oncogene in lymphoid tissue 
(McDonnell et al., 1989). Lymphoid hyperplasia, with polyclonal expansion of non­
dividing B cells, occurred in the spleen of bcl-2-lg transgenic mice between 8 and 19 
weeks of age (McDonnell et al., 1989; McDonnell et al., 1990). This non-cycling 
augmentation of lymphoid cells was consistent with the observed function o f bcl-2 in 
enhancing cellular survival by inhibiting cell death (Hockenbery et a l, 1990). The 
benign, follicular hyperplasia o f bcl-2-Ig mice progressed to high-grade malignant 
lymphoma after a latency of approximately 15 months (McDonnell and Korsmeyer,
1991). The need for secondary changes to proceed from the bcl-2-Ig initiated B-cell 
accumulation to clonally transformed tissue was implicated by the long latency o f the 
lymphomas. Indeed, spontaneous c-myc rearrangements were detected in half o f the 
malignant tumours but not in any o f the bcl-2 over-expressing preneoplastic cells 
(McDonnell and Korsmeyer, 1991).
The human bcl-2 gene was targeted to the T-cell lineage using the lymphoid-specific 
tyrosine kinase, lek promoter. Over a period of 24 months, 26% of mice carrying the 
Ick-bcl-2 transgene presented with large-cell lymphoma at a mean age o f 18 months 
(Linette et al., 1995). T-cell origin of the lymphomas was confirmed by flow cytometry 
analysis. The tumour cell population was predominantly CD4+CD8- which is compatible 
with a mature peripheral T-cell phenotype. The long latency o f these tumours is similar 
to that seen with the bcl-2-lg follicular lymphomas, but unlike the bcl-2-Ig transgenic
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mice (McDonnell and Korsmeyer, 1991), Ick-bcl-2 mice were not found to harbour 
spontaneous myc rearrangements.
1.7.4.3p im -l and other oncogenes.
The pim -1 gene was first discovered as a common viral integration site in T-cell 
lymphomas induced by Moloney murine leukaemia virus, MoMuLV (Cuypers et al., 
1984). Ep-p/w-1 transgenic mice developed a low incidence (5-7%) of spontaneous T 
cell lymphomas by 7 months of age, with no apparent preneoplastic abnormalities (van 
Lohuizen et a l,  1989). Although tumour frequency was low in E|i-p//w-l transgenic 
mice, these mice were highly susceptible to T-lymphomagenesis induced by MoMuLV. 
The true oncogenic potential of pim -l was recognized by its ability to collaborate with 
other oncogenes in B- and T-cell tumours.
A number of other known oncogenes, including SV40 T antigen, H-ras, bcr-abl and neu, 
have been shown to induce lymphomagenesis in transgenic mice (reviewed by Adams 
and Cory, 1991a). Transgenic mice expressing the transcription factor rbtn-2 in the T- 
cell compartment confirmed the involvement of this gene in T-cell lymphoma (Larson et 
al., 1994). CD2-rbtn-2 mice were predisposed to lymphoblastic lymphoma with a 
latency of between 5 and 15 months. Constitutive expression o f the growth factor 11-9 in 
a transgenic model has also been observed to induce a low incidence o f clonal T-cell 
tumours (Renauld eta l., 1994).
1.7.5 Transgenic Models Of Oncogene Synergy.
It is now widely accepted that tumourigenesis occurs as a multistep process (Bishop, 
1991; Weinberg, 1989). Studies using transgenic mice further validate this hypothesis. 
In general, transgenic mice carrying a single oncogene develop tumours which arise 
sporadically after a considerable latency period. Tumours do not ensue from every 
transgene expressing cell but rather are usually clonal in origin. Moreover, a 
proliferative hyperplasia is often evident prior to neoplastic transformation (Hanahan, 
1988), as has been observed with transgenic animals expressing myc and bcl-2
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oncogenes (Langdon et al., 1986; McDonnell et a l , 1990). Additional events are 
therefore necessary for the complete progression to malignancy. Naturally occurring 
spontaneous mutations have been identified in some transgenic tumours, for example in 
bcl-2-Ig follicular lymphomas where rearrangement o f the c-myc gene occurred in at 
least half o f the tumours (McDonnell and Korsmeyer, 1991). Rearrangements o f the c- 
myc gene have also been observed in a high proportion o f plasmacytomas arising in Ejx- 
v-abl mice (Rosenbaum et a l , 1990).
The predisposed state of the transgenic mouse to neoplasia provides an ideal model to 
investigate secondary genetic changes. These events can be experimentally introduced 
by the retroviral introduction of genes, by proviral insertional mutagenesis, or by 
crossing transgenic lines containing oncogenes directed to the same tissue (Bems et a l, 
1989; Christofori and Hanahan, 1994). Using retroviral vectors, Langdon et al. (1989) 
introduced v-H-ras and v-raf oncogenes into the germline o f E|u-/wyc transgenic mice to 
show that both of these genes could collaborate with myc in transforming B cells. 
Alexander et a l (1989) used in vitro experiments to demonstrate that E \x-myc bone 
marrow cells infected with retroviruses bearing the v-H-ras and v-raf oncogenes 
generated a rapid polyclonal expansion of pre-B cells which grew as tumours in nude 
mice. Conversely, v-abl did not collaborate with constitutive myc expression to promote 
accelerated lymphomagenesis either in vivo or in vitro (Langdon et a l,  1989; Alexander 
etal., 1989).
1.7.5.1 Proviral insertional mutagenesis.
Proviral insertional mutagenesis has also been used to identify collaborating oncogenes in 
transgenic mice. Slow-transforming retroviruses, such as MoMuLV, do not contain their 
own oncogene and so rely on activation, or inactivation, of host genes in order to 
transform the cell. To achieve this, the retrovirus integrates into the host genome and 
activates cellular proto-oncogenes (reviewed by Kung et a l, 1991). Proviral insertion is 
a random process, however in many tumour cells integration apparently occurs at 
nonrandom common integration loci (reviewed by Tsichlis and Lazo, 1991). This is 
probably due to selection o f the cells which carry integrations resulting in a growth
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advantage. Van Lohuizen et al. were the first to use this procedure to look for 
collaborating oncogenes in transgenic mice. These authors demonstrated that insertion 
o f the provirus acted as a tag by which to identify collaborating host genes (van 
Lohuizen eta l., 1989).
Proviral insertion has been used with some success to identify cooperating oncogenes in 
E [i-myc transgenic mice. Two independent laboratories observed that infection of Ep- 
myc mice with MoMuLV accelerated the rate o f B cell lymphoma development 
indicating the action o f a cooperating event(s). Several common proviral integration 
sites in these tumours were identified. Insertions at the pim-\ locus occurred in 19 - 
35% of MoMuLV induced E \x-myc tumours (van Lohuizen et a l,  1991; Haupt et al., 
1991) implicating pim -1 as a probable myc collaborating gene. In addition, insertions at 
novel loci, bmi-1, emi-1 and pal-\ were identified. No rearrangements o f the abl, raj\ 
bcl-2, myb, ras, cbl, or rel proto-oncogenes were identified by proviral insertion in these 
studies. Frequent proviral insertions at the bmi-1 locus were observed, with 35 - 47% of 
the Ep-/77yc tumours carrying this integration (van Lohuizen et a l, 1991; Haupt et a l, 
1991). Integrations at this locus had previously been unknown and it was suggested that 
the bmi-\ gene may play an exclusive role in B cell transformation (van Lohuizen et al.,
1991). The oncogenic potential o f this gene was confirmed in Ep-&/w/-l transgenic mice 
(Haupt et al., 1993). By crossing the E ]i-bmi-\ transgenic mice with Ep-/wyc mice it 
was established that the bmi-1 transgene markedly accelerated the onset o f pre-B and B- 
cell lymphomas from greater than 10 weeks to less than 5 weeks of age, confirming the 
collaboration between these genes.
Some of the proviral insertions in the E \x-myc mice were found to co-exist within the 
same tumour. Van Lohuizen et al. found co-existing pim -1 and bmi-\ mutations in 3 
tumours, and co-existing mutations in pal-1 and pim -1 in 4 other tumours (van Lohuizen 
et a l, 1991). Insertions at both pim-\ and bmi-1 were also observed by Haupt et al. 
(1991), occurring in 2 out of 30 tumours. This group also found co-existing insertions in 
both bmi-1 and emi-1 (2/36) and in emi-1 and pim -1 (1/30). These results could infer 
the existence o f different complementation groups. As myc, pim -1 and bmi-1 can 
effectively cooperate in tumourigenesis, these oncogenes probably belong to different
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complementation groups, contributing separate functions to the neoplastic process. That 
co-existing mutations in bmi-1 and pal-1 were not observed suggests that these 
oncogenes could belong to the same complementation group. A study of feline lymphoid 
tumours similarly reported the existence o f complementary and non-complementary 
oncogenes (Tsatsanis e ta l ,  1994).
While pim -1 insertions were common in B-cell tumours induced by MoMuLV infection 
o f E \i-myc mice, reciprocal experiments demonstrated that c-myc and N -myc insertions 
consistently arose in T-cell lymphomas o f E\x-pim-\ transgenic mice infected with 
MoMuLV (van Lohuizen et a l , 1989). These results show that the collaboration 
between the myc and pim -1 oncogenes can occur in both the B- and T-cell lineages.
1.7.5.2 Transgenic crosses.
A further indication of the potency of the collaboration between the E\x-myc and Ep- 
pim-l genes has been observed in crossing these two transgenic lines. Mice carrying 
both the E \i-myc and E\x-pim-\ transgenes exhibited pre-B-cell lymphoma in utero and 
did not survive to birth (Verbeek et a l , 1991). Similarly, double transgenic mice with 
both the E\\.-pim-\ gene and the Ep-N- or Ep-L-m^c gene generated lymphoid tumours 
at an accelerated rate compared to those of either transgene alone (Moroy et a l , 1991). 
That the Eyi-pim-l mice crossed with Ep-N and L-myc mice survived to after birth, 
whereas E\x-pim-\fE\x-c-myc mice died in atero may reflect the weaker oncogenic action 
o f N-myc and L-myc.
Dramatic acceleration in tumour development was also observed when mice expressing 
MMTV-H-ras' were crossed with MMTV-wyc mice to generate double transgenic mice 
(Sinn et a l , 1987). Hybrid mice accentuated the tumour phenotype of the single 
transgenic animals, developing primarily mammary adenocarcinomas but with a 
significantly reduced latency. Likewise, an E\x-mycfE\i-bcl-2 transgenic cross resulted in 
a rapid onset of lymphomagenesis (Strasser et a l, 1990). These double transgenic mice 
developed disseminated malignant lymphoma at 5 - 6 weeks, considerably faster than the 
Ep-myc and Ep-SV-6e7-2 parental groups. The mechanism of cooperation between
43
these two events has been ascribed to bcl-2 suppression of c-myc associated apoptosis 
(Marin et a l, 1995). A transgenic cross has also demonstrated collaboration between 
the pim -1 and bcl-2 oncogenes (Acton et a l, 1992). This collaboration was relatively 
weak with an average latency period of 30 weeks. Retroviral insertion of E[i-pim-\/bcl- 
2-Ig hybrid mice with MoMuLV indicated common integration sites at N-myc, c-myc 
and pal-1. It is possible that activation of these genes acted as a tertiary event in the 
stepwise progression of T-cell lymphoma.
Although two and three genetic collaborations have been identified in these transgenic 
models, it has been intimated that these events alone are still insufficient for total 
neoplastic transformation. Even the strong synergy between the pim-l and c-myc 
oncogenes requires further events as evident from transplantation experiments (Verbeek 
et al., 1991). One exception to the multistep transgenic model has been observed with 
the c-nen oncogene (homologue of erbB-2) linked to the MMTV promoter. 
Synchronous, polyclonal adenocarcinomas in all mammary glands arose in the MMTV-c- 
neu mice at a young age (Muller et al., 1988), suggesting that this gene alone was 
sufficient to induce tumours in mammary epithelium. This may be due to the particular 
combination of oncogene and tissue type as expression of c-neu in the parotid gland and 
epididymis did not initiate full malignant transformation.
1.7.6 Transgenic Knockout Mice.
The deletion and disruption of endogenous mouse genes by gene targeting and 
homologous recombination has made it possible to depict the normal function o f a 
number of cellular genes and proto-oncogenes by creating null mice (recently listed in 
Brandon et al, 1995). The role of the bcl-2 gene as an inhibitor of apoptosis was 
confirmed in bcl-2 null mice (Veis et al., 1993). These mice exhibited several 
abnormalities including fulminant apoptosis of the thymus and spleen. A c-myc null 
mutation demonstrated the need for a functional c-myc gene during normal embryonic 
development when this mutation resulted in embryonic lethality (Davis et al., 1993). 
Null transgenics have been particularly informative in the case o f tumour suppressor 
genes, where in conventional transgenics the desired loss of function phenotype could
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not be simulated. As negative growth regulators, it was necessary to inactivate or delete 
both alleles o f these genes.
1.7.6.1 The RB  knockout mouse.
To investigate the role o f the ft#  gene in mammalian development and tumourigenesis, 
several laboratories generated RB knockout mice using homologous recombination (Lee 
et a l , 1992; Jacks et al., 1992; Clarke et a l,  1992). Mice homozygous for this mutated 
allele, which produces a non-fimctional protein, were non-viable and died between days 
14 and 15 of gestation. Severe abnormalities of the nervous and haematopoietic systems 
occurred in these embryos from day 10 of gestation due to massive cell death (Lee et a l, 
1992; Jacks et a l, 1992; Clarke et a l, 1992). Therefore, RB was shown to be essential 
for normal mouse development. The heterozygous phenotype o f these RB  knockout 
mice surprisingly showed no evidence of retinoblastoma or retinal abnormalities but did 
demonstrate a predisposition to pituitary tumours. These tumours were shown to have 
lost the remaining RB wild type allele providing formal evidence for the role o f RB as a 
tumour suppressor.
1.7.6.2 The p53 knockout mouse.
Inactivation of the p53 tumour suppressor gene has been described in several different 
transgenic knockout models (Donehower et a l, 1992; Purdie et a l,  1994; Jacks et a l,
1994). Unlike the RB homozygous null mouse, p53 nullizygous mice were viable and 
appeared normal at birth. However, the p53 null mice were observed to spontaneously 
develop a wide range of tumour types between 3 and 10 months o f age, with a 
predominance for T-cell lymphoma. Heterozygous p53 null mice were also found to be 
predisposed to tumour development, albeit with a longer latency and a significantly 
different tumour spectrum, sarcoma type tumours predominating. These tumours were 
often found to be associated with loss of the remaining wild type p53 allele (Harvey et 
a l,  1993a; Purdie et a l, 1994; Jacks et al., 1994). These observations confirmed the 
role of p53 as a general tumour suppressor gene.
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Studies employing p53 knockout animals were important in establishing the requirement 
for p53 in DNA-damaged induced apoptosis (Lowe et a l,  1993a; Clarke et a l,  1993). 
These groups independently observed that p53 null thymocytes were unable to elicit an 
apoptotic response to irradiation and etoposide but were susceptible to cell death on 
treatment with glucocorticoid. Furthermore, heterozygous null cells showed an 
intermediate susceptibility to radiation-induced apoptosis. The use o f these tumour 
prone animals has also been applied to in vivo carcinogenesis studies. Harvey et a l,  for 
example, demonstrated that p53 heterozygote mice were more susceptible to carcinogen- 
induced liver tumours than wild type mice when treated with dimethylnitrosamine 
(Harvey et a l, 1993a). Also, the initiation o f skin papillomas following chemical 
induction was found to be independent o f p53 loss, but malignant progression was 
greatly enhanced in the absence of functional p53 (Kemp et a l,  1993). As these 
examples demonstrate, the p53 null and heterozygote null mice have provided a valuable 
tool for studying the function and role o f the p53 tumour suppressor gene. Many 
applications of this model are currently in use.
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CHAPTER 2. 
MATERIALS & METHODS.
2.1 A n im a l s .
All animal work was carried out under Home Office regulations.
2.1.1 Transgenic Mouse Stocks.
The generation o f CD2-myc transgenic mice was carried out by Dr. E. Cameron and has 
been described previously (Stewart et a l , 1993). In order to target the c-myc gene to 
the T-cell lineage, the human c-myc locus (Hindlll-EcoRI fragment in plasmid pMC41) 
was fused to a regulatory domain of the human CD2 locus (5.5 kb BamHI-Xba 
fragment) to construct the CD2-myc plasmid (Figure 2.1) as described in Stewart et al., 
1993. This work was carried out by Dr. M. Stewart. The linearized CD2-myc plasmid 
was then microinjected into C57B1/6J x CBA/Ca F2 (B6/CBA) fertilized eggs according 
to standard protocols (Hogan et a l , 1986). Two transgenic lines were established, the 
CD2-wyc-800 and the CD2-wyc-900 lines. The CD2-/wyc-800 line (hereafter referred to 
as CD2-myc) was selected for use in this study and was maintained on an indiscriminate 
B6/CBA background.
Mice deficient for a functional p53 tumour suppressor gene were derived using 
homologous recombination in murine ES cells by L. Donehower and co-workers (1992). 
A null mutation with an inserted polll-neo expression cassette and 106 bp deletion in 
exon 5 of the p53 gene was introduced into the germ line of 129/Sv ES cells. Chimaeric 
mice, generated by introducing the targeted ES cells into C57B1/6 blastocysts, were 
crossed onto a C57B1/6 background. These mice were subsequently bred onto the NIH 
strain (Kemp et a l,  1993). The genetic background of the mice used in the studies 
described here were an indeterminate mix of C57B1/6, 129/Sv and NIH strains. The use 
o f the p53-deficient mice (hereafter referred to as p53 null or p53‘/_) has been with the 
kind permission of Dr. Larry Donehower.
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Breeding stocks o f  both the CD2-myc transgenic and p53 null mice were maintained with 
heterozygous animals. All experimental cohorts were established from these breeding
stocks.
Hindi II f r P2
human c-myc
EcoRl
L  _ m —
ta I
CD2 3’BamHl-Xbal 5.5kb exl ex2 e.\3
Figure 2.1. The CD2-myc Transgene.
The human c-myc locus was fused to a regulatory domain of the human CD2 locus at a PstI site 5 ’ to the 
PI initiation site as described in Stewart et al., 1993.
2.1.2 Challenge of Mice with MoMuLV.
M oM uLV  clone 1A supernatant was isolated from virus infected 3T3 cells (a gift o f  Dr. 
A. Berns) during the log phase o f  growth and filter sterilised through a 0 .45pm  filter 
(Gelmain Sciences) to remove cell debris. Aliquots o f  1ml o f  filtered supernatant were 
frozen at -70°C until required. Neonatal animals were inoculated intraperitoneally with 
0.1ml o f  supernatant, estimated at 104- 105 infectious units o f  virus, within 24 hours o f  
birth.
2.1.3 Mouse Genotype Analysis.
Positive transgenic animals were identified by screening tail DN A for the presence o f  the 
transgene/null mutation by Southern blot hybridisation.
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Potential transgenic animals were weaned from the breeding stocks at 3-4 weeks o f age 
and separated by sex. At 4-6 weeks of age, animals were anaesthetized by 
intraperitoneal administration of anaesthetic and a l-2cm biopsy o f tail taken. The tail 
wound was then cauterized. Anaesthetic was prepared from a combination o f hypnorm 
(Janssen Animal Health) and hypnovel (Roche) in sterile water at a ratio o f 1:1:8 and 
filter sterilized through a 0.45pm filter (Gelmain Sciences). Animals were tagged by an 
ear nicking identification scheme and allowed to recover. DNA extraction and Southern 
blot analysis on the tail tissue was carried out as described in section 2.3.
2.1.4 Clinical Examination and Post-mortem Investigation.
Experimental cohorts and breeding stocks of mice were maintained for defined periods of 
time and the health o f animals checked at least five times weekly. The development of 
lymphoid neoplasia in the transgenic animals presented as cachexia and tachypnoea. 
Sarcomas and carcinomas, which often developed in p53 null mice, presented as visible 
swellings, paresis or cachexia depending on the anatomical site o f the tumour. Animals 
were humanely sacrificed by cervical dislocation when clinical signs first became evident.
Post-mortem was routinely undertaken immediately after euthanasia, or as near to the 
time of death as possible, and the pathology recorded. Particular attention was paid to 
the lymphoid organs, specifically the thymus, spleen, mesenteric and subcutaneous lymph 
nodes. Evidence of metastasis to non-lymphoid organs was also noted. Total body 
weight of animals was recorded using a digital balance (Tefal). Thymic weight was 
measured using a scientific balance (Mettler). A range of tissue samples, both lymphoid 
and non-lymphoid, were taken at post-mortem. Tissues were frozen in cryotubes (Gibco 
BRL) in liquid nitrogen (BOC) for Southern and Northern analysis; fixed in 10% neutral 
buffered formalin for histopathological examination; and placed in RPMI medium (Gibco 
BRL) for cell biology experiments.
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2 .2  HlSTOPATHOLOGY.
Material for histopathological examination was fixed in 10% neutral buffered formalin, 
wax/paraffin-embedded and stained with haematoxylin and eosin. Histopathological 
processing was carried out by Mr. I. MacMillan and staff. Histopathological 
examinations were carried out by Dr. S. Toth.
2 .3  S o u t h e r n  H y b r id is a t io n  A n a l y s is .
DNA extraction and all Southern hybridisation analysis on mouse tissue was carried out 
by Dr. E. Baxter and Mrs. A. Terry. A brief description o f this procedure is given 
below.
High molecular weight DNA was prepared from mouse tissues using guanidium chloride 
or Nucleon™ II kit (Scotlab). DNA digestion with restriction enzymes, separation by 
agarose gel electrophoresis, transfer to Hybond™ N membranes (Amersham 
International pic.), hybridisation and washing of blots were all carried out as described in 
Sambrook et a l , 1989. Probes were radiolabelled by nick translation or multiprime 
labelling as described in section 2.5.4. Transgene sequences were detected using a 
human c-myc exon 3 probe (1.38kb EcoRl/Clal fragment). The 260bp p53 exon 4 
probe was generated from a plasmid subclone pLTRp53cG (Eliyahu et al., 1985) by 
polymerase chain reaction (PCR) using oligo primers 5’-CCA TCA CCT CAC TGC 
ATG G-3’ and 5’-CGT GCA CAT AAC AGA CTT GGC-3’.
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2.4 PCR A n a l y s i s  o f  G e n o m i c  D N A .
2.4.1 Isolation of Genomic DNA from Mouse Tissues and Cell 
Suspensions.
Genomic DNA was isolated from mouse tumour tissue and tumour cells using the 
Nucleon™ II method (Scotlab Bioscience). Frozen tissue was ground to a powder in 
liquid nitrogen using a chilled mortar and pestle (BDH). The tissue, or cell pellet, was 
resuspended in 2ml o f Reagent B (400mM Tris-HCL at pH 8.0, 60mM EDTA, 150mM 
NaCL and 1% SDS) in a 15ml centrifuge tube by vortexing briefly. Deproteinisation was 
carried out by adding 500pl o f Nucleon sodium perchlorate and rotary mixing for 15 
minutes at room temperature. The sample was then incubated in a shaking water bath at 
65°C for 25 minutes. DNA was extracted by adding 2ml of chloroform (BDH), which 
had been stored at -20°C. The sample was rotary mixed for 10 minutes at room 
temperature and then centrifuged at 3200 r.p.m. for 1 minute. 300pl of Nucleon silica 
suspension was added and the sample centrifuged at 4300 r.p.m. for 3 minutes. The 
DNA phase above the Nucleon silica suspension layer was transferred to a clean 15ml 
centrifuge tube and centrifuged briefly at 4200 r.p.m. to pellet residual Nucleon silica. 
The supernatant was carefully decanted into a clean 15ml centrifuge tube and two equal 
volumes of cold ethanol, at 4°C, added. The tube was inverted gently to precipitate the 
DNA. The precipitated DNA was spooled out into a 1.5ml eppendorf tube and left to 
dry. The DNA was resuspended in 200 - 400pl of ultra pure water by leaving the sample 
overnight at room temperature. The DNA concentration was determined by measuring 
the optical density of the sample at 260nm. The DNA sample was stored in an 
eppendorf tube at 4°C.
2.4.2 PCR Determination of p53 Status.
All PCR analysis was carried out by Mr. C. Johnston and Ms. J. Irvine. The following 
information was kindly provided by Mr. C. Johnston. Amplification of genomic DNA 
was carried out in a 50pl reaction mix which consisted of lpg  of DNA, 2 units o f Taq 
polymerase (Perkin Elmer), 200pM of each deoxynucleoside triphosphate, primer
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sequences to a final concentration of 0.5|iiM in lOmM Tris (pH 8.4), 50mM KC1 and 
1.5mM MgCl2. Thermal cycling was performed on a Perkin Elmer 9600 with an initial 
denaturation of 5 minutes at 94°C, followed by 35 cycles o f 1 minute at 94°C, 1 minute 
at 55°C and 1 minute at 72°C, with a final extension phase o f 7 minutes at 72°C. Primer 
sequences used to detect the wild type p53 allele were directed against regions o f intron 
4 (WP53) 5’-GTG TTT CAT TAG TTC CCC AC-3’ and exon 5 (UP3) 5’-ATG GTG 
GGG GCA GCG TCT CA-3\ The p53 null allele was detected using primer sequences 
NP5; 5’-CGG TCT TGT CGA TCA GGA TG-3’ and UP3. Primers specific for the wild 
type allele generated a 242 bp product, while primers specific for the p53 null allele 
generated a 470 bp product. The PCR products were subjected to electrophoresis, either 
on an 8% acrylamide/Bis-aery 1 amide gel at 120V for 1 hour in TBE buffer, or on a 1.5% 
agarose gel at 100V for 3 hours in TBE buffer. Gels were stained with ethidium bromide 
and photographed under ultraviolet transillumination.
2 .5  N o r t h e r n  H y b r id is a t io n  A n a l y s is .
2.5.1 B uffers.
RNA Loading Buffer
50% of formamide (Gibco BRL), 2.2M of formaldehyde solution (BDH) and lx  MOPS 
buffer (see below) were added to 1.17ml ultra pure water and stored at -20°C.
10 x MOPS Running Buffer
200mM of MOPS (Sigma), 50mM of sodium acetate (Sigma) and ImM o f EDTA 
(Sigma) were made to 1 litre ultra pure water, adjusted to pH 7.0 using 10M sodium 
hydroxide (Sigma) and stored at room temperature in a dark bottle.
24 x SSC
lOOOg of sodium chloride (Sigma) and 500g of citric acid (Sigma) were dissolved in 4.7 
litres of deionised water and stored at room temperature.
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IO x SSC
416ml of 24 x SSC was made to 1 litre in deionised water and stored at room 
temperature.
2.5.2 RNA Extraction.
Total cellular RNA was prepared from mouse tissues using the RNAzol™B method 
(Biogenesis, Bournemouth). Frozen tissue was ground to a powder in liquid nitrogen 
using a chilled mortar and pestle (BDH), and resuspended in 2ml per lOOmg of tissue, in 
cold RNAzol™B in a 15ml centrifuge tube. One tenth volume o f chloroform (BDH) 
was added to the homogenate, the sample shaken vigorously for 20 seconds and left on 
ice for 5 minutes. Samples were then centrifuged at 13000 r.p.m. at 4°C for 10 minutes. 
The aqueous phase was transferred to 1.5ml eppendorf tubes and an equal volume of 
isopropanol (Sigma) added to precipitate the RNA. Samples were stored at 4°C for at 
least 15 minutes then centrifuged at 13000 r.p.m. at 4°C for 15 minutes and the 
supernatant removed. The RNA pellet was washed with 1ml o f 75% ethanol by 
vortexing and subsequent centrifugation at 13000 r.p.m. for 5 minutes at 4°C. The 
ethanol supernatant was discarded and the pellet resuspended in 40 j j ,1 of ImM EDTA 
(Sigma) which had been treated with DEPC (Sigma). The RNA concentration was 
determined by measuring the optical density o f the sample at 260nm. The RNA sample 
was stored in an eppendorf tube at -70°C.
2.5.3 RNA Blotting.
The RNA sample, prepared as described above, was dissolved in ultra pure water to a 
concentration of 10-15pg in 10j.il. To this, 17j.il o f RNA loading buffer was added. The 
sample was then heated to 65°C for 15 minutes and placed on ice for 5 minutes. 3jil of 
loading dye, bromophenol blue (Sigma) in water, was added and the sample pulse 
centrifuged to collect the contents.
The RNA was separated on a 1% agarose gel containing 2.2M analar formaldehyde 
(BDH). For a 15cm x 15cm gel tray, 20ml of 10 x MOPS buffer and 33ml of
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formaldehyde (BDH) were heated in a 37°C water bath and added to 2g agarose (Gibco 
BRL) melted in 147ml deionised water. The gel was left to set at room temperature. 
Electrophoresis was carried out overnight in 1 x MOPS running buffer at 20V. The 
RNA gel was subsequently washed on a shaking platform in deionised water for 5 hours 
with at least three changes, stained with 50pg/100ml ethidium bromide for 30 minutes 
and destained with deionised water for 30 minutes. The gel was viewed by ultraviolet 
transillumination and photographed to confirm the presence o f RNA in the lanes.
The RNA was transferred to Hybond™ N membrane (Amersham International pic.) 
using upwards transfer in 10 x SSC as described by Sambrook et a l, 1989. The RNA 
was immobilized to the nylon membrane by crosslinking using a UV Stratalinker 1800 
(Stratagene).
2.5.4 Radiolabelled Probes.
Detection of the CD2-myc transgene was with a human c-myc exon 3 probe generated 
from a 1.38kb EcoRI/Clal fragment prepared by Ms. J. Irvine. As a control, blots were 
analysed for the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. This probe 
was generated from a 720bp fragment of rat GAPDH gene as amplified by PCR from rat 
cDNA by R. Hennigan.
Using a multiprime DNA labelling kit (Amersham International pic), c-myc and GAPDH 
fragments were radiolabelled by random priming to generate dsDNA probes. 50- 
lOOng/pl of fragment was made to 25pl with ultra pure water, boiled for 5 minutes and 
chilled on ice. 5 j l i 1 of primer, lOpl of labelling buffer and 2pl of klenow enzyme were 
added, pulse centrifuged at 13000 r.p.m. and chilled on ice. 8pl of [oc32P]dCTP (>3000 
Ci/mmol, Amersham International pic) was added and left overnight at room 
temperature. The next morning the labelled fragment was eluted through a nick column 
(Pharmacia) and stored at -20°C for up to 2 weeks.
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2.5.5 Hybridisation of RNA Blots.
Before hybridisation, RNA blots were pre-incubated with 10-20ml o f hybridisation 
solution in a roller bottle (Techne) at 65 - 68°C. Radiolabelled dsDNA probe was boiled 
for 5 minutes and chilled on ice prior to addition of 100-150ptl to the pre-hybridised 
blots. The blots were hybridised for 2-3 hours at 65°C using QuickHyb™ (Stratagene) 
or RapidHyb™ (Amersham International pic) hybridisation solutions as per suppliers 
instructions. When using QuickHyb™, 500pl of Genebloc (Immunogen International) 
was also added. Blots were washed twice at 65°C with 2 x SSC; 0.1% SDS (Sigma) for 
15 minutes and twice at 65°C with 0.2 x SSC; 0.1% SDS for 15 minutes and set up for 
autoradiography with Hyperfilm™-MP (Amersham International pic.).
2.6  T is s u e  C u l t u r e  T e c h n iq u e s .
2.6 .1  Media.
Complete RPMI
Media was prepared using aseptic techniques. RPMI 1640 medium (Gibco BRL) was 
supplemented with 10% heat inactivated foetal calf serum, lOOU/ml penicillin, lOOpg/ml 
streptomycin, 2mM L-glutamine (all from Gibco BRL) and 5 x 10‘5 M 2- 
mercaptoethanol (BDH).
Cell Freeze Down Medium
10% dimethyl sulphoxide (Merck Ltd.) and 20% foetal calf serum (Gibco BRL) was 
made up in RPMI 1640 medium and filter sterilized through a 0.45pm filter (Gelmain 
Sciences) in aseptic conditions.
2 .6 .2  Single Cell Tum our Preparation.
Tumour/thymus tissue was disaggregated aseptically in complete RPMI medium using 
sterile scalpel blades (Fisons Scientific Equipment) in a 60mm tissue culture petri dish
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(Gibco BRL). Lymphocytes were isolated on a Ficoll-Paque (Pharmacia) density 
gradient at 3000 r.p.m. for 10 minutes in a 15ml centrifuge tube (Falcon). The 
interphase layer containing the live lymphocytes was washed in 10ml complete RPMI 
medium and centrifuged at 1500 r.p.m. for 5 minutes. The supernatant was discarded 
and the cells resuspended in 5- 10ml of complete RPMI medium. A viable cell count was 
carried out either on a Coulter Counter (model ZM, Coulter Electronics Ltd.) or by 
trypan blue (Gibco BRL) exclusion on a haemocytometer.
Cells were frozen to -100°C in 1.5ml Nunc cryotubes (Gibco BRL) at a concentration o f 
5-10 x 106 cells/ml in freeze down medium using a controlled rate freezer (Planar 
Products Ltd., model Kyro 10) and stored in liquid nitrogen (BOC).
2.6.3 Tum our Cell Line Establishment.
Tumour cells were prepared as in section 2.6.2. Cells at a concentration o f 2.5 x 106 
cells/ml in complete RPMI medium were cultured in 25cm2 or 80cm2 tissue culture flasks 
(Gibco BRL) at 37°C in an atmosphere of 5% CO2 in air. Cell cultures were passaged 
every 3-4 days into fresh medium and maintained at a density of 5 x 105 - 5 x 106 
cells/ml. Cell lines established for a time greater than 6 months were frozen to -100°C as 
described above.
2.7  IMMUNOPHENOTYPE ANALYSIS.
Single cell lymphocyte suspensions were prepared as described in section 2.6.2 and 
washed in cold phosphate-buffered saline (PBS, Gibco BRL) containing 0.1% BSA 
(Sigma) and 0.01% sodium azide (BDH). Cells at 1-2 x 106 per ml were centrifuged at 
7000 r.p.m. for 3 minutes and the supernatant discarded. The cells were labelled by 
resuspending them with rat monoclonal anti-mouse antibody (Table 2.1) for 30 minutes 
at 4°C. l-2pg of antibody was used to label 1-2 x 106 cells. Samples were centrifuged at 
7000 r.p.m. for 3 minutes and washed with 200pl o f cold PBS as described above. Two 
further rounds of this washing procedure were carried out. Indirect labelling with anti­
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mouse CD3-biotin conjugate (Serotec) required a second 30 minute incubation with 
streptavidin allophycocyanin (Cambridge Bioscience) followed by three washes in cold 
PBS as described. Cells were resuspended in 500jal of cold PBS, containing 0.1% BSA 
and 0.01% sodium azide, in sterile test tubes (Sarstedt) and analysed on a Coulter Epics 
Elite using the manufacturers recommended protocol. For each fluorochrome used, 
irrelevant isotype matched antibody controls were used to set a region to exclude 
background staining. Fluorescence above this threshold was considered as positive 
fluorescence.
Table 2.1 Rat Monoclonal Antibodies to Mouse Surface Antigens
Antibodv Clone Isotvne (Supplier)
anti-mouse CD8a 
FITC conjugate
53-6.7 Rat IgG2a (Gibco BRL/Sigma)
anti-mouse CD4 
R-phycoerythrin conjugate
H129.19 Rat IgG2a (Gibco BRL/Sigma)
anti-mouse CD3 
Quantum Red conjugate
29B Rat IgG2b (Sigma)
anti-mouse CD45R  
FITC conjugate
RA3-6B2 Rat IgG2a (Pharmingen/Sigma)
anti-mouse a|3 TCR 
FITC conjugate
H57-597 Hamster IgG (Pharmingen)
anti-mouse CD3 
biotin conjugate
KT3 Rat IgG2a (Serotec)
2.8  In  S it u  D e t e c t i o n  o f  A p o p to s is .
TdT-mediated, dUTP-biotin nick end labelling (TUNEL) allows the identification of 
apoptotic cells in situ. This method has been adapted from Gavrieli et a l , 1992.
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2.8.1 Buffers.
TDT buffer
30mM Trizma base pH 7.2 (Sigma), 140mM sodium cacodylate (BDH) and ImM cobalt 
chloride (Sigma) were made to 1 litre in ultra pure water and stored at room 
temperature.
TB buffer
300mM sodium chloride (Sigma) and 30mM sodium citrate (Sigma) were made to 1 litre 
in ultra pure water and stored at room temperature.
DN buffer 
Solution A.
30mM Trizma base pH 7.2 (Sigma) and 140mM sodium cacodylate (BDH) were made 
to 1 litre in ultra pure water and stored at room temperature in a dark bottle.
Solution B.
4mM magnesium chloride (Sigma) was dissolved in Solution A and stored for not more 
than 1 week at 4°C in a dark bottle.
Solution C.
O.lmM DTT (Sigma) was made up in solution B (made fresh).
House detection diluent
1.21g Trizma base (Sigma), 2.92g sodium chloride (Sigma) and 0.2g magnesium chloride 
(Sigma) were dissolved in 80ml o f ultra pure water and adjusted to pH 8.5. 50pl of 
Tween 20 (Sigma) was added for a final 100ml volume.
2.8.2 Tissue Preparation.
Tumour and thymus material was fixed in 10% neutral buffered formalin. The tissues 
were subsequently embedded in paraffin by Mr. I. MacMillan and staff. l-2pm  sections
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were adhered to slides and deparaffinated at 70°C for 20-30 minutes then rinsed in a 
xylene substitute, histoclear (National Diagnostics), for 5 minutes. Alcohol hydration 
was carried out by washing the slides twice in 100% ethanol for 1 minute, once in 95% 
methylated spirit for 2 minutes and then held in distilled water.
2.8.3 Controls.
For each tissue sample a set of controls were prepared in addition to the test section. 
DNase treatment of the tissue section was used as a positive control. As a negative 
control, the section was incubated with TDT buffer instead o f the TdT/dUTP reaction 
mix. The test section was treated with all incubations except the DNase reaction.
2.8.4 Nick End Labelling.
All incubations were carried out with 50-100pl of solution in a humidified chamber at 
room temperature except where stated. Sections were incubated with 20jag/ml 
proteinase K (Sigma) for 30 minutes, then washed 4 times in PBS (Sigma). Positive 
control slides were treated with DNase (20|ug/ml in DN buffer solution C, Boehringer 
Mannheim) for 20 minutes and washed 4 times in PBS. Endogenous peroxidases were 
blocked by rinsing the sections in 3% hydrogen peroxide (Sigma) in methanol for 5 
minutes. The sections were washed 4 times in PBS and immersed in TDT buffer for 2 
minutes. TdT and biotin-16-dUTP (both Boehringer Mannheim) were diluted in TDT 
buffer to 1:100-1:200 (0.15-0.25U/pl) and 1:50-1:100 respectively. Sections, except 
negative controls, were incubated with the TdT/dUTP reaction mix for 60 minutes at 
37°C. The reaction was stopped by rinsing the sections in TB buffer twice for 5 minutes. 
The samples were then washed in PBS 4 times. Incorporation o f biotin-16-dUTP was 
detected by incubating the sections for 60 minutes with peroxidase conjugated 
streptavidin (Dako, Bucks) diluted 1:200 in house detection diluent. The sections were 
washed twice with PBS and stained with peroxidase substrate kit AEC (3-amino-9-ethyl- 
carbazole, Vector laboratories) for 15-30 minutes. After washing in water, the sections 
were counterstained with Mayers haematoxylin (Stevens, 1982) and mounted with 
supermount (Biomen Ltd.). Stained tissue sections were examined by light microscopy
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(Leitz) and apoptosis quantified by determining the number o f chromogen stained single 
cells and macrophages within a field at a magnification of x400. Approximately five 
fields were counted per slide.
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CHAPTER 3.
ACCELERATED T-CELL LYMPHOMAGENESIS IN MICE WITH A CD2-MYC  
TRANSGENE AND P53 NULL MUTATION.
3.1  In t r o d u c t io n .
3 .1 .1  The CDl-m yc  Transgenic Mouse Model.
CDl-myc transgenic mice carry the c-myc oncogene under the regulation o f the CD2 
dominant control region (Greaves et al., 1989) which targets expression to the T-cell 
lineage (Stewart et a l , 1993). Two transgenic lines carrying the CDl-myc construct 
were predisposed to a relatively low incidence (18% and 3%) o f spontaneous T-cell 
lymphoma, occurring at between 3 and 12 months of age (Stewart et al., 1993). High 
levels of transgene expression were detected in the thymic tumours of the CDl-myc 
mice, however, transgene mRNA was not found in normal transgenic thymus. The 
relatively low tumour incidence in these transgenic lines may be related to the lack of 
observable expression in the healthy tissues of these mice. Tumour incidence was 
however also found to be dependent on genetic background (Cameron et a l , 1996). The 
tumours arising in the CDl-myc transgenic mice were monoclonal or oligoclonal as 
determined by TcR and IgH gene rearrangements (Stewart et al., 1993). Consistent with 
the multistep process of tumourigenesis (Weinberg, 1989; Bishop, 1991), the clonality, 
latency and random occurrence of the lymphomas in the CDl-myc mice implied that 
additional events were necessary to collaborate with the transgene in the pathogenesis of 
these tumours. The hypothesis that subsequent events were required for 
lymphomagenesis was supported by the marked reduction in latency and increase in 
tumour incidence observed in MoMuLV infected CDl-myc mice (Stewart et a l,  1993). 
To investigate which genes collaborated with the CDl-myc transgene in MoMuLV- 
induced tumours, a detailed analysis of proviral insertion sites has been carried out 
(Stewart et a l,  1996). These studies have identified infrequent insertions at bmi-1 
(1/77), pim-l (3/77) and ahi-1 (2/77). Significantly, a novel common insertion locus, til- 
1, was identified in 25 of 77 CDl-myc MoMuLV-induced lymphomas (Stewart et al.,
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1996). The til-l locus, which was localised to mouse chromosome 17, is thought to 
harbour a gene which specifically collaborates with c-myc in the development o f T-cell 
lymphoma.
The CDl-myc transgenic mouse provides a useful model to investigate the genetic events 
which collaborate with deregulated c-myc in tumourigenesis. Oncogene collaboration 
can be effectively assessed by breeding together transgenic mice expressing different 
oncogenes (Berns et at., 1989). The synergistic partnership o f c-myc with each of the 
bcl-2, pirn- 1 and bmi-\ oncogenes in B-cell lymphomagenesis was demonstrated in this 
way (Strasser e ta l , 1990; Verbeek eta l., 1991; Haupt et a l, 1993).
3.1.2 Potential Collaboration Between c-myc and p53 in Tumourigenesis.
Several points of reasoning implied that loss o f function o f the p53 tumour suppressor 
gene would co-operate with deregulated c-myc in tumour development. Firstly, many 
previous studies have shown that mutations of both the c-myc and p53 genes co-exist in 
the same human tumour or tumour cell line. Co-existing alterations o f both p53 and c- 
myc have been in described in Burkitt’s lymphoma and L3-type B-cell acute 
lymphoblastic leukaemia (Farrell et a l, 1991; Gaidano et a l, 1991), diffuse large cell 
lymphomas (Farrugia e ta l ,  1994), human oral cancer cell lines (Inagaki e ta l ,  1994) and 
in the clonal evolution of malignant lymphomas (Chang et a l, 1994). Furthermore, 
evidence has emerged to suggest that complementary genetic lesions which result in 
excessive cell proliferation and a block in cell death represents a potent combination for 
tumourigenesis (McDonnell, 1993a). This has been established, for example, in the 
dramatic acceleration of tumourigenesis in transgenic animals carrying both the D\x-myc 
and D\i-bcl-2 transgenes (Strasser et a l, 1990). Loss of p53 function has been shown to 
inhibit apoptosis under certain circumstances (Clarke et al., 1993; Lowe et a l,  1993a; 
Lowe et al., 1994a; Oren, 1994). Therefore, it could be hypothesised that p53 loss 
would provide a complementary lesion to the enhanced proliferative signal o f activated 
c-myc.
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3.1.3 Experimental Aims.
The aim of this study was to use a transgenic mouse model to investigate the combined 
effects o f the CD2-myc lesion and loss of the p53 tumour suppressor gene product in 
tumour development. Mice which lack a functional p53 tumour suppressor gene 
(Donehower et a l, 1992) have proved to be an effective model for investigating the 
consequence of p53 loss in vivo. The predominance o f T-cell lymphoma in these p53 
null mice offered a distinct advantage with which to assess the potential synergy between 
deregulated c-myc and p53 loss in T-cell lymphomagenesis.
3 .2  R e s u l t s .
3 .2 .1  G eneration of Experimental Animals.
In order to assess the in vivo interaction between activated c-myc and p53 loss, hybrid 
transgenic mice with the CDl-myc transgene on a p53 null background were generated. 
This was achieved by crossing CDl-myc transgenic mice (Stewart et a l,  1993) with p53 
null mice (Donehower et a l, 1992). As the p53 mutation was recessive to the wild type 
allele, it was necessary to create an F2 generation by subsequently breeding together 
animals heterozygous for both the CDl-myc transgene and p53 null gene. Mice 
heterozygous for both lesions were also backcrossed with p53 null mice. This breeding 
programme resulted in an experimental cohort of CDl-myc transgenic mice on 
homozygous null (p53''lCD2-myc+), heterozygous null (p53 +/7CD2-myc+) and wild type 
p53 (p53+/+/CD2-wyc+) backgrounds. In addition, littermate controls o f P53*7', p53+/' and 
p53+/+ mice that did not carry the CDl-myc transgene were generated. These 
experimental groups, their genotypes and cohort numbers are given in Table 3.1. The 
various cohorts were subsequently monitored over a twelve month period.
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Table 3.1 Experimental Mouse Cohorts Generated by Breeding Together 
p53 Null and CD2-myc Transgenic Mice.
M ouse Cohorts p53 genotype status CDl-myc genotype status cohort size
p53'/7CD2-wyc+ homozygous null positive 18
p5 3 +/7  CD2-myc+ heterozygous null positive 34
p53+/+/CD2 -myc wild type positive 10
p53'7' homozygous null negative 11
p53+/" heterozygous null negative 24
p53+/+ wild type negative 10
3.2.2 Lymphoma Development In Mice Cariying Both the C D l-m yc 
Transgene and p53 Null Mutation.
Transgenic mice which carried both the CDl-myc transgene and homozygous p53 null 
mutation (p53'/'/CD2-wyc+) were viable. As was predicted from the breeding 
programme, the expected numbers of p53'/7CD2-wyc+ animals survived to birth (Table 
3.1) indicating that the combination of these mutations did not result in pre-natal death. 
These mice appeared clinically normal from birth to post-weaning with no obvious 
evidence of developmental abnormalities.
In comparison to parental groups, the combination o f CDl-myc and p53 null genotypes 
resulted in a marked acceleration in the rate o f spontaneous lymphoma development 
(Figure 3.1). All o f the p53‘/7CD2-wyc+ mice became terminally ill at between 60 and 86 
days of age, much earlier and more synchronously than all other littermates. These mice 
were found to have developed lymphoma with 100% incidence (Table 3.2). The reduced 
latency of lymphomagenesis in the p53'77CD2-wyc+ mice was highly significant (p < 
0.001, Mann-Whitney confidence test) when compared to each of the other groups in the 
study.
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Figure 3.1. Ttimour Free Survival of p53-/- CD2-myc+ Mice and Control Littermates.
T he tum our free survival over a period o f  tw e lve  m onths w as observed  for p 5 3 -/-  
CD2-m yc+ (■ , n=18); p53-/- (O, n = ll) ;  p53+/- CD2-m yc+ ( ♦ ,  n=34); p53+/- ( • ,  n=24); 
p53+/+  CD2-m yc+ ( □ ,  n=10) and p53+/+  (X, n=10) m ice. A nim als were culled w hen  
showing abnormal clinical signs. p53-/- CD2-m yc+ animals had a much reduced survival 
compared to all other littermates.
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Of the control groups, 30% of the p53+/7CD2-/wyc+ mice died with a latency of between 
4 and 8 months and 100% of p53'7' mice died at a latency o f 3 to 10 months. These 
results, shown in Figure 3.1, were comparable with the original reports o f these 
transgenic lines (Stewart et al., 1993; Donehower et al., 1992) and demonstrated the 
increased kinetics of tumour development in the mice carrying both these genetic lesions. 
From these observations it was concluded that the presence o f the c-myc transgene and 
loss o f p53 function acted synergistically during lymphomagenesis.
As evident from Figure 3.1, there was no significant difference in the tumour incidence 
between CDl-myc transgenic animals heterozygous for the p53 null mutation (p53+/' 
/CDl-myc+) and CDl-myc animals on a wild type p53 background (p 5 3 +/7  CDl-myc+) 
during the 12 month observation period (Mann-Whitney confidence test). The study of 
these animals was extended further and will be discussed in chapter 5.
3.2.3 Pathology and Histopathology of p53‘/7CD2-/wyc+ Lymphomas.
CDl-myc transgenic mice have been found to develop only thymic lymphoma, consistent 
with the targeting of the transgene to the T-cell lineage (Stewart et a l , 1993). Although 
lymphoma was the most common neoplasm observed in p53'A mice, these mice 
developed a range of tumour types (Donehower et a l, 1992). In addition, p53'/_ mice 
frequently developed two or more independent tumour types. Similarly in the current 
study, 45% of the p53*/’ mice developed non-lymphoid tumours, and 27% developed 
both a lymphoid and co-existing non-lymphoid neoplasm, as shown in Table 3.2. In 
contrast to p53*A mice, p53'/7CD2-wyc+ mice developed exclusively thymic lymphoma 
(Table 3.2). No evidence of a second primary tumour type was observed in any of the 
p53'/7CD2-wyc+ mice at post-mortem.
The development of lymphoma in the p53'/7CD2-/wyc+ mice elicited recognizable clinical 
signs. Afflicted animals were generally smaller and thinner than littermates with an 
uneven coat texture and an increased respiratory rate. The movement and responses of 
ill mice were usually slower, and occasionally animals exhibited a high gait. These 
clinical signs were similar to those of CDl-myc and p53'A animals which also developed 
lymphoma.
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Table 3.2 Tumour Development in p53"/ /CD2-myc+ Mice and Control Groups.
A. Tumour Tvpes o f p53'/7CD2-wvc+ Mice.
Tum our Type Incidence Lifespan
Thymic Lymphoma 18/18 (100%) 60 - 86 days
B. Tumour Tvpes o f p53‘/‘ Mice.
Tum our Type Incidence Lifespan
Thymic lymphoma only 6/11 (55%) 78 - 295 days
Thymic lymphoma & haeinangiosarcoma 2/11 (18%) 1 3 6 -2 0 1  days
Thymic lymphoma & fibrosarcoma 1/11 (9%) 233 days
Haemangiosarcoma 1/11 (9%) 113 days
Osteosarcoma 1/11 (9%) 237 days
C. Tumour Types o f p53+/+/CD2-/;/vc+ Mice.
Tumour Type Incidence Lifespan
Thymic lymphoma 3/10 (30%)* 126 - 238 days
*the remaining 70% of p53+/+/CD2-w>»c+ animals were healthy at the end o f  the experiment.
Gross pathological examination revealed that the thymus of all p53'/7CD2-/wyc+ mice was 
abnormally enlarged with loss of the normal bilobed structure. In most cases the thymic 
tumour filled the thoracic cavity. Histopathological examination o f the thymic tumours 
revealed that the normal architecture of the thymus tissue was replaced by large 
pleomorphic lymphoblasts showing an extremely high mitotic rate. A ‘starry sky’ pattern 
due to marked cell death and increased macrophage activity was observed. The 
histopathological findings were consistent with a diagnosis o f lymphoblastic thymic 
lymphoma and were similar to those previously found in CDl-myc tumours (Stewart et 
al., 1993).
67
3.2.4 Metastatic Spread In p53'/ /CD2-/wyc+ Lymphomas.
A characteristic feature o f the lymphomas which developed in the p53'/7CD2-/wyc+ mice 
was the high degree o f metastasis. Gross pathology showed that, without exception, all 
p53'/7CD2-wyc+ thymic tumours were accompanied by metastatic spread to the 
secondary lymphoid tissues. The spleen, mesenteric and subcutaneous lymph nodes were 
always enlarged, generally grossly so. In addition, involvement o f the liver and kidneys 
was often observed, with an increase in organ size and associated pallor. 
Histopathological diagnosis of these tissues confirmed that the lymphoblastic lymphomas 
were associated with multiorgan involvement. The spleen was usually replaced by 
lymphoblasts and often had areas of extra-medullaiy haemopoiesis. The normal 
architecture of the lymph nodes was altered by the presence o f large lymphoblasts and 
the liver and kidneys showed varying degrees of lymphoblastic infiltration. Diffuse 
infiltration of the bone marrow was frequently observed.
In contrast to the p53_/7CD2-wyc+ mice, gross pathological examination o f parental 
p53+/7CD2-wyc+ and p53'/_ groups did not always demonstrate metastatic spread and 
when metastasis did occur it was seldom as advanced as that seen in the p53'/7CD2-myc+ 
group. Four out o f nine lymphomas which developed in the p53'A controls were 
restricted to the thymus with little or no involvement o f other tissues. The other 
lymphomas in this group exhibited obvious splenic involvement but, in general, had 
limited spread to lymph nodes and non-lymphoid tissues. Two out of three of the 
p53+/+/CD2-/?7yc,+ lymphomas did demonstrate gross enlargement o f the spleen and lymph 
nodes but with little involvement o f the thymus. In these instances the architecture o f the 
thymus was still recognizable although histopathological examination did denote tumour 
activity.
3.2.5 CDl-myc Transgene Expression.
Previous studies have shown that although high levels o f human c-myc were observed in 
thymic tumours of CDl-myc transgenic mice, transgene expression was not detected in 
preneoplastic tissues (Stewart et al., 1993). Therefore to confirm that the CDl-myc
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transgene was transcriptionally active in the p53'/7CD2-wyc+ tumours, Northern analysis 
was carried out on these tissues. As Figure 3.2 illustrates, all p53'/7CD2-myc+ thymic 
lymphomas examined (14/14), expressed detectable levels o f the CDl-myc transcript. 
Transgene expression was also detected in the kidney tissue o f some o f the p53'77CD2- 
myc+ mice (Mrs. M. O’Hara, personal communication; Blyth et a l, 1995). This result 
correlates well with the metastatic spread to kidney tissue in these mice. It can be 
concluded from these results that overexpression o f the CDl-myc transgene was 
contributing to the development o f lymphoid tumours in p53*/7CD2-myc+ mice.
3.2.6 Im m unophenotype Analysis.
Cells prepared from thymus or lymph node tumour tissue were analysed by flow 
cytometry to ascertain the cell lineage of the lymphomas. The panel of antibodies used in 
this analysis is given in Table 2.1. Isotype matched antibody controls were used for each 
flourochrome to exclude non-specific staining. All p53‘/7CD2-wyc+ lymphomas studied 
were found to be of T-cell origin, staining positive for the CD3 T-cell specific marker 
(Figure 3.3.a). Furthermore, none of the lymphomas stained positive for the B-cell 
marker CD45R (B220). The T-cell composition of the tumours was confirmed by TcR 
rearrangement analysis (Mrs. A. Terry, personal communication; Blyth et al., 1995).
The tumours were also stained for expression of the T-cell surface antigens CD4 and 
CD8 (Figure 3.3.b). The most common phenotype detected in p53‘/7CD2-wyc+ tumours 
was a CD4+CD8+ double-positive phenotype, with 9 out o f 17 lymphomas consisting 
predominantly of CD4+CD8+ tumour cells (Table 3.3). None o f the p53‘/7CD2-/wyc+ 
tumours were of an exclusive single-positive mature phenotype, either CD4'CD8+ or 
CD4+CD8'. One tumour was double negative for CD4 and CD8 co-receptor expression.
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Figure 3.2. Northern B lot A nalysis of p53-/- CD2-m yc+ Thym ic Tiimours.
The thymic tumours o f p53-/- CD2-myc+ mice were assessed for CD2-myc transgene 
expression using a probe to human c-myc exon 3. Lanes 1 and 2 are positive and 
negative controls respectively. Lanes 3 to 8 represent a selection o f p53-/- CD2-myc+ 
tumours, the code name for each tumour is given. Samples were also probed for the 
murine GAPDH gene to confirm the presence o f RNA.
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Similar to that observed with the p53v7CD2-wyc+ tumours, the predominant phenotype 
o f both CDl-myc and p53'A tumours was CD4+CD8+ (Table 3.3). Due to the low 
tumour number in the p53+/7CD2-wyc+ control group o f the current study, CDl-myc 
tumour phenotype data has been taken from a separate study (Cameron et al., 1996) for 
the purpose of comparison. More than 20% (18/89) of CDl-myc tumours demonstrated 
a CD4'CD8+ single-positive phenotype. The absence o f mature single-positive 
phenotypes in p53‘/7CD2-/wyc+ tumours therefore is in contrast to that seen in CDl-myc 
tumours.
Table 3.3 The CD4/CD8 Phenotype of p53/7CD2-myc+ Lymphoid Tumours as 
Analysed by Flow Cytometry.
Tumour phenotype CD4+CD8+ CD4+CD8' CD4'CD8+ C D 4C D 8' m ixed8
No. (%) o f p53‘7C D 2- 9/17 0 0 1/17 7/17
myc+ lymphomas (53%) (6%) (41%)
exhibiting phenotype
No. (%) o f p537- 8/16 0 1/16 2/16 5/16
lymphomas exhibiting (50%) (6%) (12%) (31%)
phenotype b
No. (%) o f CDl-myc 61/89 1/89 18/89 1/89 8/89
lymphomas exhibiting (69%) (1%) (20%) d% ) (9%)
phenotype0
a mixed tumour phenotype refers to instances where more than one major population exists. 
b these results are a combination o f the current cohort o f p53'A lymphomas (n=8) and o f other previously 
unpublished results taken from a control cohort (n=8). 
c results from Cameron et al., 1996 (see text).
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Figure 3.3.a. Flow Cytometry Analysis of p53-/- CD2-myc+ Lymphomas.
T his figure illustrates the CD3 surface marker expression o f  normal mouse thymocytes (top) 
and a representative p53-/- CD2-m yc+ lymphoma (bottom). Normal thymocytes had both a 
low  and high peak o f CD3 surface expression. All p53-/- CD2-m yc+ thymic lymphomas were 
positive for CD3 surface expression and displayed a sin g le  peak o f  CD3 expression. The 
percentage o f  positive cells low  for CD3 expression (E) and high for CD3 expression (F) is 
shown.
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Figure 3.3.b. Flow Cytometry Analysis of p53-/- CD2-myc+ Lymphomas.
T h is figure illustrates the CD4 and CD8 surface m arker exp ression  o f  norm al m ouse  
thym ocytes (top left) and two p 5 3 -/-  C D 2-m yc+  lym phom as. T he m ajority o f  p 5 3 -/-  
C D 2-m yc+ thym ic tumours were C D 4+C D 8+ tumours (top right) although a num ber o f  
tumours consisted o f a mixed population phenotype (bottom). The percentage o f  positive cells  
in each quadrant is shown.
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3.2.7 Tumour Clonality.
A prominent feature of the p53'/7CD2-wyc+ lymphomas was the number o f tumours 
(7/17) with more than one discrete T-cell population (Table 3.3). These tumours 
frequently (4/7) consisted of a CD4+CD8+ population and a CD4'CD8+ population 
(Figure 3.3.b). Mixed T-cell populations were also observed in p53'/_ lymphomas (5/16). 
Although mixed T-cell populations were not unique to the p53'/7CD2-myc+ cohort, the 
frequency with which they occurred may reflect an increase in the clonal complexity of 
the tumours. Clonal complexity was further characterised by investigating IgH 
rearrangements by Southern blot analysis (carried out by Mrs. A. Terry). Rearrangement 
o f the IgH gene was a frequent event in the lymphomas which were studied. The 
oligoclonal pattern of these tumours confirmed that the p53'/7CD2-/wyc+ tumours were 
generally of greater clonal complexity than the parental p53+/+/CD2-myc and p53'/* 
cohorts (Figure 3.4).
3.2.8 Cell Line Establishment.
Lymphoid tumour cells were routinely isolated from thymic lymphomas by 
disaggregation and separation on a ficoll density gradient. The in vitro growth potential 
o f these cells was investigated in long term cell line culture. All of the p53'/7CD2-wyc+ 
tumours which were tested (13/13), readily established in long term culture without 
addition of growth factor. This result was in marked contrast to tumour cells isolated 
from CD2-myc mice which always failed to establish in culture under these conditions 
(6/6). Long term cell line establishment of p53v' lymphoma cells was frequently 
achieved. Three out of 6 p53_/' lymphomas from the current study group and 6/7 from 
previous experiments successfully established in vitro. O f the p53';‘ lymphomas which 
failed to establish in culture, 3/4 were isolated from mice which presented with a co­
existing haemangiosarcoma at post-mortem. The establishment o f p53';' tumour cells 
was also found to correlate with the age at which these mice developed lymphomas. 
Lymphomas developing in younger mice were found to establish more frequently than 
lymphoma cells isolated from older animals.
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Figure 3.4. Increased Clonal Complexity of p53-/- C D 2-m yc+ Tumours.
IgH rearrangements were used to assess the clonality o f  thymic tumours (T) and kidney 
(K) tissues o f p53-/- CD2-myc+ mice and control littermates. Three representative p53-/- 
CD2-myc+ tumours and three control genotypes are shown in this figure, adapted from  
Blyth et al. , 1995. The tumour name and mouse genotype for each sample is given above 
the blot. It can be seen that p53-/- CD2-m yc+ tumours were generally o f  greater clonal 
complexity than tumours from parental controls. These Southern blots were carried out by 
Mrs. A. Terry and have been used here with Anne's kind permission.
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3.2.9 Immunophenotype Analysis of p53"/ /CD2-mpc+ Cell Lines.
Immunophenotype analysis was carried out on a proportion o f the p53'/7CD2-myc+ cell 
lines. Six lines which had been established for a period o f greater than 6 months were 
chosen as it was thought that these lines would be stable with respect to T-cell 
differentiation. Particular attention was given to those cell lines which had been derived 
from lymphomas exhibiting mixed T-cell populations. All o f the p53*/7CD2-/wyc+ cell 
lines analysed contained monoclonal populations with respect to CD4 and CD8 
phenotype, results are shown in Table 3.4.
Table 3.4 Immunophenotype of Established Tumour Cell Lines.
M ouse
Identification
Num ber
M ouse Genotype Tumour Populations* Cell L ine Populations
p/m -31 p53'7C D2-w yc+ CD4+CD8+* & CD4'CD8+ CD4+CD8+
p/m-63 p53‘/7CD2-///vc+ CD4+CD8+* & CD4'CD8+ CD4+CD8+
p/m-64 p53'7C D2-w vc+ C D 4C D 8* & CD4 CD8+ C D 4C D 8'
p/m-65 p53'7CD2-//;vc+ CD4+CD8+ CD4+CD8'
p/m-85 p53'7CD2-///yc+ CD4+CD8+* & CD4 CD8' CD4+CD8+
p/m -103 p53‘7C D 2-///yc+ CD 4CD 8' C D 4C D 8‘
p/m-40 p53_/‘ CD4+CD8+* & CD4'CD8+ CD4+CD8+ & CD4'CD8+
p/m-97 p53'A CD4+CD8+ & CD4 CD8+* CD4 CD810 & CD4'CD8+
* represents only principal clonal populations o f greater than 30%
* indicates the major tumour population
In five of the six lines, the cell line population was a reflection of the main tumour 
population (Table 3.4). In one cell line, p/m-65, a mature CD4+CD8' population was 
observed which was in contrast to the immature CD4+CD8+ population of the tumour. 
This may have been due to downregulation of CD8 surface expression in vitro, resulting
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in the differentiation of the cells during culture. Alternatively, a minor population (15%) 
of CD4+CD8' cells which was present in the tumour may have outgrown the main 
CD4+CD8+ tumour population in vitro. Two of the p53'/_ cultured cell lines were also 
immunophenotyped (Table 3.4). Unlike the p53'/7CD2-myc+ cell lines, the p53'A lines 
were not monoclonal. One cell line had a diffuse CD4+CD8+ population and a separate 
CD4’CD8+ population. Both of these populations were present in the original tumour.
3.2.10 In situ Apoptosis Studies.
In an attempt to investigate the apoptotic status o f the p53'/7CD2-/wyc+ lymphomas, 
tissue sections were examined by the TUNEL technique. This technique involves the 
incorporation of labelled nucleotide into the DNA strand breaks o f apoptotic cells using 
terminal deoxynucleotidyl transferase. The labelled nucleotide can then be identified by 
conventional immunocytochemistry (Gavrieli et a l, 1992). Tissue sections o f p53*A 
!CDl-myc+ lymphomas were stained by this technique and compared against p53'/_ and 
CDl-myc lymphomas (Figure 3.5). Normal mouse thymus was used as a control. 
Apoptosis was found to occur in the lymphomas o f all three tumour groups tested. Two 
staining patterns were observed, staining of single cells and staining of apoptotic bodies 
engulfed within phagocytic cells. A high degree o f heterogeneity was found in the 
thymic tumours o f all genotypes. Some tumours were found to contain many positive 
cells and/or apoptotic bodies while some tumours had very few positively stained cells 
(Figure 3.5). Detailed examination of the tissue sections and quantification o f the 
apoptotic indices revealed that there was no obvious difference in the staining patterns or 
number o f apoptotic cells of p53'/7CD2-wyc+ tumours versus CDl-myc (p53+/+) and p53' 
'' lymphomas (Figure 3.6).
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»Figure 3.5.a. TUN EL Analysis, Control Sections.
Top: Normal mouse thymus (x50); Bottom left: Positive control, tumour section treated with 
DNase (x50). Bottom right: Negative control, tumour section to which TdT/dUTP enzym e 
mix was not added (x50). (Original in colour).
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Figure 3.5.b. TUNEL Analysis o f p53-/- C D 2-m yc+ Thmour Sections.
This figure illustrates TUNEL-stained sections o f two p53-/- CD2-myc+ thymic tumours (x50). 
Apoptotic cells appear as red stained cells. The level o f apoptosis was heterogenous within the 
p53-/- CD2-myc+ tumour cohort as shown by these two sections. (Original in colour).
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Figure 3.5.C. TUNEL Analysis of p53-/- Tumour Sections.
TUNEL-stained sections o f two p53-/- thymic tumours displaying the heterogeneity o f  
staining patterns observed in this tumour cohort (x50, Original in colour).
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Figure 3.5.d. TU N EL A nalysis of CD2-m yc lU m our Sections.
TUNEL-stained sections o f  two CD2-m yc thymic tumours (x50). The level o f  apoptosis was 
heterogenous within this tumour group. Obvious macrophage engulfment o f apoptotic bodies can 
be observed in the top photograph. (Original in colour).
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Figure 3.6. Assessment of Apoptosis in p53-/- CD2-myc+ Thymic Himours.
The level o f  apoptosis in each o f  fourteen p 53-/- C D 2-m yc+ tumours, six  p53-/-  
tumours and seven CD2-m yc+ tumours was assessed using the TUNEL method. 
Positive stained cells were counted in six high power light microscope fields (x400) 
for each tumour section and an average taken. Each cell or macrophage containing 
apoptotic bodies was regarded as one positive count. The standard error bars show  
the range o f the total number o f apoptotic cells which were seen for each genotype. 
There was no statistical difference in the level o f  positive apoptotic ce lls  in  the 
p 5 3 -/-  C D 2-m yc+  tum our group versus the control groups (M an n-W hitn ey  
confidence test).
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3.3 D i s c u s s i o n .
3.3.1 Synergy Between CD2-myc and p53 Loss in T-Lymphomagenesis.
The combined action o f c-myc overexpression and lack of the p53 tumour suppressor 
gene product was investigated in an in vivo tumourigenesis model. Transgenic mice 
positive for both a CD2-myc transgene and homozygous p53 null mutation were 
generated by crossing these parental strains together (Stewart e ta l , 1993; Donehower et 
al., 1992). The co-existence of these genetic lesions predisposed the ‘double transgenic’ 
animals to rapid lymphoma development. Relative to parental strains, the p53_/7CD2- 
myc mice developed lymphomas with increased frequency at a significantly accelerated 
rate. All p53'/7CD2-wyc+ mice were found to succumb to T-cell lymphomagenesis 
before 13 weeks of age. It was concluded from these observations that overexpression 
of c-myc and loss of p53 function could act synergistically to promote T-lymphoid 
tumours in mice.
Collaboration of c-myc and p53 mutations in tumourigenesis was previously suggested 
from the observed co-existence of these mutations in a number o f human cancers, 
particularly lymphomas (Farrell et a l, 1991; Gaidano et al., 1991; Farrugia et al., 1994; 
Chang et al., 1994; Ballerini et al., 1992). Moreover, p53 mutations were found to 
occur in B-cell tumours arising in E \x-myc transgenic mice (Scheuermann & Bayer, 1992; 
Adams & Cory, 1992). In contrast however, p53 mutations were an infrequent event in 
c-myc induced mouse plasmacytomas (Gutierrez et a l, 1992). Direct confirmation that a 
co-operative relationship does exist between these genetic mutations has been provided 
by the current p53'/7CD2-wj>c+ model.
3.3.2 p53'/ /CD2-wjc+ Mice Develop Malignant Thymic Lymphomas.
Consistent with the observation that p53 mutations are common in a wide spectrum of 
human cancers (Hollstein et a l, 1991; Jego et a l, 1993), p53 null mice develop a range 
o f tumour types (Donehower et a l,  1992; Purdie et a l, 1994; Jacks et a l,  1994). In 
contrast, p53'/7CD2-/?7yc+ mice developed only one tumour type, namely lymphoblastic
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thymic lymphoma. The CD2-myc transgene is targeted to the T-cell lineage and as such 
C m -m yc  transgenic mice develop only T-cell lymphomas (Stewart et a l , 1993). 
Therefore the presence of the CD2-myc transgene has restricted the tumour phenotype 
o f the ‘double transgenic’ mice. It is possible however that the early age at which the 
p53'/7CD2-wyc+ mice died may have circumvented the latency time necessary for other 
neoplasms to manifest. In general, sarcomas and carcinomas do not develop in P53*7' 
mice until after a latency of 16 weeks.
The p53'/7CD2-wyc+ lymphomas were observed to be highly metastatic exhibiting 
multiorgan involvement and associated lymphoblastic leukaemia. This high level of 
metastatic spread was not always displayed by the control p53+/7CD2-/wyc+ and p53_/' 
mice. Thus the combination of a p53 null background and overexpressed c-myc 
produced a highly malignant tumour phenotype. Based on flow cytometry analysis and 
immunoglobulin gene rearrangements, the p53*/7CD2-wyc+ lymphomas were generally of 
higher clonal complexity than the control littermates. The oligoclonality o f these 
tumours however indicated that these two events alone were insufficient for complete 
neoplastic transformation. This interpretation was confirmed by infection of p53_/7CD2- 
myc mice with MoMuLV which resulted in a further acceleration o f tumour onset (see 
chapter 6).
3.3.3 Synergy Occurs Between the p53 null Mutation and Several c-myc 
Transgenes.
Subsequent to this study, two independent laboratories reported similar findings. By 
crossing p53 null mice with E \x-myc transgenic mice, Hsu and co-workers demonstrated 
that these lesions also act cooperatively to reduce the latency time o f B-cell 
lymphomagenesis. The tumours arising in the p53+/7Ep-/wyc mice were high grade 
diffuse large cell malignant lymphomas similar to E yi-myc mice (Hsu et a l , 1995). The 
effects of the MMTV/c-myc transgene on a p53 null background was investigated in a 
separate study by Elson et a l (1995). This transgene was expressed in a variety of 
tissues and the authors postulated that the co-existing effects o f these lesions could be 
assessed in a number of cell types. Most o f the p53+/7MMTV/c-/wyc transgenic animals
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however developed pre-T and T-cell lymphomas even although the predominant tumour 
type of MMTV/c-zwyc mice was mammary carcinoma (Stewart et al., 1984a). The lack 
o f acceleration in mammary tumour formation in these mice may be a reflection that 
mouse mammary tissue is not particularly susceptible to the effects o f p53 loss, 
consistent with the rare incidence of mammary tumours in p53 null animals (Donehower 
et al., 1992; Purdie et al., 1994). However it was suggested by Elson and co-workers 
that this result may be due to a cell type specific collaboration between the c-myc and 
p53 null lesions (Elson eta l., 1995).
In contrast to p53'/7CD2-wyc+ mice, no co-operation was observed between the CD2- 
myc transgene and the heterozygote p53 mutation during the twelve month observation 
period of this study (Figure 3.1). By comparison, synergy with each o f the MMTV/c- 
myc and E \x-myc transgenes was demonstrated in animals which were genotypically 
heterozygous for the p53 null mutation (Elson et al., 1995; Hsu et al., 1995). As all 
three studies utilized the same strain of p53 null mouse (Donehower et al., 1992), it 
seems likely that these contrasting results reflect differences in either the c-myc 
transgenes and/or the targeted tissue type. The lack of acceleration in p53+/7CD2-/wyc+ 
mice compared with p53'/7CD2-wyc+ mice suggests that loss o f the wild type p53 allele 
may be an important event for the initiation of these tumours. Similarly, loss o f wild type 
p53 was observed during the tumourigenesis process in p53+/7MMTV/c-/wyc and p53+/' 
fE\i-myc mice resulting in a reduction to homozygosity in a significant proportion o f the 
heterozygote tumours (Elson et al., 1995; Hsu etal., 1995).
3.3.4 Mechanisms of Synergy in p53'/ /CD2-myc+ Accelerated Lymphomas.
Several plausible, but not exclusive, hypotheses could account for the genetic synergy 
between the CD2-myc and p53‘A mutations. Firstly, p53 and c-myc proteins have been 
shown to transcriptionally modulate the activity o f each other. In vitro assays 
demonstrated that wild type p53, but not mutant p53, specifically repressed transcription 
from the c-myc promoter (Moberg et al., 1992; Ragimov et al., 1993). These results 
explain the observation that induced wild type p53 activity downregulated c-myc 
expression in M l myeloid leukaemia cells during p53 mediated growth arrest (Levy et
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a l , 1993). Recent in vitro studies showed that high levels o f c-myc could abrogate p53- 
induced growth arrest which may explain why repression o f c-myc is important during 
p53-mediated growth arrest (Hermeking et a l,  1995). The c-myc protein in turn, has 
been shown to transactivate both the murine and human p53 gene by directly binding to a 
recognition motif in the p53 promoter (Reisman et a l,  1993; Roy et a l, 1994). The 
paradoxical roles for c-myc and p53 at the transcriptional level suggests a negative 
feedback loop whereby inappropriate expression of c-myc would be regulated by p53 
under normal circumstances. Loss o f p53 function may result therefore in uncontrollable 
c-myc expression leading to a highly proliferative state. As the CD2-myc transgene 
retains the PI regulatory sequences it is possible that p53 can exert a degree o f control 
on transgene expression.
Wild type p53 functions as a G1 cell cycle checkpoint, monitoring the integrity o f the 
genome (Lane, 1992) and mediating growth arrest on cellular insult (Kastan et a l, 
1991a). It has been suggested that loss o f p53 function creates a situation where genetic 
instability occurs allowing increased accumulation o f oncogenic mutations in the cell 
(Lane, 1992). With regard to the p53';7CD2-myc transgenic model, this hypothesis 
could imply that loss of p53 acts by promoting the survival o f cells containing mutations 
in other w^c-collaborating genes. It is noteworthy to recall that the CD2-myc transgene 
is not constitutively active in transgenic tissues (Stewart et al., 1993). It is possible that 
conditional transgene expression may rely on the stochastic activation o f the transgene by 
unknown genetic events which need not be oncogenic but would be related to chromatin 
configuration at the transgenic loci. Genetic instability created by p53 loss in p53‘/7CD2- 
myc cells could permit survival o f cells with sustained chromosomal damage which may 
lead to the activation o f the CD2-myc transgene. In this way, p53 loss would not have 
direct significance with respect to tumourigenesis. Recent reports demonstrated that loss 
o f p53 function in null mice was not associated with an increased accumulation of 
mutations (Sands et a l, 1995; Nishino et a l,  1995). These results would support the 
proposal that the p53 null mutation acts to directly synergize with the CD2-myc 
transgene rather than merely allowing other collaborating or activating mutations to 
occur. It should be noted nevertheless that the studies by Sands et al. and Nishino et al.
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did not account for all possible chromosomal aberrations and that undetected mutational 
events may have occurred.
A report by Metz and colleagues demonstrated that p53 loss can directly contribute to 
immortalisation and tumourigenesis, possibly by abrogating an intrinsic senescence 
pathway (Metz et a l,  1995). Studies o f mouse embryo fibroblasts isolated from p53 null 
mice demonstrating increased in vitro growth without crisis (Harvey et a l,  1993c; 
Tsukada et a l, 1993) support the idea of wild type p53 as an enforcer of senescence. 
Metz et a l  found that although p53 loss greatly facilitated immortalisation and 
transformation of haematopoietic cells, it was in itself insufficient and required 
expression of both myc and ra f oncogenes for indefinite cellular proliferation. This 
observation is reflected in cell line establishment of p53'/7CD2-/wyc+ and p53v' lymphoma 
cells where p53‘/7CD2-wyc+ cells, expressing the CD2-myc transgene, consistently 
established in culture but only a proportion o f P53*7’ tumours did. It should be noted 
however that the p53‘A cells were derived from tumours and would be expected to have 
secondary mutations, possibly capable of complementing the p53'A genotype in 
immortalisation. The results of Metz et a l indicated that the absence o f p53 had a direct 
effect on cellular expansion and that immortalisation was not due to uncontrolled growth 
o f cells which had sustained a mutation in a senescence gene.
3.3.5 Loss of p53-Dependent Apoptosis To Explain Synergy with c-myc.
Under certain conditions, the c-myc oncogene can induce apoptosis rather than 
proliferation (Evan et a l, 1992; Shi et a l, 1992; Askew et a l,  1991). The specific 
inhibition of c-myc mediated apoptosis by the bcl-2 oncogene may well have accounted 
for the potent synergy observed between these oncogenes (Bissonnette et a l,  1992; 
Fanidi et a l, 1992; Marin et a l, 1995). Loss o f p53 associated apoptosis has been 
shown by Lowe and co-workers to directly co-operate with overexpression o f the E l A 
oncogene in the induction and progression of tumour development in vivo (Lowe et a l, 
1994a; Symonds et a l, 1994). Therefore it is possible that the collaboration observed 
between p53 loss and deregulated c-myc may occur as a result o f attenuated apoptosis.
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Several lines of evidence support the hypothesis that loss of p53-dependent apoptosis is 
important for the synergy observed between c-myc and p53'7' lesions. Firstly, Wang and 
co-workers observed that reconstitution of wild type p53 into two established cell lines 
deficient for p53 and overexpressing myc oncogenes resulted in rapid cell death by 
apoptosis (Wang et a l , 1993a; Ramqvist et al., 1993). Furthermore, this p53-induced 
apoptosis was inhibited by overexpression o f the bcl-2 oncogene (Wang et a l , 1993b). 
Lotem and Sachs (1993b) similarly found that overexpression o f c-myc in M l myeloid 
leukaemia cells under wild type p53 conditions induced apoptosis and that loss of p53 
resulted in the suppression of apoptosis. These authors suggested that by abrogating the 
c-myc apoptotic pathway, loss of p53 would cause c-myc expression to drive cells into 
proliferation (Sachs and Lotem, 1993). In this way p53 loss would parallel the action of 
the bcl-2 oncogene (Bissonnette et a l , 1992; Fanidi et a l, 1992). This hypothesis was 
supported by two reports demonstrating that wild type p53 was directly required for the 
execution of the c-myc induced apoptotic pathway in fibroblasts, and that lack o f p53 in 
these cells prevented c-myc associated cell death (Wagner et a l,  1994; Hermeking and 
Eick, 1994). In this respect, c-myc mediated apoptosis resembles ElA-induced 
apoptosis which also requires functional p53 protein (Lowe et a l,  1993b; Debbas and 
White, 1993; Lowe et a l, 1994a). While the combination o f wild type p53 and 
overexpressed c-myc was found to induce apoptosis in rat hepatocellular carcinoma cells, 
expression of wild type p53 in the absence o f c-myc expression did not induce apoptosis 
but rather mediated growth arrest (Saito and Ogawa, 1995). These authors concluded 
therefore that p53-mediated apoptosis was a specific response to overexpressed c-myc 
(Saito and Ogawa, 1995).
3.3.6 The Role of p53-Dependent Apoptosis in the p53'/7CD2-myc+ Model.
Cell lines derived from p53_/7CD2-wyc+ lymphomas were found to uniformly establish in 
culture whereas CT>2-myc cell lines consistently failed to do so. It could be postulated 
that this result reflects a blockage in the c-myc apoptotic pathway which is associated 
with loss of p53. In an attempt to discern the possibility that abrogation of p53- 
dependent apoptosis was important in the pathogenesis o f the tumours arising in the p53’ 
!'/CD2-myc+ mice, tumour tissue was examined by TUNEL analysis. Preliminary
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investigations have indicated that the degree o f apoptosis in p53'/7CD2-/wyc+ tumours 
was no different to that observed with both CD2-myc and p53*A control tumours. These 
results are consistent with those of Hsu et a l (1995) who similarly used TUNEL analysis 
to demonstrate that there was no significant difference in apoptotic levels between Ejx- 
myc tumours with and without wild type p53. These authors suggested that the 
accelerated lymphoma development in p53+/7Ep-/wyc tumours was not due to a reduction 
in apoptosis but rather to the loss of p53 growth arrest function, and that p53 was not 
required for c-myc mediated apoptosis during lymphomagenesis (Hsu et al., 1995).
However, it should be noted that apoptosis does occur in p53‘/_ lymphomas as was 
previously described by Purdie et a l (1994). This was also observed in the p53'A 
lymphomas analysed by TUNEL in the current study where apoptosis levels were 
comparable to that o f CD2-myc and p53'/7CD2-wyc+ tumours. These results confirm 
that apoptosis occurs by p53-dependent and p53-independent pathways (Clarke et a l , 
1993; Lowe et a l , 1993a). Indeed, it has been shown that c-myc induced apoptosis can 
occur by p53-dependent and p53-independent pathways (Sakamuro et al., 1995). It 
would be expected therefore that p53v7CD2-myc* cells would be capable of executing 
more than one apoptotic pathway. Moreover, it should be emphasized that the p53’7* 
/CD2-wyc+ tissues analysed in this study were tumours which may have sustained 
multiple genetic hits. Any one o f these events may have influenced apoptotic programs. 
Consequently the apoptosis exhibited by p53'/7CD2-/wyc+ tumours may not be 
specifically associated with c-myc. In conclusion therefore, although these results do not 
indicate that the p53'7' lesion acts to suppress CD2-w^c-induced apoptosis in these 
tumours, neither do they discount this possibility. Further investigations with non- 
tumourous tissue would be required to formally address this issue.
As a tumour suppressor, wild type p53 can act as a cell cycle checkpoint monitoring the 
cell for damage and elicit growth arrest and/or apoptosis as required. It was perhaps not 
surprising then that loss of p53 collaborated so effectively with c-myc when one 
considers the consequence of abrogating any one or all o f these functions. A subjective 
scenario to explain this interaction could be proposed. Stochastic activation o f CD2-myc 
causes overexpression of the transgene in cells which survive due to the lack o f a p53
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cell cycle checkpoint. These wyc-overexpressing cells are unable to mediate a p53- 
dependent c-myc apoptosis pathway and so continue to proliferate. A few clones o f the 
expanded cell population undergo further mutations leading to the development of rapid, 
highly metastatic oligoclonal T-cell lymphomas. Further analyses with the p53'/7CD2- 
myc model may provide formal evidence to support part or all o f this hypothetical 
mechanism.
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CHAPTER 4.
A STUDY OF EARLY NEOPLASTIC CHANGES IN 
p53'/7CD2-myc+ TRANSGENIC MICE.
4.1 In t r o d u c t io n
It was demonstrated in the preceding chapter that the CD2-myc transgene and p53*A 
mutation co-operate to produce early onset T-cell lymphomas in transgenic mice which 
carry both of these lesions. The synergy observed in these animals may be due to 
changes in the initiation or the progression rates of tumour development. Although 
clinical signs of lymphomagenesis became apparent at between 60 and 86 days, it is not 
known when tumours were first initiated in these mice or whether pre-neoplastic 
disturbances occurred. It was important therefore to assess the course of tumourigenesis 
in these animals by investigating when tumours arose and how this related to the 
progression o f disease.
The nature of the synergy between the CD2-myc and p53v' lesions has not been 
established although a number of possible hypotheses have been put forward (as 
discussed in chapter 3). In order to understand the mechanism of synergy between these 
lesions it was necessary to first assess the role of the CD2-myc transgene in the 
pathogenesis of p53'/7CD2-wyc+ tumours. Studies of CD2-myc transgenic mice have 
found that although expression of the CD2-myc transgene is invariably associated with 
lymphoma, it is not detected in normal transgenic tissues (Stewart et al., 1993). It is 
possible therefore that the lack o f transgene expression in healthy tissues may explain the 
relatively low tumour incidence and lack of pre-lymphomatous disturbances in CD2-myc 
transgenic animals as compared to other myc transgenic models (Adams et a l,  1985; 
Langdon et a l, 1986; Schmidt et a l, 1988). CD2-myc transgenic mice on a p53*7' 
background developed tumours with 100% incidence which contrasts with the low 
tumour incidence of CD2-myc mice on a wild type p53 background. All p53'/7CD2- 
myc+ lymphomas expressed the CD2-myc transgene confirming the involvement o f CD2- 
myc in these tumours (section 3.2.5). It is possible therefore that one o f the effects of 
p53 loss may be to permit constitutive expression, or early activation, o f the CD2-myc
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transgene, perhaps as a result of the genetic instability of p53 null cells. Frequent 
stochastic activation would not necessarily lead to constitutive expression o f the 
transgene but would conceivably account for the increased frequency of CD2-myc 
expressing lymphomas.
It has been established that the c-myc oncogene induces apoptosis as well as cellular 
proliferation (Evan et a l , 1992) with the suggestion that p53 may be required for 
execution of this apoptotic pathway (Wagner et a l, 1994; Hermeking and Eick, 1994). 
Abrogation of myc-mediated apoptosis in p53 null cells may therefore result in the 
unscheduled survival of CD2-myc expressing cells. This would be concordant with 
previous studies which demonstrated that abrogation of oncogene-associated apoptosis 
by p53 loss directly influenced tumourigenesis in response to overexpression o f E l A and 
SV40 large T oncogenes (Lowe et a l, 1994a; Symonds et a l, 1994). If  the absence of 
p53 in p53*/7CD2-wyc+ cells allows constitutive CD2-myc expression then it may be 
possible to detect pre-neoplastic disturbances in the tissues of p53’/7CD2-/wyc+ mice as 
was seen in young Ep-wyc transgenic animals (Langdon et a l, 1986).
In order to address the question of whether p53 loss leads to constitutive expression of 
the CT>2-myc transgene and how this relates to tumour progression, young p53'x7CD2- 
myc+ and control animals were sacrificed at various time points prior to the time of 
clinical onset of lymphomagenesis. The tissues of these animals were subsequently 
examined for neoplastic changes and for CD2-myc transgene expression.
4 .2  R e s u l t s .
4.2.1 E xperim en ta l A n im als.
In order to generate p53‘/7CD2-/wyc+ experimental animals and the necessary p53'/‘ and 
p53+/7CD2-wyc+ parental controls, CD2-myc transgenic mice (Stewart et a l, 1993) 
were crossed with homozygous p53 null animals (Donehower et a l,  1992) to produce 
heterozygous animals, p53+/7CD2-wyc+, which were bred together or backcrossed with
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p53 null mice. In addition to generating the relevant experimental genotypes, this second 
generation breeding program produced p53+/7CD2-wyc+, p53+/' and p53+/+ littermates. A 
total of 196 animals were sacrificed at specific time intervals between 20 and 60 days o f 
age (Table 4.1). Litters o f animals were sampled and clinically examined without prior 
genotype knowledge to provide an unbiased assessment of pathological status.
Table 4.1 Experimental Animals Sacrificed Between 20 and 60 Days of Age.
Tim e
Interval
Num ber o f M ice Culled and Sam pled
p53"/7C D 2-w yc+ p 53' p53+/7CD2-/wyc+ p53+/- p53+/7C D 2-m yc+ p53+/+
60 days 
51 days
6
1*
6 13 10 5 1
50 days 
49 days
6
1*
1 19 4 10 2
40 days 6 4 13 5 5 3
30 days 7 - 9 7 5 2
27 days 3 - 2 9 4 1
20 days 2 1 12 7 3 1
Total No.
o f Mice 
Sampled
32 12 68 42 32 10
* One p53'/7CD2-///yc+ animal at each o f 49 and 51 days had to be sacrificed in advance o f  the appointed 
time interval due to manifestation o f ill health.
4.2.2 Tumour Development of p53'/7CD2-myc+ Transgenic Mice Before 60 
Days of Age.
More than 70% of p53*/7CD2-/?7yc+ mice (23/32) culled between 20 and 60 days o f age 
were found to have lymphoblastic thymic lymphoma as assessed by histopathological
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examination (Table 4.2). All p53'/7CD2-/?7yc+ animals culled at the ages of 60 days (6/6) 
and 49-51 days (8/8) were found to have pre-existing tumours (Figure 4.1). A high 
proportion of animals sacrificed at 40 days (3/6) and 30 days (5/7) were also found to 
harbour a thymic lymphoma as did 1 out of 3 animals culled at 27 days o f age (Table 4.3 
& Figure 4.1). These results demonstrate that lymphomas arise in young p53'/7CD2- 
myc mice as early as post-natal day 27. No evidence o f lymphomagenesis was found in 
two mice sacrificed at 20 days of age suggesting that the initiation o f p53‘/7CD2-/wyc+ 
tumours may be between 20 and 30 days of age.
Table 4.2 Detection of Thymic Lymphomas in p53/ /CD2-/wyc+ -Transgenic 
Mice and Control Groups.
Tim e Num ber of Anim als with Thym ic Lym phom a#
Interval p53'/VCD2-/wyc+ p 5 3 ' p53+/7C D 2-m yc+
60 days 100% (6/6) 33% (2/6) 0% (0/5)
49-51 days 100% (8/8) 0% (0/1) 0% (0/10)
40 days 50% (3/6) 0% (0/4) 0% (0/5)
30 days 71% (5/7) - 0% (0/5)
27 days 33% (1/3) - 0% (0/4)
20 days 0% (0/2) 0% (0/1) 0% (0/3)
# as determined by histopathological examination.
A number of control animals were also assessed for histological evidence of 
lymphomagenesis. Two out of 12 (17%) of the p53_/‘ parental controls were found to 
have a pre-existing lymphoma at the time of sampling (Table 4.2). Both of these animals 
were sacrificed at 60 days of age. None of the 32 p53+/+/CD2-/wyc+ controls had 
developed a thymic lymphoma (Table 4.2). Likewise, none of the p53+/‘ or p53+/+ 
littermates showed evidence of lymphoma development however, one p53+/7CD2-/wyc+ 
mouse (1/68), which was sacrificed at post-natal day 50, had a lymphoblastic thymic 
lymphoma with splenic involvement.
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Figure 4.1. Developm ent o f Thym ic Lym phom a in p53-/- C D 2-m yc+ M ice B etw een  
20 and 60 Days of Age.
This figure illustrates the number of p53-/- CD2-myc+ animals which had histologically 
defined thymic lymphomas when sacrificed at appointed time intervals. Shaded boxes 
represent the number o f mice which had thymic lymphoma and open boxes those which  
showed no obvious signs o f lymphoma development at histopathological analysis. It is 
evident that a high percentage o f p53-/- CD2-myc+ mice had developed thymic tumours 
at ages o f between 30 and 60 days.
□ n o r m a l thymus 
®  thymic lymphoma
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4.2.3 Clinical and Pathological Findings in Young p53'/7CD2-/fiyc+ Mice.
A number of criteria were used to assess the pathological status o f p53'/7CD2-/wyc+ 
animals sampled at various time intervals between 20 and 60 days o f age. Based on 
clinical signs, gross pathology observations, histopathological examination and thymic 
weight, a range o f pathologies were observed (Table 4.3).
A number of p53_/7CD2-wyc+ animals which showed abnormalities in all o f the above 
criteria were found to be in advanced stages o f disease progression. Seven of the 32 
(22%) p53’/7CD2-w^c+ animals exhibited obvious clinical signs characterised by cachexia 
and tachypnoea. Clinical onset was observed in animals aged between 49 and 60 days 
(Table 4.3). It is not clear why a number o f p53*/7CD2-wyc+ animals displayed overt 
clinical signs at times earlier than previous cohorts (chapter 3). This may be due to 
differences in genetic background, animal house conditions or increased cohort size. As 
expected, these animals displayed gross thymic enlargement and metastasis to secondary 
organs when examined at post-mortem. Thymic weight was clearly accentuated in these 
animals constituting between 2% and 9.5% of the total body weight as compared to an 
average of 0.6% for normal control thymus. Histopathological diagnosis confirmed that 
these animals had lymphoblastic thymic lymphoma and multiorgan involvement.
Histopathological examination of the tissues of p53'/7CD2-wyc+ animals revealed a 
spectrum of pathologies ranging from lymphoblastic thymic lymphoma to no detectable 
abnormality (Table 4.3). In many cases (16/32) the normal architecture o f the thymus 
was totally replaced by lymphoblasts showing a high mitotic rate consistent with 
lymphoblastic thymic lymphoma (Figure 4.2). These lymphomas were frequently 
accompanied by metastatic spread to the spleen (12/16) and occasionally also showed 
lymphoblastic infiltration of other organs (5/16). Early, but obvious, stages in the 
progression of thymic lymphoma were observed in another 7 p53'/7CD2-/«yc+ animals 
(Table 4.3). The normal architecture of the thymus was still recognisable in these tissues 
however the cortex, and occasionally the medulla, was partially replaced by islands of 
lymphoblasts (Figure 4.2). The degree of lymphoblastic infiltration in these tissues 
ranged from small focal accumulation o f tumour cells to near total replacement of the
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normal tissue. Infrequent metastatic spread (1/7) was observed in animals which 
exhibited these early stages of thyoma.
Post-mortem observations o f p53'/7CD2-/wyc+ mice often, but not always, reflected 
histopathological diagnosis. A number of animals which had histologically defined stages 
of thymic lymphoma displayed no obvious thymic enlargement at post-mortem (9 o f 23). 
Many animals did however display obvious thymic enlargement and increased thymic 
weight at necropsy. The extent of thymic expansion varied from slight to gross 
enlargement and was related to age with animals sacrificed at between 50 and 60 days 
displaying a larger increase in thymus size than animals culled at an earlier age. It is 
noteworthy that one p53'/7CD2-wyc+ animal which had an obviously enlarged thymus at 
necropsy, exhibiting a higher than average thymic weight, did not have histological 
evidence of lymphomagenesis. It may be possible that the section o f tissue which was 
analysed by microscopy was free of tumour cells in which case histological diagnosis may 
have underestimated the total number of animals in this study with lymphoma.
There was no obvious evidence to suggest that pre-lymphomatous disturbances occurred 
in young p53*/7CD2-w>'c+ mice. Three p53'/7CD2-w>>c+ animals, culled between the ages 
of 27 and 40 days o f age, did have an increased rate of mitotic activity. However as 
several control tissues were also described as displaying an increased mitotic rate, it is 
probable that this feature was not significant with respect to tumourigenesis. One P53'7' 
lCD2-myc+ mouse (p60pml54), which was sacrificed at 30 days of age, was found to 
exhibit possible pre-lymphomatous changes as assessed by microscopic examination. 
The thymic cortex of this mouse was populated by polymorphic small dark lymphocytes 
and large pale blast cells, which may have represented early tumour development. The 
significance of this finding was unclear however as the presence o f blast cells was 
occasionally seen in the thymic tissues of p53+/+/CD2-myc and p53‘A mice suggesting it 
may represent an incidental finding.
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Table 4.3 Summary of Criteria used to Assess Clinical and Pathological Status
of Young p53'/_ICD2-myc+ Mice.
Clinical & Pathological 
Observations
60
days
(n=6)
No. o f A nim als at each Tim e Interval 
4 9 - 5 1  40 30 27 
days days days days 
(n=8) (n=6) (n=7) (n=3)
20
days
(n=2)
Total 
No. of 
Anim als
Clinical Signs 
Overt ill health 2 5 0 0 0 0 7
No obvious illness 4 3 6 7 3 2 25
Histopathology of Thymus 
Lymphoblastic thymic lymphoma 4 8 2 1 1 0 16
Early, but obvious, thymic lymphoma 2 0 1 4 0 0 7
Prelymphomatous changes? (see text) 0 0 0 1 0 0 1
Increased mitotic rate 0 0 2 0 1 0 3
No abnormality 0 0 1 1 1 2 5
Metastasis (based on histopathology) 
Multiorgan 1 4 0 0 0 0 5
Spleen only 2 3 1 2 0 0 8
None observed 3 1 5 5 3 2 19
Gross Pathology of Thymus 
Obvious enlargement 4 7 4 2 0 0 17
Normal size 2 1 2 5 3 2 15
% Thymic Weight* 
Above average 3 7 2 2 0 1 15
Within normal range 3 1 4 5 3 1 17
* % thymus weight to total body weight o f  animal. Normal range was based on age-matched control 
littermates.
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Figure 4 .2 . s l  Normal Mouse Thymus.
Haematoxylin and eosin (H&E) stained normal mouse thymus. (Original in colour).
Top: This figure demonstrates the normal thym ic architecture show ing the pale coloured  
medulla and darker staining, denser cortex (H&E, xlO). Bottom: The uniformity o f the darker 
staining, sm all cortex cells can be seen at the higher magnification o f  mouse thymus (H&E, 
xlOO).
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Figure 4.2.b. Thymus Tissue of Young p53-/- CD2-myc+ Mice; Normal and Lymphoma.
Top: Thym us o f  a young p 53-/- C D 2-m yc+ m ouse w hich  showed no h istop ath o log ica l 
abnormalities (H&E, xlOO). Bottom: Thymus o f a young p53-/- CD2-myc+ mouse which had a 
thym ic lym phom a. The normal thym us cells have been replaced by large, pale stain ing  
lymphoblasts showing a high mitotic rate (H&E, xlOO). (Original in colour).
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Figure 4.2.c. Early Stages of Thymic Lymphoma Development in p53-/- CD2-myc+ Mice.
This figure illustrates an early stage in the progression o f a thymic lymphoma in a young p53-/- 
CD2-myc+ mouse. (Original in colour). Top: At low m agnification the left hand side o f the 
thym us appears normal show ing cortex and m edullary regions, w hile  to the right o f the 
photograph replacement o f normal cells with large pale staining lym phoblasts can be seen  
(H&E, xlO ). Bottom: H igh m agnification o f  early stage thym ic tumour w ith  islands o f  
lymphoblast cells partially replacing the small, dark normal thymus cells (H&E, xlOO).
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4.2.4 CD2-myc Transgene Expression.
Northern blot analysis revealed that histologically normal p53'/7CD2-/wyc+ thymic tissue 
did not express CD2-myc transgene mRNA (Figure 4.3). In contrast, all o f the p53*7* 
ICD2-myc+ thymic lymphomas which were examined did express CD2-myc mRNA. 
These results demonstrate that the pattern of transgene expression in p53'/7CD2-/wyc+ 
tissues is comparable to that o f CD2-myc transgenic mice (Stewart et a l , 1993) and that 
loss o f p53 does not result in constitutive expression o f the transgene. CD2-myc 
expression was closely correlated with lymphoma development in p53'/7CD2-/wyc+ 
animals as tissues with early stages of thymic lymphoma development were found to 
express transgene mRNA (Figure 4.3). Importantly, the p53*/7CD2-/w>,c+ mouse 
described above which exhibited possible pre-lymphomatous changes at 30 days o f age 
(p60pml54), showed detectable levels o f CD2-myc mRNA (Figure 4.3). No expression 
was detected in tissues which had showed an increased mitotic rate. Two p53+/+/CD2- 
myc control mice which had displayed possible early neoplastic changes, characterised 
by an expanded cortex and a high mitotic rate, showed no detectable expression o f the 
transgene.
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Figure 4.3, Northern Blot Analysis of Thym us Tissue of Young p53-/- CD2-m yc+ M ice.
Thymus sam ples o f  young p 53-/- C D 2-m yc+ m ice were exam ined for C D 2-m yc transgene 
expression using Northern blot analysis. Lanes 1 and 2 are positive and negative controls 
respectively. Lanes 3 and 4 represent h istologically normal p53-/- CD2-m yc+ thymus tissue. 
Lanes 5 and 6 were malignant thymic lymphomas. Lanes 7 and 8 represent thymus tissue which  
was in the early stages of thymic lymphoma. Lane 9 was a mouse (p60pm l54) which displayed 
histological changes without obvious neoplastic development. Samples were also assessed for 
expression o f the murine GAPDH gene to confirm the presence o f RNA in the lanes.
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4 .3  D i s c u s s i o n .
4.3.1 Thymic Lymphomas are Detected in Young p53‘/ /CD2-/wyc+ Mice 
from Post-Natal Day 27.
Clinical onset of lymphomagenesis in p53v7CD2-/wyc+ animals was previously shown to 
present at between 60 and 86 days o f age. To examine at what age these lymphomas 
first arose, litters of p53'/7CD2-/wyc+ and control animals were sacrificed at various time 
intervals prior to the expected time o f clinical onset. A large proportion o f p53_/7CD2- 
myc animals (72%) sacrificed between 20 and 60 days o f age were found to have pre­
existing thymic lymphomas as assessed by histopathological analysis. By contrast only 
3/164 (2%) of littermate controls showed histological evidence o f lymphoblastic 
lymphoma. Tumours were detected in p53'/7CD2-w>>c+ transgenic mice as early as post­
natal day 27, often without apparent clinical signs or overall thymic enlargement. 
Manifestation o f clinical onset was found to correlate with advanced stages o f disease 
involving gross pathological enlargement of the thymus and metastatic spread. Detection 
o f lymphomas as early as 27 days of age suggested that these tumours could pre-exist in 
animals for at least a further 22 days before causing apparent distress to the animal. It is 
likely that additional genetic events take place during this latency period although no 
direct evidence is available to support this hypothesis. No evidence o f tumour 
development was observed in animals sacrificed at 20 days of age. It could be proposed 
from these results that tumours probably arise in p53_/7CD2-/wyc+ mice between 20 and 
30 days o f age. It should be noted nevertheless that these studies cannot rule out the 
possibility that 20 day old animals did have small tumours which were not detected by 
the methods applied. Furthermore, a definite conclusion cannot be drawn on the analysis 
of such a small sample size of 20 day mice.
4.3.2 Early Neoplastic Changes and the Role of the CD2-myc Transgene.
The thymus of one p53'/7CD2-wyc+ animal (p60pml54) which was sacrificed at day 30 
showed signs to indicate possible early neoplastic changes with the abnormal presence of 
polymorphic small dark and large pale lymphoid cells in the cortex. Expression of the
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CD2-wyc transgene in the thymic tissue of p60pml54 was consistent with the idea that 
these changes reflected an early stage in the pathogenesis o f p53'/7CD2-/wyc+ tumours. 
Apart from this observation, no consistent pattern of pre-neoplastic changes was 
recorded in the tissues of p53*/7CD2-/wyc+ mice. An increased mitotic rate was displayed 
in the thymus of a number of p53*/7CD2-/wyc+ animals, however control mice also 
exhibited this feature which suggested that this histological finding was unlikely to be 
relevant to tumour development. Northern blot analysis failed to detect transgene 
expression in the thymic tissues o f p53'/7CD2-wyc+ mice which had increased mitotic 
activity.
Lack of detectable CDl-wyc expression in normal tissues indicated that the CD2-myc 
transgene was not consistently expressed in p53*/7CD2-wyc+ tissues, which presumably 
explains the absence of a pre-neoplastic phenotype. Nonetheless, expression of the 
transgene was found to correlate with lymphoma development in the double transgenic 
mice. The pattern o f transgene expression in p53'/7CD2-wyc+ mice was therefore 
equivalent to that of parental CD2-myc mice (Stewart et al., 1993).
4.3.3 Implications for the Synergy Between CD2-myc and p53'/_.
It can be concluded from these studies that lack o f functional p53 did not result in 
constitutive CDl-wyc expression in the thymic tissue o f p53‘/7CD2-/wyc+ animals. This 
result has implications for the proposed mechanisms by which p53 loss cooperates with 
the CDl-wyc transgene. It had been suggested previously (chapter 3) that the CDl-wyc 
transgene may be transcriptionally down-regulated by wild type p53, however this now 
seems highly improbable as the pattern o f CDl-wyc expression in p53'/7CD2-/wyc+ 
animals was no different to that of p53+/7CD2-wyc+ animals. Lack o f constitutive 
expression is also inconsistent with the theory that p53 loss rescues cells from apoptosis 
caused by an early phase of transgene expression in CDl-wyc animals.
A more plausible explanation is that CDl-wyc transgene expression occurs as a result o f 
stochastic activation throughout the life o f the CDl-wyc mouse, but that sustained 
expression is dependent on other cellular events. The absence o f p53 in p53*/7CD2-/wyc+
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cells evidently increases the rate of activation and/or provides an environment capable o f 
sustaining transgene expression. Frequent, or premature, stochastic activation o f the 
transgene may occur as a result of genetic instability created by the loss of a p53 cell 
cycle checkpoint (Lane, 1992). The absence o f p53 in this way would affect the rate o f 
tumour initiation in CD2-myc animals. This is consistent with the observation that all 
p53‘/7CD2-wyc+ animals developed tumours by 50 days whereas none o f the p53+/+/CD2- 
myc controls did. Previous studies have suggested that loss o f p53-dependent apoptosis 
is an important determinant for the transformation of oncogene-expressing cells 
(Symonds et a l , 1994; Lowe et a l , 1994a). Sustained proliferation o f CD2-/wyc 
expressing cells may therefore occur as a result o f attenuated p53-dependent, myc- 
mediated apoptosis. However, if a block in apoptosis is the only mechanism by which 
p53 loss contributes to lymphoma development it would suggest that stochastic 
activation of the transgene is a relatively common event which is not entirely consistent 
with the lack of transgene expression in preneoplastic tissues. Furthermore, it was 
apparent from the results described previously (section 3.3.10) that the level o f apoptosis 
in p53'/7CD2-/7/yc+ tumours was not significantly reduced compared to the p53+/+/CD2- 
myc tumours which suggested that inhibition o f apoptosis had not obviously contributed 
to the pathogenesis of the double transgenic tumours.
It is apparent that loss of p53 affects the rate of initiation of lymphoma development in 
the p53'/7CD2-wyc+ transgenic model. However, functional loss o f p53 may also affect 
the progression rate of these tumours. Evidence suggests that tumours arise at around 
post-natal days 20-30, yet a number of animals developed highly malignant lymphoma 
and showed overt clinical signs at 50-60 days o f age. It is possible that attenuated 
apoptosis, while not affecting tumour initiation, may influence the rate o f tumour 
progression in these mice by permitting survival of proliferating cells. This would be 
consistent with the studies of Symonds and co-workers who reported that abrogation of 
p53-dependent apoptosis in transgenic mice expressing the SV40 large T antigen 
resulted in rapid and aggressive tumour progression but did not affect tumour initiation 
(Symonds et al., 1994). TUNEL analysis o f preneoplastic p53'/7CD2-wyc+ tissues from 
young mice may discern whether reduced apoptosis is important for tumour progression 
in the p53’/7CD2-w^c+ model. Analysis of early neoplastic stages differs from the
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analysis carried out previously with tumour tissues (chapter 3) as apoptosis would be 
assessed prior to the time in which multiple genetic event presumably occur. In this way 
an assessment of apoptosis levels influenced by the p53'A and CD2-myc lesions alone can 
be made.
CHAPTER 5.
TUMOUR DEVELOPMENT IN CD2-A/YC TRANSGENIC MICE 
HETEROZYGOUS FOR A P53 NULL MUTATION.
5.1 In t r o d u c t io n .
The synergistic interaction between the CD2-myc transgene and homozygous p53 null 
mutation was demonstrated by the results presented in chapters 3 and 4. To continue 
this study, the combined effects of the CD2-myc transgene with the heterozygous p53 
mutation were examined. Mice genotypically heterozygous for the p53 null mutation, 
hereafter referred to as heterozyotes or p53+/', differ from homozygous p53 null mice 
(p53'/_) in that they carry a single wild type p53 allele and therefore produce functional 
p53 protein (Donehower et al., 1992). Heterozygote animals were found to remain 
healthy for a longer period o f time than homozygous null animals but succumbed to 
spontaneous tumour development between nine and eighteen months o f age (Harvey et 
al., 1993a). Genetic background may influence the tumour latency of p53 heterozygote 
animals as Purdie et a l (1994) reported that a significant proportion of the heterozygote 
animals in their study developed tumours before nine months o f age. The rate of tumour 
development in homozygous null mice was similarly shown to be altered by genetic 
background (Harvey et al., 1993b). Tumours which develop in heterozygote animals are 
frequently associated with loss of the remaining wild type p53 allele (Harvey et al., 
1993a; Purdie et al., 1994; Jacks et al., 1994). These tumours are effectively 
homozygous null for the p53 protein. The loss o f wild type allele in the murine tumours 
reflects the loss of heterozygosity often observed in human tumours (Nigro et al., 1989; 
B a k e rs  al., 1989; Malkin et al., 1990; Levine et al., 1991).
The results presented in this chapter describe a transgenic model designed to assess the 
consequence of the p53+/‘ mutation in animals carrying the CD2-myc transgene. This 
study also considers the status of the wild type p53 allele in the tumours o f p53+/'/CD2- 
myc mice to investigate if loss of the remaining wild type allele is important for the 
progression of CD2-myc induced lymphomas.
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5 .2  R e s u l t s .
5.2.1 Experimental Animals.
Transgenic mice heterozygous for both the p53 null mutation and CDl-myc transgene 
(p53+/7CD2-wyc+) were generated by breeding CDl-myc transgenic and homozygous 
p53 null animals (Stewart et al., 1993; Donehower et al., 1992). An experimental cohort 
o f p53+/7CD2-wyc+ mice (n=34), in addition to parental controls p53+/+/CD2-wyc+ 
(n=10) and p53+/' (n=24), were generated by the breeding program as previously outlined 
in chapter 3 (Table 3.1). These animals were monitored over an eighteen month period 
for signs of tumour development.
5.2.2 Tumour Development In Control Groups.
The survival and tumour incidence o f parental controls was similar to that previously 
reported. CDl-myc transgenic mice develop tumours at a relatively low incidence, 
usually between 3 and 12 months of age (Stewart et al., 1993). These mice develop 
exclusively T-cell lymphomas. Conditional expression of the CDl-myc transgene in 
neoplastic but not healthy tissues has linked the transgene with the pathogenesis of 
tumours arising in these mice (Stewart et al., 1993). In accordance with the results of 
Stewart et al., 30% (3/10) o f the p53+/7CD2-wyc+ control mice in this study developed 
lymphomas at between 4 and 8 months o f age (Figure 5.1). One p53+/+/CD2-wyc+ 
mouse developed a renal cell carcinoma at 13 months, a tumour type not commonly 
observed in CDl-myc transgenic mice. This tumour was examined by Northern blot 
analysis and was found not to express transgene mRNA (Figure 5.2). It is likely 
therefore, that the development of this tumour was incidental and unrelated to the CD2- 
myc transgene.
As demonstrated by Figure 5.1, 75% (18/24) of p53+/' control mice developed tumours, 
with clinical signs occurring at between 9 and 18 months of age. Consistent with the 
observations of other authors (Harvey et al., 1993a; Purdie et al., 1994; Jacks et al., 
1994), tumours arising in the p53+/‘ mice were predominantly non-lymphoid (Table 5.1).
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Sarcomas occurred in about 39% (7/18) o f the tumour bearing p53+/' animals and 
carcinomas in approximately 22% (4/18). 39% (7/18) of animals which succumbed to 
tumourigenesis developed lymphoma. Two p53+/‘ mice presented with multiple tumours, 
one mouse had a co-existing liver cell carcinoma and lung adenocarcinoma and another 
mouse had fibrosarcomas at two different anatomical sites. Wild type control littermates 
(p53+/+) did not develop tumours within the eighteen month observation period (n=10).
5.2.3 Tumour Development in p53+/7CD2-wyc+ Mice.
Survival and tumour incidence of mice which carried both the CDl-myc and p53+/‘ 
genetic lesions (p53+/7CD2-wyc+) are illustrated in Figure 5.1. Although the latency 
period was reduced for a proportion of p53+/7CD2-wyc+ mice, there was no difference in 
the end survival of p53+/7CD2-wyc+ animals compared to p53+/‘ littermates. Over the 
eighteen month period, p53+/7CD2-wyc+ and p53+/' cohorts were equally susceptible to 
tumour development with 76% (26/34) of p53+/7CD2-w>>c+ mice and 75% (18/24) of 
p53+/‘ controls developing tumours. The p53+/7CD2-wyc+ animals were found to 
succumb to a variety of tumour types, the range o f tumours being similar to that 
observed in the p53+/' group (Table 5.1). The most common tumour type observed in the 
p53+/'/CD2-myc+ mice was lymphoma with 62% (16/26) o f tumour bearing mice 
developing lymphoblastic lymphoma. Sarcomas, predominantly fibrosarcomas and 
osteosarcomas, occurred in approximately 27% (7/26) of animals which developed 
tumours and adenocarcinomas in about 19% (5/26). It should be noted that these figures 
represent tumours per tumour bearing mice and animals which developed multiple 
tumour types have been included more than once. Two p53+/7CD2-/wyc+ mice had more 
than one tumour type at post-mortem (Table 5.1). One mouse had a co-existing 
lymphoma and fibrosarcoma while a second animal had a co-existing osteosarcoma and 
tubular adenocarcinoma.
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Figure 5.1. Survival and Thmour Incidence of p53+/- CD2-myc+ Mice and Littermate 
Controls.
A) Comparing the overall survival rates o f p53+/- C D 2-m yc+ ( ♦ ,  n=34), p 53+/- ( # ,  n=24), 
p53+/+ CD2-m yc+ ( □ , n=10) and p53+/+ mice (X, n=10) over an eighteen month observation 
period. M ice were humanely culled when showing abnormal clinical signs. B ) Percentage o f  
animals from each o f these groups which succumbed to obvious tumour development.
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Table 5.1 Tumour Development in p53+/7CD2-/wyc+ and p53+/' Mice.
A. Tumour Types o f p53+/7CD2-wvc+ Mice.
Tumour Type Incidence of Tumour Bearing Mice
Lymphoma 15/26 (58%)
Osteosarcoma 2/26 (7.5%)
Fibrosarcoma 2/26 (7.5%)
Tubular adenocarcinoma 2/26 (7.5%)
Lung adenocarcinoma 2/26 (7.5%)
Spindle cell tumour 1/26 (4%)
Tubular adenocarcinoma & osteosarcoma 1/26 (4%)
Fibrosarcoma & lymphoma 1/26 (4%)
B. Tumour Types o f d53+a Littermate Controls.
Tumour Type Incidence of Tumour Bearing Mice.
Lymphoma 7/18 (39%)
Osteosarcoma 3/18 (17%)
Fibrosarcoma(s) 2 /18(11% )
Mammary adenocarcinoma 1/18 (5.5%)
Tubular adenocarcinoma 1/18 (5.5%)
Lung adenocarcinoma 1/18 (5.5%)
Undifferentiated sarcoma 1/18 (5.5%)
Leiomyosarcoma 1/18 (5.5%)
Liver cell carcinoma & lung adenocarcinoma 1/18 (5.5%)
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Figure 5.2. Northern Blot A nalysis of p53+/+ CD2-m yc+ Renal Cell Carcinom a.
The renal cell carcinoma winch developed in a p53+/+ CD2-myc+ mouse at 13 months of 
age was examined for expression o f the CD2-myc transgene to determine if  the transgene 
had contributed to the pathogenesis o f this tumour. Lane 1 is a CD2-myc negative control, 
lane 2 is a CD2-m yc expressing tumour as a positive control and lane 3 is the p53+/+  
CD2-m yc+ renal cell carcinoma, the tumour name is shown above the lane number. The 
blot was also assessed for GAPDH expression to confirm the presence o f RNA in each lane.
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In addition to the 26 p53+/7CD2-wj>c+ mice which developed obvious tumours, gross 
pathology and histopathology failed to identify a reason for ill health in two other mice, 
while extensive autolysis prevented diagnosis on a third animal. It is possible that these 
mice had a neoplastic condition but that the tumours were not detected during routine 
pathological investigations. For example, one mouse which presented with slight paresis 
may have harboured an osteosarcoma, or similar lesion, compressing the spinal cord. 
This would be consistent with observations by Purdie et al. (1994) who reported the 
presence of previously unidentified osteosarcomas in p53+/' animals with the use of 
skeletal x-rays.
A higher percentage of p53+/7CD2-wyc+ mice developed lymphomas compared to p53+/‘ 
parental controls, 62% versus 39%. These lymphomas involved the thymus and had 
varying degrees of metastatic spread to other lymphoid tissues. The pathology o f these 
lymphomas was not dissimilar to that observed for both p53+/‘ and p53+/+/CD2-myc 
control mice. Immunophenotype analysis was carried out on p53+/7CD2-wyc+ 
lymphomas to determine the cell type of these tumours. With one exception, all 
lymphomas stained positive for at least one of the T-cell surface markers, CD4, CD8 or 
CD3. None of the tumours were found to be strongly positive for the B-cell marker 
CD45R (B220), although one lymph node tumour did have a small population of 
B220+CD3+ cells. The most common phenotype of the pS3+l'ICDl-myc+ lymphomas was 
an immature CD4+CD8+ double-positive phenotype occurring in 8 out of 14 tumours 
(Table 5.2). CD4+CD8+ phenotypes are frequently displayed by CDl-myc and p53+/* 
lymphomas (Stewart et al., 1993; Purdie et al., 1994). One of the early pS3+l'ICDl-myc+ 
lymphomas (p/m-28) had a CD4'CD8+ single-positive phenotype similar to that observed 
in early CDl-myc tumours (Cameron et al., 1996).
5.2.4 Tumour Development in p53+/ /CD2-/wjc+ Mice May Reflect Additive 
CDl-myc  and p53+/‘ Pathologies.
While p53+/' mice do not generally succumb to tumour development until after nine 
months o f age, it was observed that a small proportion (29%) of p53+/'/CDl-myc+ mice 
developed tumours between two and nine months (Figure 5.1). A 30% tumour incidence
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was similarly displayed by p53+/+/CD2-wyc+ control mice, occurring between two and 
nine months of age. It is possible therefore that the p53+/7CD2-wyc+ tumours which 
developed before nine months of age were due to the CDl-myc lesion and were 
unrelated to the p53+/' mutation. Furthermore, it could be postulated that tumour 
development in the cohort of p53+/7CD2-/wyc+ mice over a period of eighteen months, 
occurred as a result o f additive pathologies associated with independent CDl-myc and 
p53+/* events. A number of experiments and comparative studies were applied to 
investigate this possibility.
Tumour latency of p53+/7CD2-wyc+ mice was compared against each of the parental 
controls as illustrated by Figure 5.3. It was apparent that p53+/7CD2-wyc+ tumours 
which developed before nine months did not reflect that of p53+/‘ mice but were 
coincident with the latency of CDl-myc tumours. It should be noted that the CDl-myc 
tumours presented in Figure 5.3.C have been taken from a cohort (n=31) outwith the 
current study but are representative of the p53+/7CD2-wyc+ littermate controls (n=3) in 
this experiment. The majority of CDl-myc tumours (including the p53+/7CD2-/wyc+ 
tumours o f the current study) arose between three and ten months o f age. Although 
large numbers of CDl-myc transgenic mice have not been kept for long periods o f time, 
very few of those kept beyond twelve months develop tumours. The late peak o f p53+/* 
ICDl-myc tumours which occurred between eleven and eighteen months are therefore 
unlikely to represent CDl-myc related tumours. Rather, these tumours were 
characteristic of the tumour latency observed with p53+/' control littermates (Figure 
5.3.B).
The spectrum of tumour types which p53+/7CD2-wyc,+ mice developed was also 
compared to that of parental controls (Figure 5.4). All of the p53+/7CD2-myc+ tumours 
occurring before ten months of age were lymphomas, analogous to the observed 
pathology in CDl-myc transgenic mice. In contrast tumours occurring after ten months 
of age were predominately non-lymphoid tumours. These tumour types were found to 
reflect the tumour spectrum observed with p53+/‘ mice and occurred with the same 
latency as the parental controls.
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Figure 5.3. Latency of Tbmour Development in p53+/- CD2-myc+ Mice and Parental 
Controls.
This figure illustrates the number o f  m ice w hich developed tumours w ithin a given  time 
period expressed as a percentage o f  the number o f  m ice in the cohort w hich developed  
tumours (n). A) p53+/- CD2-m yc+ m ice (n=26) are compared with B) p53+/- parental 
controls (n=18) and C) CD2-myc+ parental controls (n=31). It should be noted that due to 
the small number o f p53+/+ CD2-myc+ tumours in the present study, a representative group 
o f CD2-myc tumours outwith the current experimental group have been used for this figure.
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Figure 5.4. Ihmour Spectrum of p53+/- CD2-myc+ Mice and Parental Controls.
This figure illustrates the percentage o f  animals which developed lymphomas, sarcomas 
and carcinom as at a given time interval. Numbers are expressed as a percentage o f  the 
total anim al cohort number (n). A) p53+/- C D 2-m yc+ anim als (n=34) are com pared  
against parental groups B) p53+/- (n=24) and C) CD2-myc (n=86). It should be noted that 
the results displayed in C) represent a combination o f the p53+/+ CD2-m yc+ m ice taken 
from the current study (n=10) and o f  an experimental group o f CD2-m yc+ animals outwith 
the current cohort (n=76).
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5.2.5 CDl-myc Transgene Analysis of p53+/7CD2-wyc+ Tumours.
Evidence from tumour latency and tumour spectrum analysis was consistent with the 
theory that p53+/7CD2-wyc+ mice developed additive pathologies associated with either 
genetic lesion in an independent manner. This hypothesis suggested that tumours 
developing before nine months of age would be related to the CDl-myc transgene while 
tumours which developed with a later latency would be related to the p53+/' lesion. In 
order to explore this theory further, p53+/7CD2-wyc+ tumours were assessed for CD2- 
myc transgene expression. Transgene expression has been invariably associated with 
neoplastic development in mice which carry the CDl-myc transgene and is not detected 
in the untransformed cells o f these mice (Stewart et a l , 1993). For the purpose o f this 
study, transgene expression was used as an indication that the CDl-myc transgene had 
contributed to the pathogenesis of p53+/7CD2-w^c+ tumours. Firstly, the sarcomas and 
carcinomas, tumour types not normally associated with the CDl-myc transgene, which 
developed in p53+/7CD2-w^c+ mice were analysed for CDl-myc expression. None of the 
six sarcomas and four carcinomas which were analysed had detectable levels o f CDl-myc 
mRNA (Figure 5.5 & Table 5.2). This result reflects the tissue restriction o f the CD2- 
myc transgene and validates the hypothesis that these late developing (12 to 18 months), 
non-lymphoid p53+/7CD2-/77>,c+ tumours did not involve the CDl-myc lesion.
In contrast to the non-lymphoid tumours, almost all (14/15) o f the p53+/7CD2-/wyc+ 
lymphomas were found to express detectable levels o f CDl-myc mRNA (Figure 5.6). 
The only lymphoma which did not express transgene mRNA developed in an aged mouse 
(18 months) which had a co-existing fibrosarcoma (p/m-46). The latency and pathology 
exhibited by this mouse were characteristic of p53+/' pathology. All other lymphomas, 
which developed between 2.5 and 17 months o f age were found to express transgene 
mRNA (Table 5.2). These results suggest that the CDl-myc transgene has contributed 
to the pathogenesis of most of the p53+/7CD2-/77yc+ lymphomas irrespective o f the age at 
which these tumours presented.
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Figure 5.5. Northern Blot A nalysis of p53+/- CD2-m yc+ Non-lym phoid Ihm ours.
The sarcomas and carcinomas which developed in p53+/- CD2-myc+ mice were assessed for 
CD2-m yc transgene expression to determine if  the transgene had contributed to the 
pathogenesis of these tumour types. Lanes 1 and 7 are positive controls and lanes 2 to 6 are a 
representative group of p53+/- CD2-myc+ tumours. The tumour name is given above the lane 
number. Tumours p/m-14 and p/m-46 were sarcoma type neoplasms and p/m-3, p/m-79 and 
p/m-88 were carcinoma type neoplasms. Samples were also probed with a GAPDH probe to 
confirm the presence of RNA in the lanes.
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Figure 5.6. Northern Blot Analysis of p53+/- CD2-m yc+ Lymphomas.
The thymic lymphomas which developed in p53+/- CD2-myc+ mice were assessed for 
CD2-myc transgene expression. Lanes 1 and 2 are negative and positive controls 
respectively Lanes 3 to 7 represent a selection of p53+/- CD2-myc+ lymphomas with 
the tumour name given above the lane number. Samples were also probed for the 
murine GAPDH gene to confirm the presence of RNA in the lanes
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5.2.6 Loss of Heterozygosity Analysis of p53+/7CD2-/wyc+ Tumours.
It has been demonstrated previously that tumours which develop in p53+/‘ mice are 
frequently associated with loss of the wild type p53 allele (Harvey et a l,  1993a; Purdie 
et a l, 1994; Jacks et a l, 1994). It was o f interest therefore to assess the status o f the 
wild type p53 allele in the p53+/7CD2-/wyc+ tumours, especially in the lymphomas of 
these animals which were positive for transgene expression. It could be postulated that if 
no loss of the wild type allele was observed in the early p53+/7CD2-/wyc+ lymphomas that 
these tumours were a direct consequence o f the CD2-myc lesion without the need for 
p53 loss. Thirteen of the p53+/7CD2-wyc+ lymphomas which developed between 2.5 and 
18 months of age were examined by PCR analysis in order to assess loss of 
heterozygosity. It should be noted that this approach cannot discount the possibility that 
the wild type allele has been inactivated by mechanisms which are outwith the scope of 
detection by PCR analysis, for example by point mutation or by MDM2 overexpression. 
The band representing wild type p53 was absent or obviously under-represented in 12 of 
the 13 p53+/7CD2-w>’c+ lymphomas (Figure 5.7 & Table 5.2). PCR analysis o f one 
lymphoma (p/m-28) showed no significant loss o f the wild type p53 band, however 
Southern blot analysis of this tumour demonstrated that there was a reduction in the 
intensity of the band representing the wild type allele (Figure 5.8). A selection of six 
p53+/7CD2-/77yc+ sarcomas and carcinomas were also analysed by PCR analysis and 
found to exhibit reduced intensity of wild type band in most instances (Table 5.2). It was 
apparent from these results that loss of the wild type p53 allele was occurring in at least 
some, if not all, of the tumour population in most of the p53+/7CD2-/?Tyc+ tumours. 
While the remaining hybridisation signals at the wild type band is probably due to 
contaminating non tumour cells, it is possible that some of the tumours consisted of a 
mosaic of both p53 positive (p53+) and p53 negative (p53*) populations. PCR analysis 
also revealed the presence o f a rearranged band in a number of the p53+/7CD2-/wyc+ 
lymphomas (Figure 5.7). These rearrangements may result in mutations altering or 
obliterating the normal p53 function. It is possible however that this band is 
representative of single stranded DNA, the presence of which could be formally 
demonstrated either by using a denaturing gel or mung bean nuclease.
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Figure 5.7. PCR A nalysis o f p53+/- CD2-m yc+ Lymphomas.
PCR analysis was used to assess loss of heterozygosity for p53+/- CD2-myc+ lymphomas. 
Tumour DNA was amplified for both the null allele (n) and the wild type allele (wt). A 
dramatic reduction in the intensity of the wild type allele can be seen for most of the 
p53+/- CD2-myc lymphomas. Controls for the null, heterozygote and wild type genotypes 
are shown. The PCR analysis of these tumour samples and electrophoresis o f PCR 
products was carried out by Mr. C. Johnston
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Table 5.2 A Summary of Analysis of p53+/7CD2-wiyc+ Tumours.
M ouse
N um ber
Age
(months)
Tumour
Type
CD2 -myc 
Expression
Loss o f W ild  
Type p53**
Im m unophenotype
A nalysis
p/m-54 2.5 lymphoma n/d n/d n/d
p/m-45 2.5 lymphoma positive yes CD4+CD8+ & CD4 CD8'
p/m-28 3 lymphoma positive yes CD4CD8+
p/m-93 4.5 lymphoma positive yes CD4+CD8+
p /m -109 5 lymphoma positive yes CD4+CD8+
p/m-47 5.5 lymphoma positive yes CD4+CD8+
p/m-87 6 lymphoma positive n/d n/d
p /m -108 7 lymphoma positive yes CD4+CD8+
p/m-48 7.5 lymphoma positive yes CD4+CD8+
p/m-77 8 lymphoma positive yes CD4+CD8' & CD4+CD8+
p/m-56 10 lymphoma positive yes CD4+CD8+
p/m-30 11 lymphoma positive yes CD4+CD8+ & CD4'CD8+
p/m-96 11 lymphoma positive yes CD4+CD8+
p/m-99 12 fibrosarcoma negative yes n/a
p/m-55 12.5 fibrosarcoma negative n/d n/a
p /m -14 13.5 osteosarcoma negative yes n/a
p/m-52 14 lymphoma positive yes CD4+CD8+
p/m-79 14.5 adenocarcinoma negative n/d n/a
p/m-25 14.5 spindle cell tumour negative n/d n/a
p/m-88 16 adenocarcinoma negative yes n/a
p/m-59 17 1) adenocarcinoma n/d n/d n/a
2) osteosarcoma negative no n/a
p/m-3 17 adenocarcinoma negative n/d n/a
p/m-8 17 lymphoma positive yes CD4CD8"
p/m-3 4 17 osteosarcoma n/d n/d n/a
p/m-46 18 1) lymphoma negative yes CD4+CD8' & CD4 CD8'
2) fibrosarcoma negative yes n/a
p/m-57 18 adenocarcinoma negative yes n/a
n/d = not determined; n/a = not applicable
** loss o f wild type p53 was assessed by PCR and Southern blot analysis. The amount o f allele loss was 
highly variable among the tumours ranging from total to partial loss o f wild type band (refer to text).
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5.2.7 Loss of Wild Type p53 in Metastatic Tissues and Cell Lines.
The finding that some of the p53+/7CD2-wyc+ lymphomas contained both p53+ and p53‘ 
populations posed the hypothesis that loss of the wild type p53 allele may be occurring 
as a progression event in CDl-myc induced tumours. In support o f this hypothesis, loss 
o f the wild type allele was also observed in the metastatic tissues o f p53+/7CD2-/wyc+ 
mice which developed lymphomas (Figure 5.8). These non-lymphoid tissues contained 
levels o f wild type p53 comparable to that present in the tumour. Given that these 
tissues should contain a large population o f normal cells, a likely interpretation would be 
that the metastatic population of infiltrating lymphoid cells consisted mainly of p53* cells.
The in vitro growth potential of lymphoma cells isolated from p53+/7CD2-wyc+ mice was 
investigated by placing these cells in long term cell culture. Out o f eleven cell lines 
which were set up in culture, eight (73%) established in long term culture and three 
(27%) did not. PCR analysis of five of the established lines demonstrated complete loss 
of the wild type p53 allele (Figure 5.9). This result suggests that loss of functional p53 
activity may be advantageous for the in vitro culture of these cell lines. Consistent with 
this hypothesis, it was previously observed that p53'/7CD2-wyc+ lymphoma cells always 
established in long term culture while CDl-myc cells on a wild type p53 background did 
not (chapter 3). That total loss o f p53 activity is required for in vitro growth is in 
accordance with the role of p53 loss in tumour progression.
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Figure 5.8. Southern Blot Analysis of p53+/- CD2-m yc+ Thmours and M etastases.
The status o f the wild type p53 allele in the tumours and metastatic tissues of p53+/- CD2-inyc+ 
mice was examined by Southern blot analysis. This figure, which has been adapted from Blyth et 
al., 1995, illustrates the loss o f the wild type p53 a lle le  from the primary tumours (T) and 
metastatic kidney (K) and liver (L) tissues o f p53+/- CD2-m yc+ mice. The tumour name and 
mouse genotype is given for each sample. A control tumour wild type for p53 is also shown 
(p/m -68). These Southern analyses were carried out by Mrs A. Terry and have been used here 
with Anne's kind permission.
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Figure 5.9. PCR A nalysis of p53+/- CD2-m yc+ Cell Lines.
PCR analysis was used to assess loss of heterozygosity in the cell lines derived from 
p53+/- CD2-myc+ thymic lymphomas. Each sample was amplified for both the null 
(n) and wild type (wt) p53 alleles. A p53 heterozygote control is also shown. It can 
be seen that each of the cell lines has lost the band corresponding to the wild type 
allele. PCR analysis of the cell lines was carried out by Ms. J Irvine.
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5 .3  D is c u s s i o n .
5.3.1 T-Lymphomagenesis is not Accelerated in Animals Heterozygous 
for the p53 Null Mutation and the CDl-myc Transgene.
Transgenic animals heterozygous for the p53 null mutation (p53+/*) and the CDl-myc 
transgene do not accelerate either the CDl-myc or p53+/' phenotypes, suggesting that 
these two events do not collaborate during in vivo tumourigenesis. This result contrasts 
with the dramatic synergy observed between the CDl-myc and p53'A lesions and 
suggests that the absence of only one wild type p53 allele does not predispose CDl-myc 
transgenic mice to accelerated lymphoma development.
The incidence, latency and spectrum of tumour types which developed in the p53+/7CD2- 
myc cohort strongly suggested that these animals died as a result o f additive pathologies 
pertaining to either the CDl-myc or p53+/' lesions. A proportion o f the p53+/7CD2-/wyc+ 
mice were found to succumb to tumours before nine months o f age. The incidence and 
latency of these tumours were characteristic of CDl-myc transgenic mice. Furthermore, 
these tumours were all T-cell lymphomas and exhibited the same pathology and 
immunophenotype as CDl-myc tumours which develop in transgenic animals on a wild 
type p53 background (Stewart et al., 1993). In contrast, p53+/7CD2-/wyc+ tumours 
which developed after nine months were predominantly non-lymphoid and were found to 
reflect the tumour pattern normally associated with the p53+/* lesion (Harvey et al., 
1993a; Purdie et al., 1994; Jacks et al., 1994). The proportion o f mice ultimately 
succumbing to neoplasia in the p53+/7CD2-/77yc+ cohort was the same as that o f the p53+/* 
control cohort. Therefore the presence o f the CDl-myc transgene did not alter the 
overall incidence o f tumours in p53+/' mice.
Northern analysis of p53+/7CD2-wyc+ tumours confirmed that the CDl-myc transgene 
was transcriptionally active in the T-cell lymphomas which developed in p53+/7CD2-wyc+ 
mice prior to nine months of age. As would be expected, transgene mRNA was not 
detected in the non-lymphoid tumours which developed with a latency o f more than ten 
months in p53+/7CD2-myc+ mice. This result was consistent with the specificity o f the
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CD2 element to the T-cell lineage (Greaves et al., 1989) and demonstrated that the CD2- 
myc transgene was not involved in the pathogenesis o f p53+/' induced sarcomas and 
carcinomas. Based on tumour latency analysis (Figure 5.3) it had been expected that 
lymphomas which developed after ten months o f age would, like the sarcomas and 
carcinomas, be related to the p53+/‘ lesion and would arise independently of the CD2-myc 
transgene. However four out of five lymphomas occurring between ten and eighteen 
months were positive for transgene expression (Table 5.2), suggesting that the CDl-myc 
transgene had contributed to the pathogenesis o f most o f the p53+/'/CD2-myc 
lymphomas. This result was not in accordance with the hypothesis that p53+/7CD2-myc+ 
mice developed additive pathologies distinct to each o f the genetic mutations.
5.3.2 The p53+/' Mutation Co-operates with Ep-#wyc and MMTV-c-myc 
Transgenes.
The lack of co-operation between the p53+/‘ and CD2-myc lesions in this study is in 
contrast to two other reports describing dramatic synergy between the p53+/* mutation 
and c-myc transgenes. The Eyv-myc and MMTV-c-myc transgenes in combination with 
the p53+/' mutation resulted in accelerated B-cell and T-cell lymphomagenesis 
respectively (Hsu et al., 1995; Elson et al., 1995). The p53 null mutation was the same 
for each of these studies discounting this as a possible reason for the differences between 
these models. It is possible however that differences in genetic background, c-myc 
transgenes and/or tissues types could account for these contrasting results. Although all 
o f these models used the same p53 null mouse (Donehower et al., 1992), the genetic 
background was distinct in each case, with the p53+/'/CD2-wyc+ animals being an 
undetermined mix of C57B1/6, CBA/Ca, 129/Sv and NIH strains. Genetic background 
has previously been shown to influence the rate and spectrum of tumours in p53 null 
animals (Harvey et al., 1993b). Nonetheless, it is unlikely that the lack of co-operation 
between CDl-myc and p53+/' is due to genetic background in view of the dramatic 
synergy observed in p53'/7CD2-w^c+ littermates (chapters 3 & 4). It is also doubtful that 
the cell context of this study influences the ability o f CDl-myc to co-operate with p53+/‘, 
particularly as the combination of p53+/' and MMTV-c-myc resulted in accelerated T-cell 
lymphomas (Elson et al., 1995). A more probable explanation for the difference between
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the p53+/7CD2-wyc+ model and the other p53+/7c-/wyc models would be with regard to 
the transgenic constructs. Both the E \x-myc and MMTV-c-zwyc transgenes are 
constitutively expressed at low levels in various transgenic tissues (Stewart et a l , 1984a; 
Leder et al., 1986; Schmidt et a l, 1988). The CDl-myc transgene, by contrast, is only 
found to be expressed in tumourous tissues and is not detected in healthy, untransformed 
tissue (Stewart et a l, 1993). Therefore synergy between c-myc transgenes and the p53+/* 
mutation may require that the transgene is constitutively expressed in transgenic tissues. 
The presence of overexpressed c-myc in these tissues may predispose towards early loss 
o f the second wild type allele, possibly because o f increased cell division and the 
increased chance of accumulating allelic mutations.
5.3.3 p53 Loss as a Progression Event in p53+/7CD2-/wyc+ Lymphomas?
Loss of heterozygosity at the p53 locus is a common event in human malignancy (Nigro 
et a l,  1989; Baker et a l, 1989; Malkin et a l, 1990) and has been recognised to occur as 
a late progression event in a number of tumour types including colorectal carcinoma 
(Baker et a l, 1990a). Furthermore, loss of the remaining wild type allele frequently 
occurs in tumours of p53 heterozygote mice (Harvey et a l,  1993a; Purdie et a l,  1994; 
Jacks et al., 1994). It is possible that loss o f both p53 alleles may also be important for 
the pathogenesis of tumours in which co-existing p53 and c-myc lesions exist. 
Inactivation of both wild type p53 genes have been observed in human tumour cell lines 
(Gaidano et a l, 1991; Farrell et a l, 1991; Inagaki et a l, 1994), and in virus-induced 
mouse erythroleukaemias (Dreyfus et a l, 1990) which have a deregulated c-myc gene. 
In addition, Elson et al. and Hsu et al. reported that loss of the remaining wild type p53 
allele frequently occurred in the tumours of their p53+/7c-wyc models.
Significantly, loss of the wild type p53 allele was exhibited by the CDl-myc expressing 
p53+/7CD2-wyc+ lymphomas. Total allele loss nevertheless was only demonstrated in 
one of the CDl-myc expressing lymphomas. The remaining tumours, while exhibiting 
partial loss of allele to varying degrees, still retained a proportion o f the wild type allele 
as determined by PCR analysis. It is probable that residual wild type p53 represents 
contaminating non-tumourous tissue and that functional loss o f the wild type allele is
129
necessary for the initiation of these tumours. However the finding that some o f the p53+/' 
ICD2-myc+ tumours contained apparently substantial populations o f wild type p53 may 
indicate that wild type allele loss was occurring as a late progression event in those 
tumours. Consistent with this hypothesis, loss o f wild type allele was observed in the 
metastatic tissues and in cell lines derived from the thymic tumours of these mice. The 
observation that at least partial loss of the wild type allele occurred in p53+/7CD2-/wyc+ 
tumours indicates that there was a selective advantage associated with loss o f the second 
allele. Nevertheless, despite this obvious selective advantage, loss o f allele did not 
influence the overall incidence or latency of p53+/7CD2-wyc+ tumours.
5.3.4 The Role of p53 M utations in CDl-myc Induced Tum ours.
It has been demonstrated that the CDl-myc transgene dramatically synergises with the 
p53‘/* lesion (chapter 3) but not the p53+/‘ lesion (this chapter). This observation leads to 
the suggestion that inactivation o f the remaining wild type p53 allele is a rate limiting 
step in the evolution o f the p53+/7CD2-wyc+ lymphomas and demonstrates the 
importance of the p53_/" lesion as an early event in accelerated CDl-myc tumours. The 
lack of synergy between CD2-wyc and p53 loss in p53+/7CD2-wyc+ tumours may be a 
reflection of the time required to lose the second allele which could be superseded by the 
activation and/or inactivation o f other genetic events. Indeed, it has been shown that p53 
is not a genetic target in MoMuLV-accelerated CDl-myc lymphomas (Stewart et al., 
1996) and that other events are involved in the pathogenesis o f these tumours.
Evidence from the p53'/7CD2-w>,c+ and p53+/7CD2-wyc+ transgenic models described 
here, and the p53+/7c-wyc models described by other authors (Hsu et al., 1995; Elson et 
al., 1995), leads to the conclusion that these mice require at least three (but probably 
more) genetic events for lymphoma development. One of these events would be the 
deregulated expression of the c-myc oncogene, while inactivation of the p53 tumour 
suppressor gene would require two additional events. Mice which are genotypically 
p53+/7Ej.i-wyc and p53+/TMMTV-c-/77yc are born with two of these events. These 
animals have sustained loss of one p53 allele and constitutively express a c-myc 
transgene in a number o f their cells. Loss of the second allele in any one o f these cells
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will presumably favour tumour development. Inactivation o f both p53 alleles in p53’/_ 
/CD2-myc+ animals means that two genetic events have also occurred in the cells o f these 
mice. Stochastic activation of the CD2-myc transgene in one or a few o f these cells 
subsequently provides a third event. By contrast, p53+/7CD2-wyc+ animals are born with 
only one genetic lesion, namely loss o f one wild type p53 allele. Theoretically these mice 
require activation of the CD2-myc transgene and loss o f the second p53 allele and/or 
other unknown events. The fact that a greater number o f genetic ‘hits’ must 
spontaneously occur in p53+/7CD2-myc+ tumours reasonably explains the lack of synergy 
in these mice as compared to p53'/7CD2-wyc+, p53+/7Ep-wyc and p53 +/7MMTV-c-myc 
mice.
Although the p53+/7CD2-wyc+ model has proven to be a complex one, it is in many ways 
a more accurate comparison to naturally occurring tumours than the models provided by 
other authors (Elson et al., 1995; Hsu et al., 1995). It is conceivable that loss of one 
p53 allele could occur early in the lifetime of a cell but for simultaneous overexpression 
of an oncogene to occur at this time would be unlikely. Nevertheless, stochastic 
activation of an oncogene, as seen in the p53+/7CD2-wyc+ model, would not be 
unexpected. The p53+/'/CD2-myc+ model demonstrates that loss o f only one p53 allele 
would be insufficient to co-operate with the spontaneous activation o f the c-myc 
oncogene. It is worth noting however that the p53 null lesion results in deletion of the 
protein and so requires inactivation of the second allele for loss of function, but p53 
mutations which occur in spontaneous tumours may result in dominant negative mutants 
(Milner et al., 1991) in which case only one p53 allele would need to be mutated for loss 
o f function. It is apparent however that the synergistic interaction between p53 loss and 
c-myc requires inactivation of both wild type p53 alleles. The mechanics o f the synergy 
may be due to abrogation of a c-myc induced apoptotic pathway for which loss o f both 
alleles are necessary (Hermeking and Eick, 1994; Wagner et al., 1994). Alternatively, 
genetic instability generated by total loss of p53 may be necessary for the early stochastic 
activation of an oncogene, or in this case the CD2-myc transgene, which would normally 
be under the regulation of a p53 cell cycle check-point (Lane, 1992).
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CHAPTER 6.
T-CELL LYMPHOMAGENESIS IN P53 NULL MICE INFECTED WITH 
MOLONEY MURINE LEUKAEMIA VIRUS.
6.1 In t r o d u c t io n .
Moloney murine leukaemia virus (MoMuLV) is a slow transforming retrovirus which 
induces murine T-cell lymphomas at a latency of between three and nine months o f age 
(van Lohuizen and Bems, 1990; Tsichlis and Lazo, 1991). MoMuLV induced- 
lymphomagenesis involves insertional activation of host genes which contribute to the 
neoplastic process (reviewed by van Lohuizen and Bems, 1990; Kung et a l,  1991). 
Numerous cellular genes which are affected by proviral insertion have been identified 
(Tsichlis and Lazo, 1991). The most frequently activated genes in MoMuLV-induced T- 
cell lymphomas are c-myc, N-myc and pim - 1 (reviewed by van Lohuizen and Bems,
1990). The common occurrence of these genes suggests that they may be important for 
the pathogenesis of MoMuLV-induced tumours. It has been demonstrated that 
MoMuLV infection can accelerate tumourigenesis in several transgenic mice which are 
predisposed to lymphoma development (Berns et a l,  1989; Adams and Cory, 1991a). 
Proviral insertion of MoMuLV sequences into the host DNA results in activation of 
cellular genes which collaborate with the transgene in the development o f lymphoma. 
Collaboration of c-myc with pim - 1 and bmi- 1 has been demonstrated in this way (van 
Lohuizen et a l, 1989; van Lohuizen etal ,  1991; Haupt etal., 1991).
The aim of the study described here was to determine if loss of functional p53 could co­
operate with MoMuLV infection in the pathogenesis of murine T-cell lymphoma. Mice 
homozygous for a null allele of the p53 gene are predisposed to the development o f T- 
cell lymphoma (Donehower et a l, 1992). Therefore MoMuLV infection o f p53_/* mice 
may provide an opportunity to assess which genes, activated by provirus insertion, act in 
concert with p53 loss in T-lymphomagenesis. In previous chapters, p53 loss was shown 
to co-operate with the CD2-myc transgene, therefore MoMuLV infection o f p53'/7CD2- 
myc mice was also carried out to address if additional events to p53 loss and a c-myc 
transgene were required for the development of T-cell lymphoma in this model.
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6 .2  R e s u l t s .
6.2.1 Generation of MoMuLV Infected Experimental Animals.
Mice homozygous for the p53 null mutation, p53'/_, were generated by crossing together 
animals which were heterozygous for the null allele, p53+/' (Donehower et a l,  1992). 
Neonatal p53v', p53+/' and p53+/+ animals were infected with MoMuLV within 24 hours 
o f birth and monitored for signs of tumour development over a twelve month period. A 
small number of infected animals (7/86), o f all p53 genotypes, developed thymic atrophy 
and parasitic infections around the time of weaning. Although the reason for this 
occurrence is unclear, it is possible that viral inoculation predisposed these animals to 
immunosuppression (Onions and Jarrett, 1987). In addition, several other young animals 
died or had to be culled due to unrelated causes, primarily anaesthetic overdose and 
behavioural problems. These animals were excluded from the long term experimental 
cohort. Non-infected p53‘/_ and p53+/' control animals o f a comparative genetic 
background were also monitored for signs o f tumour development. The genetic 
background of all animals was an undetermined mix o f C57B1/6, 129/Sv and NIH strains 
(Donehower et a l, 1992; Kemp et a l, 1993).
6.2.2 Accelerated Tumour Development of MoMuLV Infected p53_/* Mice.
The tumour free survival of p53v' mice infected with MoMuLV is illustrated by Figure
6.1. Survival of infected p53'7' mice was significantly reduced compared to non-infected 
p53_/' control mice (p < 0.05, Mann-Whitney confidence test). MoMuLV infected p53'7' 
mice were found to succumb to tumour development at a markedly increased rate with 
71% (15/21) of infected p53'A animals dying between the ages o f 70 and 150 days o f age. 
By comparison, only 41% (9/22) of non-infected p53';' mice had developed tumours at 
this time (Figure 6.1.A). It can be concluded from these observations that MoMuLV 
accelerated tumour development in p53_/' mice. As shown in Figure 6.1.B, survival of 
MoMuLV infected p53‘;' mice was also significantly reduced compared to MoMuLV 
infected wild type mice, p53+/+ (p < 0.001, Mann-Whitney confidence test). Only 10% 
(2/20) of infected p53+/+ mice were found to develop tumours by 150 days o f age.
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Figure 6.1. Survival Analysis o f M oM uLV Infected p53-/- M ice.
A) Compares the percentage o f surviving MoMuLV infected p53-/- m ice (■ , n=21) with 
non-infected p53-/- m ice (O, n=22) at nine months o f  age. B) Percentage survival o f  
MoMuLV infected p53-/- m ice (■ , n=21), MoMuLV infected p53+/- m ice ( • ,  n=31) and 
MoMuLV infected p53+/+ mice (□ , n=20) at twelve months o f age.
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An unexpected finding was that a small number of infected p53'7' mice (4/21) survived to 
beyond 350 days of age, particularly as the majority of infected p53';* mice had died 
before 150 days of age. Serum analysis (kindly carried out by Q1 Biotechnology, 
Glasgow) revealed that these four surviving animals were not viraemic. The absence o f a 
persistent viral infection therefore provides a likely explanation for the extended survival 
o f these animals. While it cannot be ruled out that infection o f other animals had been 
unsuccessful, the presence of viral integrations in the thymic tumours o f infected p53_/' 
mice revealed that MoMuLV had contributed to the pathogenesis o f all MoMuLV 
infected p53‘7' lymphomas (Baxter et a l, 1996).
6.2.3 Tum our Phenotype of M oMuLV Infected p 5 3 A Mice.
Previous reports have demonstrated that MoMuLV infected mice develop lymphoblastic 
T-cell lymphomas involving the thymus, spleen or both organs (Pepersack et a l,  1980; 
Spira et a l, 1981; Ott et a l, 1992). Although it has been shown that a high number of 
p53‘/_ mice also develop T-cell lymphomas (Donehower et a l , 1992), a proportion of 
these animals also develop non-lymphoid neoplasms. It was important therefore to 
examine the tumour spectrum of MoMuLV infected p53*/' animals to establish if 
MoMuLV infection had altered the tumour phenotype of p53'7' mice. A comparison of 
the observed tumour types of infected and non-infected p53'7' groups is given in Table
6 . 1.
MoMuLV infection of p53*7' mice resulted in an increased proportion o f animals 
developing lymphoma. Gross and histopathological analysis revealed that o f 15 infected 
p53‘7' mice for which the cause of death was known, 14 (93%) developed lymphoblastic 
lymphoma, with 3 mice also presenting with a haemangiosarcoma. Only one infected 
p53'/_ animal, culled at 189 days of age with a giant cell sarcoma, did not have 
pathological evidence of lymphoma development. It should be noted nevertheless that 
the viraemic status of this mouse was not investigated and a successful viral infection 
may not have occurred. The cause of death for two additional animals could not be 
determined due to extensive autolysis at necropsy. In comparison, o f 18 non-infected 
p53‘/_ mice for which the cause of death was known, only 13 (72%) were found to
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succumb to lymphoma development with 5 of these mice presenting with an additional 
tumour, usually a haemangiosarcoma. It was apparent therefore that MoMuLV infection 
had restricted the tumour spectrum of P53'7' mice.
Table 6.1 Tumour Spectrum of p53'7' and MoMuLV Infected p53'7' Mice.
A. Tumour Tvpes of p53‘/' Mice.
Incidence Lifespan
Lymphoma 36% (8/22) 9 6 -2 3 1  days
Lymphoma & haemangiosarcoma 18% (4/22) 148 - 214 days
Lymphoma & fibrosarcoma 4.5% (1/22) 123 days
Fibrosarcoma 4.5% (1/22) 138 days
Haemangiosarcoma 4.5% (1/22) 231 days
Teratoma & sarcoma 4.5% (1/22) 122 days
Haemangiosarcoma & adenocarcinoma 4.5% (1/22) 188 days
Adenocarcinoma 4.5% (1/22) 435 days
Not determined * 18% (4/22) n/a
B. Tumour Types o f MoMuLV Infected p53"/_ Mice.**
Incidence Lifespan
Lymphoma 65% (11/17) 71 -1 3 5  days
Lymphoma & haemangiosarcoma 17% (3/17) 112 - 139 days
Giant cell sarcoma 6% (1/17) 189 days
Not determined * 12% (2/17) n/a
* reason for death was not determined by routine pathological investigations, or extensive autolysis 
prevented diagnosis.
** excludes the four non-viraemic mice which survived beyond 350 days.
Gross pathological examination revealed that the majority o f MoMuLV infected p53'7' 
mice which developed lymphoma displayed marked enlargement o f the thymus (9/14).
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Frequent, but variable, involvement of the spleen and lymph nodes (8/9) was also 
observed in these animals. Several other animals displayed a more generalised 
enlargement of all lymphoid organs (4/14). In these animals the thymus was found to be 
only slightly enlarged but there was gross enlargement o f the spleen, mesenteric and 
subcutaneous lymph nodes. Metastasis to the kidney was evident in a number of infected 
p53'A animals (6/14). One mouse which showed no post-mortem evidence o f a lymphoid 
tumour was found to have a thymic lymphoma when examined by microscopy. 
Histopathological examination o f infected p53‘A tissues was consistent with 
lymphoblastic lymphoma. Infected p53+/+ littermates and infected p53+/' mice were also 
diagnosed with lymphoblastic lymphoma. There was no difference in the organ 
distribution of lymphomagenesis between infected p53'/_ mice and infected p53+/+ or 
infected p53+/* mice. The pathologies of lymphoma observed in this study were similar to 
previous reports of MoMuLV infected mice (Pepersack et a l, 1980; Spira etal., 1981).
6.2.4 Im m unophenotype Analysis of M oM uLV Infected p53'A Mice.
To investigate the cell type of the lymphomas induced in MoMuLV infected p537* mice, 
cells were isolated from primary tumours, either thymus or lymph node, labelled with 
monoclonal antibodies (CD3, CD4, CD8, CD45R, apTCR) and sorted by flow 
cytometry. All MoMuLV infected P53'7' lymphomas were found to be o f T-cell origin as 
assessed by expression of at least one of the surface markers CD3, CD4, CD8 or 
apTCR, or by exclusion of the B-cell marker CD45R. Virtually all o f the infected p53';* 
lymphomas were positive for, or contained positive populations of CD3+/aPTCR+ cells 
but varied in their expression of CD4 and CD8 surface markers (Table 6.2). The 
tumours of infected p53*/' mice were found to represent a variety o f T-cell differentiation 
stages as based on CD4 and CD8 phenotypes, ranging from immature double-negative to 
more mature single-positive populations. A similar range o f phenotypes was observed in 
the lymphomas of infected p53+/‘ and infected p53+/+ littermates, and in lymphomas of 
non-infected p53'A mice (Table 6.2). Lymphomas of infected p53+/', infected p53+/+ and 
non-infected p53'A mice were all found to be of T-cell origin. It was noted however that 
a higher proportion of infected wild type tumours consisted o f populations which were 
negative for expression of CD3 and apTCR markers.
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Table 6.2 Flow Cytometry Analysis of MoMuLV Infected Tumours.
A. CD3 & apTCR Surface Marker Expression.
M ouse Status CD3 ap T C R
p53 M oM uLV + +/- - + +/- -
-/- + 4/12 8/12 0/12 3/11 7/11 1/11
+ /- + 12/18 4/18 2/18 10/17 4/17 3/17
+/+ + 2/10 4/10 4/10 2/10 3/10 5/10
-/- - 4/8 2/8 2/8 n/d n/d n/d
+ represents a positive population; - represents a negative population and + /- indicates where the tumour 
had both a positive and negative population, n/d = not determined.
B. CD4 & CD8 Marker Expression.
M ouse Status Cell Surface Phenotype
p53 M oM uLV CD4+CD8 CD4+CD8+ C D 4C D 8 C D 4C D 8+ mixed*
-/- + 1/12 4/12 2/12 3/12 2/12
+/- + 4/18 4/18 0/12 2/18 8/18
+/+ + 0/10 3/10 2/10 2/10 3/10
-/- - 0/8 3/8 2/8 0/8 3/8
* mixed populations consisted o f at least more than one major T-cell population, often with a diffuse and 
heterogeneous staining pattern.
The phenotypic heterogeneity of MoMuLV T-cell lymphomas, irrespective o f p53 
genotype, is consistent with previous reports of MoMuLV tumours (Lazo et ah, 1990; 
Ott et al., 1992). The p53_/* mutation therefore did not obviously restrict the T-cell 
phenotype o f MoMuLV lymphomas. A number of individual tumours, o f all p53 groups, 
were found to exhibit a heterogeneous T-cell phenotype with more than one major T-cell 
population. Diversity within individual MoMuLV infected tumours has also been 
reported by Lazo et a l (1990). These authors suggested that the phenotypic
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heterogeneity of MoMuLV-induced T-cell tumours may be due to viral transformation o f 
immature T lymphocytes which undergo limited differentiation during oncogenesis.
6.2.5 Tumour Development of Heterozygote Mice infected with MoMuLV.
MoMuLV infected heterozygote mice, p53+/', were found to succumb to tumour 
development at a rate significantly faster than infected wild type controls (p < 0.05, 
Mann-Whitney confidence test) but displayed intermediate survival compared to infected 
p53'/_ animals (Figure 6.1.B). This observation suggests that loss o f one p53 allele may 
predispose to accelerated tumour development upon MoMuLV infection. Infected p53+/* 
animals also developed tumours with a much reduced latency when compared to non- 
infected p53+/' animals (Figure 6.2). Consistent with results o f Harvey et a l  (1993a), 
non-infected p53 heterozygotes spontaneously developed a wide range o f tumour types 
with a latency greater than seven months (Table 6.3 & Figure 6.2). By contrast, tumour 
development in MoMuLV infected heterozygotes occurred from three months o f age and 
was almost exclusively restricted to lymphoma development (Table 6.3). Only two 
infected p53+/‘ animals, sacrificed after 300 days of age, failed to develop lymphoma. It 
was apparent therefore that MoMuLV infection had skewed the tumour phenotype o f 
p53+/' animals.
Table 6.3 Tumour Spectrum of Infected and Non-infected p53+/' Mice.
Tum our Type M oM uLV Infected p53+/' M ice N on-infected p53+/* M ice
Incidence Lifespan Incidence Lifespan
Lymphoma 71% (22/31) 99 - 300 days 3% (1/38) 502 days
Sarcoma 6% (2/31) 326 -3 5 3  days 53% (20/38) 2 1 6 -6 0 1  day
Carcinoma 0 n/a 16% (6/38) 357 - 554 days
Not determined* 0 n/a 18% (7/38) n/a
* cause o f death was not determined during routine pathological examinations, or extensive autolysis 
had occurred, n/a = not applicable.
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Figure 6.2. Reduced Survival of p53+/- M ice Infected with MoMuLV.
This figure compares the survival o f MoMuLV infected p53+/- m ice ( • ,  n =  31) 
with non-infected p53+/- m ice (O, n = 38) over a twelve m onth observation  
period.
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Gross pathological examination o f infected p53+/* lymphomas revealed gross thymic 
enlargement with variable metastasis in 16/22 (73%) o f animals and disseminated 
lymphomas with gross enlargement of the spleen and lymph nodes in 6/22 (27%) of 
mice. Thirteen of the infected p53+/' animals also had metastasis to non-lymphoid tissues, 
namely kidney or liver. As discussed previously, all MoMuLV infected p53+/* 
lymphomas were of T-cell origin (Table 6.2) and showed phenotypic heterogeneity as 
commonly observed with MoMuLV infected tumours. The status of the wild type p53 
allele was examined in six o f the MoMuLV infected p53+/* thymic lymphomas and was 
found to be at least partially lost as assessed by reduced intensity o f the wild type band 
by Southern analysis (E. Baxter, personal communication; Baxter et a l , 1996). Loss of 
the wild type allele was also observed in the metastatic tissues of p53+/* mice indicating 
that loss was indeed associated with tumour progression.
6.2.6 Cell Line Establishment.
A number of thymic tumours derived from MoMuLV infected p53v', p53+/' and p53+/+ 
animals were examined for their in vitro growth capacity. Successful cell line 
establishment was achieved for 9/10 of the infected p53'7' lymphomas, 3/12 o f the 
infected p53+/' lymphomas and 3/8 of the infected p53+/+ tumours. All of the MoMuLV 
infected p53+/* lymphomas which established in long term culture were found to have 
completely lost the wild type p53 allele (Baxter et al., 1996). The primary tumours of 
these three lines had also shown loss of allele.
6.2.7 MoMuLV Infection of p53'/7CD2-ffiyc+ Mice.
It was demonstrated in chapters 3 and 4 that the combination o f the p53'7' mutation with 
the CD2-myc transgene resulted in accelerated tumourigenesis but that additional events 
were required. MoMuLV infection can accelerate tumourigenesis in both parental CD2- 
myc and p53_/* animals (Stewart et a l , 1993; this chapter), therefore it was of interest to 
determine if MoMuLV could accelerate tumourigenesis in p53*/7CD2-/wyc+ transgenic 
mice. To address this, CD2-myc and P53'7' parental controls (Stewart et a l , 1993; 
Donehower et a l, 1992) were crossed to generate p53+/7CD2-/wyc+ mice. First
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generation p53+/7CD2-/wyc+ animals were subsequently bred together to create a cohort 
o f p53'/'/CD2-wyc+ mice (n = 11) which were inoculated with MoMuLV within 24 hours 
o f birth. Non-infected p53'/7CD2-wyc+ controls (n = 18), described previously (chapter 
3), were of comparable genetic background consisting of C57B1/6, CBA/Ca, 129/Sv and 
NIH strains.
MoMuLV infection of p53‘/7CD2-/;7yc+ mice significantly accelerated tumourigenesis as 
compared to non-infected p53'/7CD2-/wyc+ mice (p < 0.001, Mann-Whitney confidence 
test). Infected p53'/7CD2-/77yc+ mice died with a latency of between 41 and 63 days of 
age compared to that o f between 60 and 86 days for non-infected mice (Figure 6.3). All 
MoMuLV infected p53'/7CD2-w>»c+ mice developed thymic lymphoma with gross 
enlargement of the thymus and consistent metastatic spread to the spleen, mesenteric 
lymph nodes and subcutaneous lymph nodes. Virtually all animals (10/11) also displayed 
pathological evidence o f metastasis to the kidney. It can be concluded therefore that 
MoMuLV, CD2-myc and p53_/' collaborate to induce accelerated lymphomagenesis in 
this transgenic mouse model. The latency of at least 41 days however suggests that 
further events may still be required. This hypothesis is supported by the observation that 
MoMuLV/p53'/7CD2-w^c+ lymphomas are not polyclonal but consist o f clonal 
populations as assessed by TcR and IgH gene rearrangements (E. Baxter, personal 
communication).
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Figure 6.3. Tumour Free Survival Analysis of p53-/- CD2-myc+ Mice Infected with 
MoMuLV.
The tumour free survival time o f  MoMuLV infected p53-/- CD2-m yc+ m ice ( ♦ ,  n = l l )  was 
dram atically reduced compared to non-infected p 53-/- C D 2-m yc+ m ice (O, n=18). A ll 
infected and non-infected p53-/- CD2-myc+ mice developed thymic lymphoma.
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6 .3  D i s c u s s i o n .
6.3.1 Accelerated T-Lymphomagenesis in MoMuLV Infected p53'7' Mice.
Viral infection of homozygous p53 null mice has revealed that MoMuLV can co-operate 
with functional inactivation of the p53 gene to accelerate the onset of murine T-cell 
lymphomas. MoMuLV infected p53'/‘ mice were found to succumb to tumour 
development faster than infected wild type littermates and non-infected p53'/_ control 
mice. The intermediate survival o f MoMuLV infected heterozygote mice and the loss of 
the wild type allele from the tumours of these mice further supports the hypothesis that 
loss of p53 function may be important for the pathogenesis o f MoMuLV induced 
tumours.
Inactivation of the p53 gene has also been described in the progression of virally 
transformed leukaemias induced by Friend murine leukaemia virus (F-MuLV) and 
Abelson murine leukaemia virus (Wolf and Rotter, 1984; Mowat et a l , 1985; Chow et 
a l , 1987; Ben-David et al., 1988; Munroe et a l , 1990). Loss o f p53 function, often by 
gene rearrangement, appears to be an obligatory event for the pathogenesis o f F-MuLV 
induced mouse erythroleukaemias (Ben-David and Bernstein, 1991). The importance of 
p53 loss in the evolution of F-MuLV was supported by the infection o f p53 transgenic 
mice with F-MuLV. Transgenic mice which express a dominant-negative mutated p53 
allele (Lavigueur et a l , 1989) developed accelerated onset of late stage erythroleukaemia 
compared to infected wild type control animals (Lavigueur and Bernstein, 1991).
6.3.2 Weak Synergy Between MoMuLV and p53 Loss.
The synergy between the p53‘/_ mutation and MoMuLV infection was however not as 
pronounced as the synergy observed with each of these lesions in concert with the CD2- 
myc transgene. Transgenic mice co-expressing the CD2-myc transgene and the p53‘7* 
mutation succumbed to rapid T-cell lymphoma development before 86 days o f age 
(chapter 3). Similarly, all MoMuLV infected CD2-myc transgenic mice developed 
tumours between 53 and 84 days o f age (Stewart et a l , 1993). The weaker synergy
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observed between MoMuLV and the p53_/~ mutation could be due to differences in the 
genetic background of infected animals as susceptibility to MoMuLV infection can be 
determined by mouse strains (Tsichlis and Lazo, 1991). It is also possible that viral 
inoculation of some p53'/_ mice did not result in established infection. Indeed four 
animals which were found to survive beyond ten months o f age were examined and 
found not to be viraemic. However viral infection was successful in most animals as 
evident from the unique proviral integrations in the thymic tumours o f infected p53*7* 
mice (Baxter et al., 1996). Although non-persistent viral infection of a few animals and 
genetic background could play a small part in determining the survival o f MoMuLV 
infected p53'7' mice, it is unlikely that these alone could account for the relatively weak 
synergy between p53'/_ and MoMuLV.
It could be proposed that the weaker synergy of MoMuLV with p53'7' may reflect an 
overlap in the functions of p53 loss and MoMuLV infection in the pathogenesis of 
lymphoma development. Likewise, it was reported that the lack o f synergy between the 
p53'7' mutation and a bcl-2 transgene was due to a functional overlap o f these genetic 
events (Marin et a l 1994). It was suggested by Marin and co-workers that p53 loss and 
overexpression of the bcl-2 oncogene were effectors of a common apoptotic pathway, 
both acting to inhibit cell death. It is possible that MoMuLV infection may, like bcl-2, 
have anti-apoptotic properties. This would explain the lack of synergy o f MoMuLV 
infected bcl-2 transgenic mice described by Acton et al. (1992) and the weak synergy 
described by other workers (Shinto et a l , 1995). However acceleration of 
tumourigenesis in MoMuLV infected p53‘7' mice, and bcl-2 transgenic mice, does 
indicate that such a functional overlap cannot be completely redundant and that 
MoMuLV may also result in activation of other oncogenic events which co-operate with 
loss of p53 and overexpression of bcl-2.
Nevertheless, the results of MoMuLV infected p53'7' and bcl-2 mice suggests that the 
collaboration between MoMuLV infection and survival genes may be less potent than the 
collaboration between MoMuLV and proliferating genes. For example, MoMuLV 
strongly collaborates with c-myc and pim- 1 transgenes to accelerate lymphomagenesis 
(Stewart et al., 1993; van Lohuizen et al., 1989). As MoMuLV replication requires
145
proliferating cells, the potent collaboration o f MoMuLV with c-myc and pim -1 may be 
due to the enhanced frequency of viral insertion thereby increasing the chance of gene 
activation or inactivation. Alternatively, a larger set o f virus-activated oncogenes may 
collaborate with c-myc and pim-\ whereas a specific subset o f less potent oncogenes will 
collaborate with p53 loss or bcl-2. Furthermore, if MoMuLV has anti-apoptotic 
activities then an enhanced cell survival signal will effectively synergise with the 
proliferation signal of an oncogene in a similar manner to the synergy observed between 
bcl-2 with c-myc (Strasser et a l, 1990) and p53'/_ with c-myc (chapter 3; Blyth et a l , 
1995).
6.3.3 Gene Targets of Proviral Insertion.
MoMuLV induces oncogenic effects by proviral insertional mutagenesis (van Lohuizen 
and Berns, 1990). Characterisation of the sites o f MoMuLV provirus integration has 
previously led to the identification of numerous collaborating oncogenes in 
lymphomagenesis (van Lohuizen et a l, 1989; van Lohuizen et a l, 1991; Haupt et a l,
1991). MoMuLV infection of p53_/* mice provided an opportunity to investigate which 
genetic activation events preferentially co-operated with the loss of p53. In a study 
carried out by Dr. Euan Baxter, 3/11 p53'A tumours were found to have rearrangements 
at the c-myc gene (Baxter el a l, 1996). This result is consistent with the observed 
synergy between the p53*/_ mutation and the CD2-myc transgene (chapter 3) confirming 
the strong synergistic relationship between these genetic events in T-cell lymphoma 
development. No rearrangements at bmi- \ , ahi-l, N -myc or pim -1 were observed in 
infected p53'/_ mice but one tumour did have an insertion at pal-\ (Baxter et a l,  1996). 
Although pim-1 insertions were not found in p53‘/_ tumours, they occurred in p53+/' 
tumours which had lost the wild type allele suggesting that pim -1, like c-myc, was a 
potential collaborating event in co-operation with p53 loss. Insertions at c-myc and pim- 
1 were also demonstrated in the tumours of MoMuLV infected bcl-2 transgenic mice 
(Shinto et a l, 1995).
Retroviral insertion of F-MuLV sequences has been shown to occur within the p53 gene 
leading to functional inactivation (Chow et a l, 1987; Ben-David et a l, 1988). Indeed
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one cell line was described in which F-MuLV sequences had integrated independently 
into both alleles o f the p53 gene (Hicks and Mowat, 1988). In contrast to F-MuLV, 
MoMuLV apparently does not integrate within the p53 gene as assessed by examination 
of six MoMuLV infected p53+/' tumours (Baxter et a l , 1996). The lack of viral insertion 
of MoMuLV sequences in the p53 gene is consistent with the hypothesis that p53 
inactivation and MoMuLV infection share functional properties. However that loss o f 
the wild type p53 allele was found to occur in p53+/‘ tumours suggests that inactivation 
of p53 function, evidently by a non-viral mechanism, can contribute to MoMuLV 
induced lymphomagenesis.
6.3.4 MoMuLV Determines the Phenotype of Infected p53'A Tumours.
Gross pathology and flow cytometry analysis of MoMuLV infected p53'7' tumours 
revealed that almost all mice developed T-cell lymphoma, although three animals also 
had co-existing haemangiosarcomas. As a higher proportion o f infected mice developed 
T-cell lymphoma compared to non-infected mice it is likely that MoMuLV infection 
restricted the tumour phenotype of p53'A mice. Likewise, MoMuLV infection was found 
to skew the tumour phenotype of p53+/‘ mice. Flow cytometry analysis of MoMuLV 
p53_/' infected lymphomas indicated phenotypic heterogeneity with tumours representing 
a variety of T-cell differentiation stages. Heterogeneous T-cell phenotypes, which 
occurred between and within individual tumours, were also found in infected p53+/' and 
p53+/+ groups. These results are consistent with other studies which described 
phenotypic heterogeneity of MoMuLV infected tumours (Lazo et a l,  1990; Ott et a l,
1992). It was apparent therefore that MoMuLV was the phenotypic determinant of 
MoMuLV infected p53'/* tumours. It could be proposed that initiation o f infected p53'A 
tumours was a result o f MoMuLV and that loss of functional p53 contributed to tumour 
growth by reducing the time for tumour progression. In support of this hypothesis clonal 
integrations of viral sequences were observed in the infected p53'/_ tumours indicating 
that viral insertion had preceded the expansion of the tumour clone (E. Baxter, personal 
communication).
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6.3.5 Collaboration Between M oM uLV, the CD2-myc Transgene and Loss 
of p53 In T-cell Lymphomagenesis.
The combined synergistic action of p53 loss with the CD2-myc transgene has been 
detailed in previous chapters. However, the clonality and latency o f tumours in p53'/' 
!QD2-myc mice suggested that these two events alone were insufficient for lymphoma 
development. This interpretation has been confirmed by infection o f p53’/7CD2-/wyc+ 
mice with MoMuLV which resulted in a further acceleration o f tumour onset. All 
infected mice developed thymic lymphoma similar to uninfected p53*/7CD2-/wyc+ mice 
but at a much reduced latency. MoMuLV infection, which has previously been shown to 
collaborate with the CD2-myc transgene (Stewart et a l , 1993) and the P53'7' mutation 
(this chapter), can therefore act in co-operation with these two events in T-cell 
lymphomagenesis. However as infected p53’/7CD2-myc+ mice developed clonal tumours 
after a latency of 40 days it is likely that more than one additional event was required for 
tumour development. Exploitation of provirus insertional mutagenesis o f infected p53'A 
/CD2-myc+ tumours should narrow the search for those genes which can preferentially 
collaborate with c-myc deregulation and p53 loss. It is possible that this approach will 
identify a set of genes not previously considered to be strong oncogenes but whose 
function is distinct from the effects o f c-myc deregulation and p53 inactivation and 
specifically complements these actions in the pathogenesis of murine T-cell lymphomas.
148
FUTURE W O RK
The results described here demonstrate that certain genetic lesions can collaborate in the 
pathogenesis of murine T-cell lymphoma. It has been shown that inactivation o f the p53 
tumour suppressor gene can co-operate with a human c-myc transgene to dramatically 
reduce the latency time to lymphoma development but that loss o f both functional p53 
alleles is required for this synergy. These two events alone are insufficient for 
tumourigenesis however and it is likely that other events, which can be provided by 
MoMuLV infection, are required for tumour development.
Future work will concentrate on exploiting the p53'/7CD2-wyc+ transgenic mouse model 
to identify those genes which can co-operate with c-myc and p53 loss in T-cell 
lymphomagenesis, and conversely, which oncogenic events are rendered redundant by 
the presence of deregulated c-myc and the absence of p53. These studies may allow the 
assigning of oncogenes to complementation groups based on their ability to co-operate. 
The identification o f collaborating genes in the p53‘/7CD2-myc+ model may reveal 
distinct mechanisms which specifically complement the effects o f c-myc and p53 loss. 
Studies of proviral insertional mutagenesis, which are currently underway, have not yet 
identified any known common integration sites in the p53‘/7CD2-w^c+ tumours. It is 
possible therefore that these studies may uncover novel cancer associated genes. These 
genes may not necessarily be involved in the initiation of tumour development but may 
influence secondary tumour characteristics such as malignant progression and metastasis.
The mechanism of how the CD2-myc transgene collaborates with p53 loss to induce T- 
cell lymphomagenesis remains unclear. It will be important to investigate this further to 
understand the nature of collaboration between c-myc and p53 loss in tumourigenesis. 
The primary effects of deregulated c-myc on thymocytes, whether cell proliferation or 
cell death, have been difficult to determine using the current CD2-myc mouse model. To 
address this issue, a transgenic model in which c-myc expression can be induced in 
thymocytes is currently being developed. Such a model may delineate the cellular 
environment and genetic events that can influence the fate o f c-myc expressing 
thymocytes.
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